

ENCALS

European Network to Cure ALS

**ENCALS MEETING 2026
MADRID • SPAIN**

24-25-26 JUNE 2026

PRE-CONGRESS DAY: JUNE 23

www.encals-congress.com



FINAL PROGRAM



INDEX

FIRST SECTION

Welcome letter	03
Venue	04
Main Contact details	04

Committees

ENCALS Executive Board	05
Speakers	06

SCIENTIFIC PROGRAM**Scientific Grid**

Pre-Congress	08
Congress	09-11

Program

Tuesday (Pre-Congress)	12
Wednesday (Congress)	16
Thursday (Congress)	20
Friday (Congress)	25

Posters (Go to page - click here)	27
--	----

SECOND SECTION**Industry Sponsored session**

Tuesday 14.00-16.30h (Go to page - click here)	128
Wednesday 11.45-13.00h (Go to page - click here)	129
Wednesday 11.30-13.00h (Go to page - click here)	130
	131
	131



WELCOME LETTER

Dear colleagues and partners,

On behalf of the ENCALs Executive Board and the Organizing Committee ENCALs Madrid 2026, it is our pleasure to welcoming you to the Annual Meeting of the European Network for the Cure of ALS, which is taking place in Madrid, from June 23rd to 26th, 2026, at the Palacio Municipal de Congresos.

ENCALS is the leading European forum for researchers, clinicians, and professionals dedicated to the study of amyotrophic lateral sclerosis (ALS) and other motor neuron diseases. Each year, this meeting brings together the most active and innovative teams in the field to share scientific discoveries, foster collaboration, and accelerate the translation of knowledge into meaningful therapeutic advances.

Madrid is hosting more than 1.000 researchers, neurologists, clinical teams and healthcare professionals during ENCALs 2026, presenting the latest progress in genetics, molecular biology, biomarkers, neuroimaging, clinical trials, technological innovation, and multidisciplinary care.

We would like to thank all the companies participating in ENCALs 2026. Your support is essential to make this event possible, and your participation directly contributes to both scientific progress and social impact in the fight against ALS.

With our warmest regards,

Leonard van den Berg and Orla Hardiman

on behalf of the ENCALs Executive Committee

Alberto García Redondo and Jesús Esteban Pérez

on behalf of the Organizing Committee ENCALs Madrid 2026

VENUE




PALACIO MUNICIPAL DE CONGRESOS DE MADRID (PALACIO MUNICIPAL - IFEMA MADRID)

Av. Capital de España, 7, 28042 Madrid (Spain)

[Website - click here](#)



The IFEMA Palacio Municipal in Madrid, Spain, is a modern and versatile convention center known for hosting a wide range of events, conferences, and exhibitions. Conveniently located near the city center, it offers state-of-the-art facilities and easy access to transportation, making it a prime venue for international gatherings.



MAIN CONTACT DETAILS

ENCALS HEADQUARTERS

P.O box 85500
3508 GA Utrecht
The Netherlands
info@encals.eu
www.encals.eu

ENCALS

European Network to Cure ALS

TORRESPARDO Association Management

ENCALS 2026 TECHNICAL SECRETARIAT

Registration Manager
Carolina Rovira
registration@torrespardo.com

Scientific Manager
Desirée Muñoz
d.munoz@torrespardo.com

Sponsorship Manager
Miss Asun Marzo
a.marzo@torrespardo.com

COMMITTEES

ENCALS Executive board

Chair:

Leonard van den Berg
(The Netherlands)

Co-chair:

Orla Hardiman
(Ireland)

Treasurer:

Adriano Chio
(Italy)

Caroline Ingre
(Sweden)

Philip van Damme
(Belgium)

Markus Weber
(Switzerland)

Monica Povedano
(Spain)

Peter Andersen
(Sweden)

Francois Salachas
(France)

Magdalena Kuzma
(Poland)

Sharon Abrahams
(Scotland)

Julian Grosskreutz
(Germany)

Ammar Al-Chalabi, chair award committee
(England)

Thomas Meyer
(Germany)

Vincenzo Silani
(Italy)

Philippe Corcia
(France)

Blaž Kortnik
(Slovenia)

Martin Turner
(England)

Christopher McDermot
(England)

SPEAKERS



Prof. Ammar Al-Chalabi

Maurice Wohl Clinical Neuroscience Institute
King's College London
London, United Kingdom



Prof. Andrea Calvo

Università degli Studi di Torino
AOU Città della Salute e della Scienza
di Torino Hospital
Turin, Italy



Dr. Alejandro Caravaca Puchades

Hospital Universitari de Bellvitge - IDIBELL
Barcelona, Spain



Prof. John Landers

UMass Medical School
Worcester, MA, USA



Dr. Mónica Povedano Panadés

Hospital Universitari de Bellvitge - IDIBELL
Barcelona, Spain



Dr. Teresa Salas Campos

Hospital Universitario La Paz/Carlos III
Madrid, Spain



Dr. Alexander Thompson

University of Oxford
Oxford, United Kingdom



Prof. Nicola Ticozzi

Istituto Auxologico Italiano, University of Milan
Milan, Italy



Dr. Ruben van Eijk

University Medical Center Utrecht
Utrecht, The Netherlands



Prof. Christine Vande Velde

Université de Montréal
Montreal, Canada



Prof. Jochen Weishaupt

Universitäts und Rehabilitationskliniken Ulm
(RKU)

Ulm, Germany

ENCALS

European Network to Cure ALS

SCIENTIFIC PROGRAM



Scientific Grid Pre-Congress Day

TUESDAY June 23rd

	FIRST FLOOR		SECOND FLOOR		FOURTH FLOOR
	BUENOS AIRES - HAVANA - MEXICO ROOM	PRENSA ROOM	CARACAS - BOGOTÁ ROOM	LA PAZ - MONTEVIDEO ROOM	BRATISLAVA ROOM
09:00-10:00					
10:00-11:00		INARC MEETING		PRECISION ALS	premodiALS Consortium
11:00-12:00					
12:00-13:00					
13:00-14:00	Break				
14:00-15:00	Industry session (see page 130-131)	INARC MEETING			
15:00-16:00				ALS App Europe Initiative	
16:00-17:00					
17:00-18:00					

WEDNESDAY June 24th

	FIRST FLOOR		SECOND FLOOR		FOURTH FLOOR
	BUENOS AIRES - HAVANA - MEXICO ROOM	PRENSA ROOM	CARACAS - BOGOTÁ ROOM	LA PAZ - MONTEVIDEO ROOM	BRATISLAVA ROOM
09:00-10:00		Neuropsychology workshop		SEED Consortium	
10:00-11:00	(08.15-11.50) TRICALS				
11:00-12:00					
12:00-13:00	(11.50 - 13.00) Industry session (see page 131)		(11.30 - 13.00) Industry session (see page 131)		

Scientific Grid ENCALS Meeting

WEDNESDAY June 24th

	AUDITORIUM
13:00-13:30	WELCOME ADDRESS
13:30-15:00	GENETICS AND GENOMICS IN ALS: FROM DISCOVERY TO PRECISION THERAPIES Plenary Speaker: John Landers (Worcester, MA, United States)
15:00-15:30	Coffee break and posters
15:30-17:00	PRESYMPTOMATIC & BIOMARKERS Plenary Speaker: Alex Thompson (Oxford, United Kingdom)
17:00-17:20	RAPID FIRE PRESENTATIONS
17:20-19:00	ENCALS RESEARCH FORUM – POSTERS SESSION

Scientific Grid ENCALS Meeting

THURSDAY June 25th

	AUDITORIUM
08:30-10:00	INNOVATIVE PRECLINICAL MODELS: BRIDGING MECHANISMS AND TRANSLATION Plenary Speaker: Jochen Weishaupt (Ulm, Germany)
10:00-10:25	Coffee break and posters
10:25-10:30	Group photo
10:30-11:40	EPIDEMIOLOGY AND PHENOTYPING Plenary Speaker: Mónica Povedano Panadés (Barcelona, Spain)
11:40-12:30	DEBATE: ARE WE READY TO REDEFINE ALS THROUGH PRECISION AND EARLY INTERVENTION? Speakers: Andrea Calvo (Turin, Italy) and Ammar Al-Chalabi (London, United Kingdom)
12:30-12:50	RAPID FIRE PRESENTATIONS
12:50-13:50	Lunch time and posters
13:50-14:50	ALS AS A MULTISYSTEM DISORDER: BEYOND MOTOR NEURON DEGENERATION Plenary Speaker: Teresa Salas Campos (Madrid, Spain)
14:50-15:15	RAPID FIRE PRESENTATIONS
15:15-15:45	Coffee break and posters
15:45-17:00	RETHINKING ALS PATHOGENESIS: EMERGING MOLECULAR PARADIGMS Plenary Speaker: Christine Vande Velde (Montreal, Canada)
17:00-18:15	ENCALS RESEARCH FORUM – POSTERS SESSION

20:00	NETWORKING DINNER (Not included in the registration fee)
-------	---

Scientific Grid ENCALS Meeting

FRIDAY June 26th

	AUDITORIUM
09:00-10:15	CLINICAL TRIALS, STRATIFICATION AND CLINICAL OUTCOMES Plenary Speaker: Ruben van Eijk (Utrecht, The Netherlands)
10:15-10:45	YOUNG INVESTIGATOR AWARD
10:45-11:15	Coffee break
11:15-12:45	ADVANCED CLINICAL PHENOTYPING USING NEW TECHNOLOGIES Plenary Speakers: Alejandro Caravaca Puchades (Barcelona, Spain) and Nicola Ticozzi (Milan, Italy)
12:45-13:15	CLOSING SESSION

Tuesday June 23th - Pre-Congress

INTERNATIONAL NETWORK FOR ALS - RESEARCH AND CARE (INARC)

Tuesday, June 23th

09.30-16.45

Prensa room

Please note that this is a closed meeting. Prior registration is mandatory for attendance. We cannot accommodate walk-ins.

Please contact inarc@tricals.org for questions about this meeting.

PERSON-CENTRED APPROACHES TO CARE AND RESEARCH FOR PEOPLE WITH MND/ALS

09.30-09.45 **Welcome and introduction to the day**

09:45-11:00 THE HOLISTIC APPROACH: ENSURING OPTIMAL AND APPROPRIATE PRACTICE

Fouke Ombelet ALS/MND Nurse Specialist,

KU Leuven Center for Brain & Disease Research

Explore MDT roles, ethical considerations, and contextual factors that support patient-centred decisions

11:00-11:30 Coffee Break

11:30-12:30 COMMUNICATING EFFECTIVELY ABOUT RESEARCH WITH PEOPLE WITH AND AFFECTED BY MND

Michaela Waltho, Clinical Nurse Specialist,

National Hospital for Neurology and Neurosurgery, London

Investigate empathic, professional communication in emotionally challenging situations, focusing on what patients need to feel heard and understood.

Scenarios include disease progression, delivering bad news, and trial ineligibility.

12:30-13:15 Lunch

13:15-14:15 RESPIRATORY SYSTEMS – A HANDS-ON WORKSHOP

Saúl Marín Esteban, Physiotherapist and Clinical Trial Coordinator.

La Paz University Hospital

Paul Matthew Burnham, Specialist Respiratory Physiotherapist.

Gregorio Marañón Hospital.

Miguel Valdazo Alonso, Respiratory Physiotherapist.

Breas Medical

Pilar Carbajo Gullón, Clinical Trials Research Nurse.

La Paz University Hospital

This interactive session introduces respiratory devices, SNIP, FVC and peak flow, and their use in research.

Tuesday June 23th - Pre-Congress

14:15-15:00 COGNITIVE AND BEHAVIOURAL CHANGE: PROVIDING GOOD CARE & ENABLING RESEARCH PARTICIPATION WHEN THESE ARE PRESENT

Professor Eneida Mioshi, University of East Anglia

This session will present current evidence while exploring experiences of those involved in care and research recruitment when cognitive and behavioural changes are present. We will share some potential parameters to support care and research participation practices across all affected by MND/ALS.

15:00-15:15 Comfort break

15:15-16.30 PRACTICAL CHALLENGES IN MND RESEARCH

Alizé Chalançon, Project Manager, National Clinical Research Network France.

In this session you will share the launch of the new Start Up package – a guide to setting up clinical trials.

16:30-16:45 Evaluation of the day

ALS APP EUROPE INITIATIVE MEETING

Tuesday, June 23th

15:00-18:00

Caracas-Bogotá Room

15.00-15.15 Welcome coffee

15.15-15.45 Revised self-explanatory ALSFRS-R

15.45-16.15 Introduction of ALS Center App

16.15-16.45 Coffee break

16.45-17.30 ALS-OPM classification: correlation with ALS progression, NfL and survival

17.30-18.00 ALS-OPM in multiple languages

Tuesday June 23th - Pre-Congress

PRECISION ALS

Tuesday, June 23th

12.00-18.00

La Paz -Montevideo room

- 12.00-12:30 Lunch and Registration
- 12.30-12.45 Introduction to the Largest ALS Dataset in the World**
- 12.45-13.45 PRECISION ALS Platform**
Ronan McDonnell and the Technical Team
- 13.45-14.15 Discussion
- 14.15-14.30 Data Harmonisation, Update and Progress**
- 14.30-15.00 Biomarkers: Neurofilaments, Proteomics, Transcriptomics**
- 15.00-15.15 Discussion
- 15.15-15.30 Coffee
- 15.30-15.45 Digital Health Technologies**
Marc Elliot
- 15.45-16.15 Social Determinants of Health**
Miriam Galvin
- 16.15-16.45 AI & Machine Learning**
Robert Ross
- 16.45-17.30 Discussion and Next Steps**
- 17.30-17:50 Summary and Date for the Next Meeting**

Tuesday June 23th - Pre-Congress

PREMODIALS

Tuesday, June 23th

13.00-15.30

Bratislava room

- 13:00-13:05 **Welcome and Introduction**
(Lingor)
State of the analysis and plan of future analysis
- 13:05-13:20 **Overview of current analysis**
(Tzeplaeff / Lingor / Galhoz / Menden)
- 13:20-13:40 **Future analyses**
Speech analysis – Ki-elements
(Thies)
miRNA analysis
(Magen / Hornstein)
Cell free DNA analysis
(Lingor)
- 13:40-13:55 **Predicting Phenoconversion to Clinically Manifest ALS**
(Benatar)
- 13:55-14:15 **Discussion on the stage of the data, plans, publication strategies**
(all)
Ongoing and future Recruitment
- 14:15-14:45 **Overview of the international recruitment**
France - Tours (Corcia)
Slovakia (Turčanová)
Turkiye - Antalya (Uysal)
Switzerland (Weber / Neuwirth)
Israel (Lerner / Alhlim)
Czech Republic (Vlčkova / Betík)
Germany - Rostock (Hermann)
Germany - Munich (Lingor)
- 14:45-15:00 **Presentation of the new recruitment centers**
France (Couratier / Guy / Danel Brunaud / del Mar Amador / Soriani / Bernard)
Turkiye - Istanbul (Ofłazer)
Spain (Rubio)
Belgium (Masroni)
- 15:00-15:20 **Discussion on recruitment planning and goals (all)**
Future of premodiALS – how to maintain a sustainable structure?
- 15:20-15:30 **Prolongation of premodiALS and novel opportunities**
(Lingor / all)
- 15:30 **End of the official meeting**

Wednesday June 24th - Pre-Congress

TRICALS

Wednesday, June 24th

08.15-11.50

Buenos Aires – Havana - Mexico room

Insights in recent and current clinical trial results

During the TRICALS satellite meeting, Companies will present their trial results, and several companies will provide updates on their ongoing studies. There will be ample opportunity for questions and discussion. This meeting represents an important moment to showcase the current state of clinical research in ALS and to highlight what lies ahead.

08:15-08:45 Breakfast, networking and walk-in

08:45-09:00 Opening by Prof. Leonard van den Berg

09:00-10:15 Study results: Magnet lithium, Quralis, argenx, AL-S pharma, Corcept, Neurosense, Axoltis

10:15-10:30 Coffee break

10:30-11:10 Study updates: VectorY, Leal Therapeutics Inc., Ionis, Trace Neuroscience, Zydyus Therapeutics Inc., NuraBio, Eli Lilly, ProjenX

11:10-11:30 Panel discussion with Group 2 presenters

11:30-11:50 PREVAiLS study update

NEUROPSYCHOLOGY WORKING GROUP

Wednesday, June 24th

09.00-12.30

Prensa room

Findings from last year

Joke De Vocht

Introduction to this year's theme

Ratko Radakovic, Caroline McHutchison

Talks from young researchers

[TBD]

Interactive session: Understanding Behaviour in ALS

Ratko Radakovic, Caroline McHutchison

Wednesday June 24th - Pre-Congress

SEED-ALS

Wednesday, June 24th

09.00-11.30

La Paz - Montevideo Room

09:00-09:05 **Welcome**

Carlos Sanz

09:05-09:20 **PROJECT UPDATE**

Financial status

Carlos Sanz

Overall project status

Adolfo López de Munain

09:20-10:00 **CLINICAL CORE**

Carmen Paradas

10:00-10:30 **TRASLATIONAL CORE**

Cellular Core

Ana Martínez, Patricia Gómez Suaga

Lipidomics and metabolism

Estela Área,

Carmen María Fernández Martos

10:30-12:00

Open Discussion,

Questions and General Remarks



Wednesday June 24th - Congress

13:00-13:30 WELCOME ADDRESS

13:30-15:00 GENETICS AND GENOMICS IN ALS

Moderators:

Wouter van Rheenen (University Medical Center Utrecht, The Netherlands)

Juan Francisco Vázquez Costa (Hospital Univ. La Fe, Valencia, Spain)

13:30-13:45

Plenary talk:

Transitioning ALS Genetic Discoveries Into Therapeutic Treatments

John Landers

(UMass Medical School, Worcester, MA, United States)

13:45-13:50

Discussion

13:50-14:00

Analysis Of ARPP21 Mutations In Familial And Sporadic Amyotrophic Lateral Sclerosis In The Spanish Population

Álvaro Carbayo Viejo, Spain

14:00-14:10

Rare Pathogenic Neurologic And Neurodevelopmental Variants In Als Associate With Onset, Survival And Family History

Ciara O'Donoghue, Ireland

14:10-14:20

Using Dutch Archive Data To Reconstruct Als Superpedigrees At Scale

Daphne van Oosten, The Netherlands

14:20-14:30

The Shared And Differential Genetic Risk Factors Of Neurodegeneration

Tomas Gomes, Ireland

14:30-14:40

U7 SnRNAs Based Gene Therapies Targeting Cryptic Splicing Events Involved In ALS/FTD

Alessandro Marrero Gagliardi, United Kingdom

14:40-14:50

Restoring TDP-43 Function: The Translational Potential Of AP-2 In ALS

Ana Martinez, Spain

14:50-15:00

Arc-Mediated TDP-43 Encapsulation Drives Intercellular Propagation In ALS: A Novel Therapeutic "Firewall" Validated By Lenacapavir Repositioning

Gorka Gereñu Lopetegui, Spain

15:00-15:30

Coffee Break and Posters

15:30-17:00 PRESYMPTOMATIC & BIOMARKERS

Moderators:

Jenna Gregory (Institute of Medical Sciences, University of Aberdeen, United Kingdom)

Miguel Ángel Rubio Pérez (Hospital del Mar, Barcelona, Spain)

15:30-15:45

Plenary talk:

Understanding the earliest events in ALS

Alexander Thompson

(University of Oxford, Oxford, United Kingdom)

15:45-15:50

Discussion

Wednesday June 24th - Congress

- 15:50-16:00 **Presymptomatic Changes In Brain Structure In Sporadic And C9orf72 Mutation Carrying ALS Patients**
Pauline van Lieshout, The Netherlands
- 16:00-16:10 **Plasma Lipidomic Signatures Contribute To Biological Stratification Of ALS Progression**
Bernat Bertran Recasens, Spain
- 16:10-16:20 **A Large Scale Study Of Urinary P75ECD In Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis And Mimics**
Koen C. Demaegd, The Netherlands
- 16:20-16:30 **Muscle Proteins Dominate The Circulating Proteomic Signature Of ALS And ALS Phenotypes**
Louisa Azizi, Sweden
- 16:30-16:40 **Sweat Gland TDP-43 Pathology Precedes Symptom Onset In Amyotrophic Lateral Sclerosis**
Katie Hanna, United Kingdom
- 16:40-16:50 **Lipid And Muscle Biomarker Trajectories Before ALS Or FTD**
Christos V. Chalitsios, United Kingdom
- 16:50-17:00 **Multiparametric Muscle Ultrasound In Early Amyotrophic Lateral Sclerosis: Morphological And Textural Biomarkers As Diagnostic Discriminators**
José Ríos-Díaz, Spain
- 17:00-17:20 RAPID FIRE PRESENTATIONS**
Moderators:
Magdalena Kuzma-Kozakiewicz (Medical University of Warsaw, Poland)
Janne M. Toivonen (Univ. Zaragoza, Spain)
- 17:00-17:02 **Different Contribution Of Nucleus Accumbens And Amygdala Subnuclei To The Emergence Of Positive And Negative Behavioural Symptoms In Amyotrophic Lateral Sclerosis**
Alessio Maranzano, Italy
- 17:02-17:04 **Spinal Cord Atrophy Across Clinical Phenotypes And Stages In Amyotrophic Lateral Sclerosis: Results From a large multicentre MRI Cohort**
Giorgia Querin, France
- 17:04-17:06 **The Effect Of An UNC13A Polymorphism On Neuroimaging In ALS**
Justus van Nispen tot Sevenaer, The Netherlands
- 17:06-17:08 **Quantifying Survival Differences Between ALS Clinical Trial Participants And Population Cohorts: Evidence of prognostic enrichment in clinical trials**
Emeka Uzochukwu, United Kingdom
- 17:08-17:10 **Replication Of Beta EEG Oscillations Related To The Sustained Attention To Response Task In Irish And Dutch Cohorts**
Marit Boxum, The Netherlands

Wednesday June 24th - Congress

17:10-17:12 **Frontotemporal Alpha Power Is Reduced In People With ALS But Alpha Modulation Remains Intact**

Narin Suleyman, Ireland

17:12-17:14 **Global Taskforce On Genetic Counselling And Testing In ALS/MND: Developing Consensus-Based Guidelines**

Ammar Al-Chalabi, United Kingdom

17:14-17:20 Discussion

17:20-19:00 ENCALS RESEARCH FORUM – POSTERS SESSION I

Poster's defense of the following topics:

- Clinical management and support
- Clinical trials and trial design
- Cognition
- Epidemiology
- In vitro experimental models / Cellular models
- In vivo experimental models / Animal models
- Phenotyping / Disease stratification
- Pre-clinical therapeutic strategies
- Presymptomatic
- Translational research, networks and platforms

[\(Complete list of posters in page 28 - click here\)](#)

Thursday June 25th - Congress

08:30-10:00 INNOVATIVE PRECLINICAL MODELS:

BRIDGING MECHANISMS AND TRANSLATION

Moderators:

Andrea Malaspina (UCL Queen Square MND Centre, London, United Kingdom)

Sonia Alonso-Martín (Biogipuzkoa, San Sebastián, Spain)

08:30-08:45 Plenary Talk:

Preclinical models: Approaches to translation

Jochen Weishaupt

(Universitäts und Rehabilitationskliniken Ulm (RKU), Ulm, Germany)

08:45-08:50 Discussion

08:50-09:00 Elucidating The Pathological Interplay Between Cytoskeletal Alterations And MRNA Metabolism In Profilin1-Mutant Human Motor Neurons

Christina Steffke, Germany

09:00-09:10 ALS Susceptibility Gene ARPP21 Assembles Into Dynamic RNA Granules And Drives TDP-43 Proteinopathy

Afra Aabdien, United Kingdom

09:10-09:20 Targeting The PP2A-AKT-GSK3 Axis In ALS: Implication Of FMRP

Benedetta Frizzi, Belgium

09:20-09:30 Dissecting The Mechanisms And Rescue Of Astrocyte Toxicity In Sporadic Amyotrophic Lateral Sclerosis (SALS)

Katie Bowden, United Kingdom

09:30-09:40 Dysregulated Skeletal Muscle Signaling And Extracellular Vesicle Cargo Disrupt Muscle-to-neuron Communication In ALS

Amaia Elicegui, Spain

09:40-09:50 TDP-43 Pathology Induces CD8 T Cell Activation Through Cryptic Epitope Recognition

Matteo Zanovello, United Kingdom

09:50-10:00 RIG-I Mediated Neuron-Specific IFN Type 1 Signaling In FUS-ALS Induces Neurodegeneration And Offers New Biomarker-Driven Individualized Treatment Options For (FUS-)ALS

Marcel Naumann, Germany

10:00-10:25 Coffee Break and Posters

10:25-10:30 Group photo

Thursday June 25th - Congress

10:30-11:40 EPIDEMIOLOGY AND PHENOTYPING

Moderators:

Elisabetta Pupillo (Mario Negri Institute for Pharmacological Research, Milano, Italy)

Alejandro Caravaca Puchades (Hospital Universitari de Bellvitge, Barcelona, Spain)

10:30-10:45

Plenary Talk:

ALS in a Changing World: Environmental Exposures, Climate Change, and Neurodegeneration

Mónica Povedano Panadés

(Hospital Universitari de Bellvitge – IDIBELL, Barcelona, Spain)

10:45-10:50

Discussion

10:50-11:00

The Risk Of MND In A Large Cohort Of Male UK Former Professional Footballers

Elisabetta Pupillo, Italy

11:00-11:10

The Multistep Pathogenic Hypothesis Of Amyotrophic Lateral Sclerosis Is Incompatible With The Epidemiological Data

Guglielmo Foffani, Italy

11:10-11:20

Examining The Age-Incidence Curves Of ALS Across European Register: The Multistep Hypothesis revisited

Robert McFarlane, Ireland

11:20-11:30

Exposome-Wide Association Study (ExWAS) In ALS

Laura van der Schoor, The Netherlands

11:30-11:40

Motor Function And Symptom Burden In Advanced ALS – ALS Functional Rating Scale Assessment Proximate To Death

Susanne Spittel, Germany

11:40-12:30 DEBATE

ARE WE READY TO REDEFINE ALS THROUGH PRECISION AND EARLY INTERVENTION?

Chair:

Orla Hardiman (Trinity College of Dublin, Ireland)

Plenary Speakers:

Andrea Calvo

(Università degli Studi di Torino and AOU Città della Salute e della Scienza di Torino Hospital, Turin, Italy)

Ammar Al-Chalabi

(Maurice Wohl Clinical Neuroscience Institute and King's College London, London, United Kingdom)

12:30-12:50 RAPID FIRE PRESENTATIONS II

Moderators:

Helene Blasco (University of Tours, France)

Raúl Juntas (Hospital Vall d'Hebron, Barcelona, Spain)

12:30-12:32

Large-Scale Exome Analyses Reveal Novel Rare Variant Contributions In Amyotrophic Lateral Sclerosis

Paul Hop, The Netherlands

Thursday June 25th - Congress

- 12:32-12:34 **Identity-By-Descent Analyses Reveals C9orf72 Discordance, Cryptic Relatedness, And Expanded ALS Pedigrees**
Ciara O'Donoghue, Ireland
- 12:34-12:36 **Genetic Architecture Of Familial ALS In The Netherlands**
Bi-Nan Wang, The Netherlands
- 12:36-12:38 **Exploring The Power To Detect Pathogenic Mutations Through Haplotype Analyses In Distantly Related patients with ALS**
Paul Beele, The Netherlands
- 12:38-12:40 **APOEε4 Homozygosity Accelerates The Onset And Progression Of ALS Neurodegeneration**
Sebastian A. Lewandowski, Sweden
- 12:40-12:42 **Integrated CSF–Blood Immune Profiling Reveals Immune Signatures Associated With Clinical Response**
Timothy Tree, United Kingdom
- 12:42-12:44 **Clustering On CSF Biomarkers And Clinical Parameters Reveals A Signature Of Neuroinflammation**
Manuela Basso, Italy
- 12:44-12:46 **Metabolic Signatures Of Ferritin And TDP-43 Co-Pathology Provide A Mechanistic Basis For Stratified Therapeutic approaches in ALS**
Holly Spence, United Kingdom
- 12:46-12:50 Discussion
- 12:50-13:50 Lunch Time and Posters
- 13:50-14:50 ALS AS A MULTISYSTEM DISORDER: BEYOND MOTOR NEURON DEGENERATION**
Moderators:
Caroline McHutchinson (University of Stirling, United Kingdom)
Juan I. López Carbonero (Hospital Clínico San Carlos, Madrid, Spain)
- 13:50-14:05 **Plenary Talk:**
Stepping into Neuropsychology at La Paz/Carlos III Hospital in Madrid
Teresa Salas Campos
(Hospital Universitario La Paz/Carlos III, Madrid, Spain)
- 14:05-14:10 Discussion
- 14:10-14:20 **Neuropsychological Sub-Phenotypes In Amyotrophic Lateral Sclerosis**
Barbara Poletti, Italy
- 14:20-14:30 **Quantifying Behavioral Changes In ALS: Longitudinal Trajectories And Functional Network 72 Correlates Of A Domain-Specific Behavioral Scale**
Laura Josephine Hagedorn, The Netherlands
- 14:30-14:40 **Cognitive Profiles In C9orf72 Families: Evidence For Nurture By Nature**
Annebelle Michielsen, The Netherlands
- 14:40-14:50 **Somatosensory Neurological Soft Signs Associate With Executive Function In Unaffected Familial ALS Relatives Independent Of C9orf72 Status**
Sarah Darcy, Ireland

Thursday June 25th - Congress

14:50-15:15 RAPID FIRE PRESENTATIONS III

Moderators:

André Maier (Charité Universitätsmedizin Berlin, Germany)

Silvia Corrochano (Hospital Clínico San Carlos, Madrid, Spain)

14:50-14:52 **C9orf72 Repeat Expansion Affects Immune Response In A Xenografted Microglia Mouse Model**

Laura Fumagalli, Belgium

14:52-14:54 **A Distinct SPP1 Microglial Subset Initiates CD44-astrocyte Crosstalk In ALS**

Jianing Lin, Sweden

14:54-14:56 **Proteomic And Histological Profiling Of The ALS Visual Cortex Reveals Early Presynaptic Dysfunction And White Matter Atrophy**

Zsófia Laszlo, United Kingdom

14:56-14:58 **Novel TDP-43 Amyloid Polymorphs Uncover Aggregation Mechanisms In ALS**

Javier Oroz, Spain

14:58-15:00 **STMN2 Protein Depletion Via Translation Deficits And Stress Granules Independent Of TDP-43 Loss Of function**

Brittany Ellis, United Kingdom

15:00-15:02 **M6A-Dependent RNA Condensation Underlies FUS Autoregulation And Can Be Harnessed For ALS Therapy**

Vedanth Kumar, United Kingdom

15:02-15:04 **TDP-43 Dysfunction Disrupts Brain Cholesterol Homeostasis And Is Exacerbated By A High-Fat Diet**

Irene García-Toledo, Spain

15:04-15:06 **Patient-Derived Cortical Brain Organoids Model Key Pathological Features Of ALS**

Beatriz Fernandez-Muñoz, Spain

15:06-15:08 **CRISPR Kinome Screens In Human Motor Neurons Reveal Druggable Modulators Of TDP-43 Pathology**

Tania Atienzar, United Kingdom

15:08-15:10 **Disruption Of The Motor Neuron Translatome Is Disease-Specific In ALS And SMA But Converges On MCM5**

Hannah Smith, United Kingdom

15:10-15:15 Discussion

15:15-15:45 Coffee Break and Posters

Thursday June 25th - Congress

15:45-16:55 RETHINKING ALS PATHOGENESIS: EMERGING MOLECULAR PARADIGMS

Moderators:

Anna Sanchez Ávila (University of Sheffield, United Kingdom)

Ana C. Calvo Royo (Univ. Zaragoza, Spain)

15:45-16:00

Plenary talk:

Rethinking ALS Pathogenesis: Emerging Molecular Paradigms

Christine Vande Velde

(Université de Montréal, Montreal, Canada)

16:00-16:05

Discussion

16:05-16:15

Glial Phagocytosis As A Mechanism Of Synapse Loss In ALS

Zsófia Laszlo, United Kingdom

16:15-16:25

Distinct Routes To Abnormal TDP-43 Oligomerisation In ALS-C9 And Sporadic ALS

Anna Sanchez Avila, United Kingdom

16:25-16:35

Longitudinal Single-Cell RNAseq Reveals Immune Lineage Diversion And Accelerated Senescence As Drivers Of ALS Progression And Neurodegeneration

Oriol Dols-Icardo, Spain

16:35-16:45

Virotrap-Based Interactomic Profiling Reveals Novel HDAC6 Interactors With Therapeutic Relevance To ALS

Dufie Strubbe, Belgium

16:45-16:55

Immune Stimulation Exacerbates Cell Autonomous Microglial Dysfunction In A Stem Cell Model Of TBK1-Associated ALS-FTD

Owen M. Peters, United Kingdom

16:55-18:10 ENCALS RESEARCH FORUM – POSTERS SESSION II

Poster's defense of the following topics:

- Biomarkers
- Disease mechanisms
- Genetics and genomics
- Imaging and electrophysiology as biomarkers
- New drugs development
- Technology, innovation and bioengineering

[\(Complete list of posters in page 28 - click here\)](#)

Friday June 26th - Congress

09:00-10:15 CLINICAL TRIALS, STRATIFICATION AND CLINICAL OUTCOMES

Moderators:

Ciara O'Donoghue (Trinity College, Dublin, Ireland)

Javier Mascías Cadavid (Hospital Carlos III-La Paz, Madrid, Spain)

09:00-09:15

Plenary talk:

Opportunities for Innovation: Considerations for Early-Phase Clinical Trials

Ruben van Eijk

(University Medical Center Utrecht, Utrecht, The Netherlands)

09:15-09:20

Discussion

09:20-09:30

Introducing A Standardized Protocol Template For Early-Efficacy Trials In ALS: Improving Phase 2-to-3 Decision-Making (MAGNET-II)

JWJ Van Unnik, The Netherlands

09:30-09:40

Towards Regulator-Aligned Synthetic Placebo Construction In ALS: A Prespecified And Externally Validated PRO-ACT Framework

Mandy Miresmaeili, United Kingdom

09:40-09:50

Efficacy And Tolerability Of-Hydroxybutyrate In Patients With Amyotrophic Lateral Sclerosis (KETO-ALS) - A Randomised, Placebo-Controlled, Double-Blind Study

Christine Herrmann, Germany

09:50-10:00

Salivary Dim-Light Melatonin Onset Predicts Functional Decline And Survival In Early Amyotrophic Lateral Sclerosis

Alessandro Bombaci, Italy

10:00-10:15

Discussion

10:15-10:45 YOUNG INVESTIGATOR AWARD

10:45-11:15

Coffee Break and Posters

11:15-12:40 ADVANCED CLINICAL PHENOTYPING USING NEW TECHNOLOGIES

Moderators:

Blaž Koritnik (Ljubljana University Medical Centre, Slovenia)

Marta Vallejo de Frutos (Heriot-Watt University, Edinburgh, United Kingdom)

11:15-11:27

Plenary talk:

From Registries to Digital Phenotypes: Redefining ALS Through Clinical Data

Alejandro Caravaca Puchades

(Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain)

11:27-11:30

Discussion

11:30-11:42

Plenary talk:

Beyond Clinical Labels: AI-Driven Phenotyping in ALS

Nicola Ticozzi

(Istituto Auxologico Italiano, University of Milan, Milan, Italy)

11:42-11:45

Discussion

Friday June 26th - Congress

- 11:45-11:55 **The Precision ALS Research Platform**
Ronan McDonnell, Ireland
- 11:55-12:05 **Machine Learning Validation Of Gene Expression-Based ALS Subtypes Across Brain And Blood Tissues**
Esteban Alberto Gomez Cifuentes, United Kingdom
- 12:05-12:15 **Symptom-Based Phenotype Discovery In Motor Neuron Disease Using Natural Language Processing Of Electronic Health Records**
Yusuf Abdulle, United Kingdom
- 12:15-12:25 **Red Flags For The Early Diagnosis Of Amyotrophic Lateral Sclerosis: Machine-Learning Algorithms Applied To Data From A Referral Center**
Enrico Matteoni, Italy
- 12:25-12:35 **Progression Of ALS Milestones Differs Across Disease Phenotypes**
Rosario Vasta, Italy
- 12:35-12:45 **Linking Clinical And Laboratory Electrophysiology Studies For Patient-Stratified Research In MND**
Daniel de la Fuente, United Kingdom
- 12:45-13:15 CLOSING SESSION: THE ROAD AHEAD IN ALS**
- Meeting Summary
 - Rapid Fire and Poster prizes
 - Welcome to Lübeck

ENCALS

European Network to Cure ALS

POSTERS



CLINICAL MANAGEMENT AND SUPPORT (included in the posters session I)

PO001 Dissociation Between Functional Decline And Quality Of Life Dynamics In ALS

Alejandro Caravaca Puchades (1,2,3), Aina Ceballos Sánchez (1), Mònica Meseguer Martínez (1), Laia Pallarès Gayo (1), Raúl Domínguez Rubio (1), Mònica Povedano Panadés (1)

1. Bellvitge University Hospital, L'Hospitalet De Llobregat, Barcelona, Spain

2. Biomedical Research Institute of Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain

3. Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain

PO002 Peak Inspiratory Flow: A Novel Marker For Early Detection Of Respiratory Dysfunction In ALS

Alessandra Maccabeo (1), Enrico Matteoni (1), Sara Cabras (1), Francesca Palumbo (1),

Antonio Canosa (1,2), Rosario Vasta (1), Emilio Minerva (1), Giorgio Pellegrino (1), Fulvia Ribolla (3),

Michela Bellocchia (3), Giuseppe Tabbia (3), Paolo Solidoro (3), Marco Michele Bardessonno (3),

Cristina Moglia (1,2), Andrea Calvo (1,2), Adriano Chiò (1,2), Umberto Manera (1,2)

1. ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Torino, Turin, Italy

2. S.C. Neurologia 1U, AOU Città della Salute e della Scienza of Torino, Turin, Italy

3. S.C. Pneumologia U, AOU Città della Salute e della Scienza of Torino, Turin, Italy

PO003 Palliative Home Visits And Survival In ALS: Insights From A Tertiary ALS Centre

Ana Kuder (1,2), Sara Kadenšek (1,2), Martin Kavcic (1,2), Lea Leonardis (1,2), Blaž Koritnik (1,2)

1. Institute of Clinical Neurophysiology, University Medical Centre Ljubljana, Ljubljana, Slovenia

2. Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

PO004 Safety And Efficacy Of Tofersen In SOD1-Associated ALS: Real-World Data From The Valencian Community

Ana Merchán Cabanillas (1), Pilar Helena García Casanova (1), Carmina Díaz Marín (2),

Laura Lorente Gómez (3), Rosa María Vilar Ventura (4), Juan Francisco Vázquez Costa (1,5)

1. Hospital Universitario y Politécnico La Fe, Valencia, Spain

2. Hospital General Universitario Doctor Balmis, Alicante, Spain

3. Hospital General Universitario de Elche, Alicante, Spain

4. Hospital General Universitario de Castellón, Castellón, Spain

5. Center for Biomedical Network Research in Rare Diseases (CIBERER), Valencia, Spain

PO005 Co-Designing A Psychoeducational Intervention For Complex Symptoms In ALS/FTD: Family Carers' Experiences And Needs

Ana Paula Trucco (1), Tamara Backhouse (1), Eneida Mioshi (1,2)

1. University of East Anglia, Norwich, United Kingdom

2. Ativar Consulting Ltd, Norwich, United Kingdom

P0006 Role Of Personalized Nutritional Support In The Short-Term Clinical And Metabolic Evolution Of Amyotrophic Lateral Sclerosis

Rachele Piras (1), Ares Pavesi (1), Francesca Dondo (2), Andrea Sini (1), Paola Mariani (1), Paolo Magni (2), Christian Lunetta (1)

- 1. ISTITUTI CLINICI SCIENTIFICI MAUGERI IRCCS, DIPARTIMENTO DI NEURORIABILITAZIONE, Milano, Italy*
- 2. Università degli Studi di Milano Statale, Milano, Italy*

P0007 The ALS Home Health And Durable Medical Equipment Medical Standard Expert Consensus Guideline Task Force

Björn Oskarsson (1), Ileana Howard (2), Sara Feldman (3), Jill Goslinga (4), Max Greene (5), Megan Allyse (1), Joyce Khowdee (6), Dominic Ferrey (7), Janice Bell (8), Orla Tonkykh (8), Jessica Famula (8), Heather Young (8)

- 1. Mayo Clinic Florida, Jacksonville, United States*
- 2. Seattle VA, Seattle, United States*
- 3. Temple University, Philadelphia, United States*
- 4. UCSF, San Francisco, United States*
- 5. Stanford University, Palo Alto, United States*
- 6. Loma Linda University, Loma Linda, United States*
- 7. UCSD, San Diego, United States*
- 8. UCD, Sacramento, United States*

P0008 Performance Of Three Generic Fatigue Questionnaires In Amyotrophic Lateral Sclerosis

*Camilla Wohnrade, Anastasia Sarikidi, Mahsa Soltani, Bogdan Bjelica, Susanne Petri
Hannover Medical School, Hannover, Germany*

P0009 Cognitive Dysfunction Is Associated With An Underestimation Of Respiratory Function In ALS

*Inês Alexandra Ribeiro Lopes Alves, Horácio Jesus, Diana Lopes, Sara Simão, Ana Catarina Leitão, Ana Catarina pronto-Laborinho, Vasco Conceição, Miguel Oliveira Santos, Mamede De Carvalho
Institute of Physiology, MUHCRI and Centro de Estudos Egas Moniz. Faculty of Medicine, University of Lisbon, Lisbon, Portugal., Lisbon, Portugal*

P0010 Sleep Disturbances And Respiratory Dysfunction In Amyotrophic Lateral Sclerosis

Kato Bracaval (1,2), Joke De Vocht (1,2), Fouke Ombelet (1,2), Laura Van Den Bulcke (3), Anne-Marie Peeters (3), Boris Deleu (2), Bart Vrijisen (4), Alexandros Kalkanis (4,5), Bertien Buyse (4,5), Dries Testelmans (4,5), Maarten Van Den Bossche (3,6), Philip Van Damme (1,2)

- 1. Laboratory of Neurobiology - Center for Neuroscience - VIB-KU Leuven, Leuven, Belgium*
- 2. Department of Neurology - UZ Leuven, Leuven, Belgium*
- 3. Geriatric Psychiatry - University Psychiatric Center - KU Leuven, Leuven, Belgium*
- 4. Department of Respiratory Diseases - Leuven University Center for Sleep and Wake Disorders - UZ Leuven, Leuven, Belgium*
- 5. Respiratory Disease and Thoracic Surgery (BREATH) - Department of Chronic Diseases and Metabolism - KU Leuven, Leuven, Belgium*
- 6. Neuropsychiatry - Department of Neurosciences - Leuven Brain Institute - KU Leuven, Leuven, Belgium*

P001 PhysioAssess: Use Of Standardized Assessments In Patients With Neuromuscular Diseases: Does This Support More Targeted Treatment?

Kirsten Großmann (1,2), Maj-Britt Bartels (2), Maike Breede (1), Anna Magdalena Hagemann (1), Greta Korte (1), Chelsea Walter (1,2), Janina Von Der Gablentz (2), Julia Meyer (2), Bernhard Elsner (1), Isabelle Buchholz (2), Julian Großkreutz (2)

1. Institute of Health Sciences, University of Lübeck, Lübeck, Germany

2. Precision Neurology of Neuromuscular Diseases, University of Lübeck, Lübeck, Germany

P0012 A Two Year Experience Of Tofersen Treatment In Patients With SOD1 ALS

Magdalena Kuzma-Kozakiewicz (1), Malgorzata Dorobek (2), Anna Gruszczak (2), Justyna Zielinska (2), Halina Bartosik-Psujek (3), Tomasz Garbacz (3), Kamila Zur-Wyrozumska (4,5), Dariusz Koziorowski (6), Anna Dutkiewicz (7), Ewa Krzyzanowska (7), Blazej Poczatek (8), Anetta Lasek-Bal (9,10), Agata Migacz (10,9), Sebastian Student (11,12), Magdalena Koszewicz (13,14), Jakub Ubysz (13,14), Krzysztof Szabat (15)

1. Department of Neurology, Medical University of Warsaw, Warsaw, Poland

2. National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland

3. Department of Neurology, Medical College of Rzeszow University, Rzeszów, Poland

4. Centre for Innovative Medical Education, Jagiellonian University Medical College, Krakow, Poland

5. Department of Neurology, J. Dietl Specialist Hospital in Krakow, Krakow, Poland

6. Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Poland

7. Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland

8. Department of Neurology, Józef Strus Multi-Specialist Municipal Hospital, Poznan, Poland

9. Department of Neurology, Faculty of Health Sciences in Katowice, Medical University of Silesia in Katowice, Katowice, Poland

10. Department of Neurology, Upper-Silesian Medical Centre, Katowice, Poland

11. Department of Engineering and Systems Biology, Faculty of Automatic Control, Electronics and Computer Science, Silesian University of Technology, Gliwice, Poland

12. Biotechnology Centre, Silesian University of Technology, Gliwice, Poland

13. Clinical Neurophysiology Laboratory, University Centre of Neurology and Neurosurgery, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland

14. Clinical Department of Neurology, University Centre of Neurology and Neurosurgery, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland

15. Department of Neurology, 7th Naval Hospital, Gdansk, Poland

P0013 Venous Thromboembolism In Patients With Amyotrophic Lateral Sclerosis: A Descriptive Study From A Multidisciplinary ALS Unit

Maria Hernandez Barral (1), Maria Alejandra Castillo Ramirez (2), M^a Antonia Gomez Mendideta (2), Ana Santiago Recuerda (2), Maria Martinez Redondo (2), Yolanda Martinez Abad (2), Maria Varela Cerdeira (3), Rosario Urbez Mir (4), Javier Mascias Cadavid (1)

1. Department of Neurology and Stroke Center. Multidisciplinary ALS Unit. Neurology and Cerebrovascular disease group. Neuroscience Area Hospital La Paz Institute for Health Research-IdiPAZ (La Paz University Hospital. Universidad Autónoma de Madrid), Madrid, Spain

2. Pneumology Department. Multidisciplinary ALS Unit. La Paz University Hospital, Madrid, Spain
3. Palliative Care Department. Multidisciplinary ALS Unit. La Paz University Hospital, Madrid, Spain
4. Rehabilitation and Physical Therapy Department. Multidisciplinary ALS Unit. La Paz University Hospital, Madrid, Spain, Madrid, Spain

**P0014 Frequency And Causes Of Hospitalization In Patients With ALS:
A Retrospective Study From A Chilean Public Hospital**

Maria Jose Cuello (1), Bastian Navarrete (1), Fabian Rubilar (2), Azucena Salvatierra (1)

1. Hospital Carlos Van Buren, Valparaiso, Chile

2. Advanced Center for Electrical and Electronic Engineering, Valparaiso, Chile

**P0015 Agile ALS Care: A Dynamic Resource Allocation Model For Multidisciplinary ALS
Management In Resource-Constrained Healthcare Settings**

Maria Jose Cuello (1), Fabian Rubilar (2), Azucena salvatierra (1)

1. Hospital Carlos Van Buren, Valparaiso, Chile

2. Advanced Center for Electrical and Electronic Engineering, Valparaiso, Chile

**P0016 Dextromethorphan/Quinidine For Bulbar Symptom Control In ALS Using Remote
ALSFRS-R Self-Assessments**

Marie-Thérèse Henke (1,2), Susanne Spittel (2,1), Torsten Grehl (3), Ute Weyen (4),

Annekathrin Rödiger (5,6), Susanne Petri (7,8), Patrick Weydt (9,10), Bettina Meike Görlicke (11),

Hanna Lapp (12), Julian Grosskreutz (13), Paul Lingor (14,15), Martin Regensburger (16), Uta Smesny (5),

Robert Steinbach (5), Sarah Bernsen (9,10,1), André Maier (1), Thomas Meyer (1,2)

1. Charité - Universitätsmedizin Berlin, Center for ALS and other Motor Neuron Disorders, Berlin, Germany

2. APST Research GmbH, Berlin, Germany

3. Alfried Krupp Krankenhaus, Department of Neurology, Center for ALS and other Motor Neuron Disorders, Essen, Germany

4. Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Department of Neurology, Center for ALS and other Motor Neuron Disorders, Bochum, Germany

5. Universitätsklinikum Jena, Department of Neurology, Jena, Germany

6. Jena University Hospital, ZSE, Zentrum für Seltene Erkrankungen, Jena, Germany

7. Diakovere Henriettenstift and Friederikenstift, Department of Neurology, Hannover, Germany

8. Medizinische Hochschule Hannover, Department of Neurology, Hannover, Germany

9. Bonn University, Department for Neurodegenerative and Neuromuscular Disorders, Bonn, Germany

10. Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Research Site Bonn, Bonn, Germany

11. Universitätsmedizin Göttingen, Department of Neurology, Göttingen, Germany

12. Technische Universität Dresden, University Hospital Carl Gustav Carus, Department of Neurology, Dresden, Germany

13. Universitätsmedizin Schleswig-Holstein, Campus Lübeck, Department of Neurology, Lübeck, Germany

14. Technical University of Munich, Klinikum rechts der Isar, Department of Neurology, Munich, Germany

15. Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Research Site Munich, Munich, Germany

16. Universitätsklinikum Erlangen, Center for Motor Neuron Disorders and HSP, Erlangen, Germany

PO017 Sleep-Disordered Breathing And Non-Invasive Ventilation In ALS: A Preliminary Study Of Clinical And Phenotypic Variability

Martin Kavcic (1,2), Sara Kadensek (1,2), Ana Kuder (1,2), Blaz Koritnik (1,2), Lea Leonardis (1,2)
1. Institute for Clinical Neurophysiology, University Medical Centre, Ljubljana, Slovenia
2. Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

PO018 Patient-Reported Feasibility Of Orodispersible Riluzole In The Presence Of Sialorrhoea

Matteo Zanovello, Federica Paredi, Giacomo Maria Minicuci, Gianni Soraru'
University of Padova, Padova, Italy

PO019 ERN EURO-NMD Patient Activities: A Focus On Motor Neuron Diseases

Michelangelo Mancuso (1,2), Cecilia Carlesi (1), Francesca Bianchi (1), Gabriele Siciliano (2)
1. Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
2. University of Pisa, Pisa, Italy

PO020 Cross-Cultural Validation Of The Italian Version Of The "Clinical Assessment Of Dysphagia In Neurodegeneration" Tool

Micol Castellari (1), Ares Pavesi (1), Sara Debue (1), Valentina Rivolta (1), Davide Mongelli (2), Rosanna Falcone (2), Manuela Locatelli (3), Sara Pezzotta (3), Elena Verzi (3), Carlo Robotti (4), Emilia Picciola (2), Nicole Pizzorni (5), Kalliopi Marinou (3), Brigida Minafra (2), Christian Lunetta (4)
1. Istituti Clinici Scientifici Maugeri IRCCS, Dipartimento di neuroriabilitazione, Milan, Italy
2. Istituti Clinici Scientifici Maugeri IRCCS, Dipartimento di neuroriabilitazione, Bari, Italy
3. Istituti Clinici Scientifici Maugeri IRCCS, Dipartimento di neuroriabilitazione, Lissone, Italy
4. Istituti Clinici Scientifici Maugeri IRCCS, Dipartimento di neuroriabilitazione, Milano, Italy
5. Università Statale di Milano, Milano, Italy

PO021 The Inclusion Of Social Determinants Of Health Enhances The Precision Of Clinical Outcomes In Real World Data _ PRECISION ALS

Miriam Galvin (1), Sarah Azzezene (1), Mark Heverin (1), Ronan Mcdonnell (2)
1. Trinity College Dublin, Dublin, Ireland
2. ADAPT Centre, Dublin, Ireland

PO022 Revisiting Prognosis In ALS: Does Gastrostomy Modify ENCALs Survival Predictions?

Alice Girbal, Pereira Bruno, Annaick Desmaison, Nathalie Guy
chu de clermont ferrand, Clermont Ferrand, France

PO023 Radiologically Inserted Gastrostomy In Advanced Amyotrophic Lateral Sclerosis: Clinical Outcomes Within A Multidisciplinary Palliative Care Model

Pilar Carbajo Gullon (1), Yolanda Moran Benito (2), Laura Urraco Nieto (3), M^a Antonia Gomez Mendieta (4), Ana Santiago Recuerda (4), Alberto Alonso Babaro (5), Maria Varela Cerdeira (5), Javier Mascias Cadavid (6), Arturo Lisbona Catalan (7)
1. Case Manager Nurse. Multidisciplinary ALS Unit. La Paz University Hospital, Madrid, Spain
2. Case Manager Nurse. Multidisciplinary ALS Unit. Health Care Nurses Research Group. La Paz Institute for Health Research-IdiPAZ. La Paz University Hospital., Madrid, Spain

3. General Practitioner. Getafe University Hospital, Madrid, Spain
4. Pneumology Department. Multidisciplinary ALS Unit. La Paz University Hospital, Madrid, Spain
5. Palliative Care Department. Multidisciplinary ALS Unit La Paz University Hospital, Madrid, Spain
6. Department of Neurology and Stroke Center. Multidisciplinary ALS Unit. Neurology and Cerebrovascular disease group. Neuroscience Area Hospital La Paz Institute for Health Research-IdiPAZ (La Paz University Hospital. Universidad Autónoma de Madrid), Madrid, Spain
7. Endocrinology Department. Multidisciplinary ALS Unit. La Paz University Hospital, Madrid, Spain

P0024 Day-To-Day Temperature Rise Triggers Amyotrophic Lateral Sclerosis Mortality: A Case-Crossover Study

Robert Steinbach (1), Maximilian Dimitrov (1), Benjamin Ilse (1), Annkathrin Rödiger (1,2), Uta Smesny (1), Julian Grosskreutz (1,3,4), Florian Rakers (1)

1. Department of Neurology, Jena University Hospital, Jena, Germany
2. Center for Rare Diseases, Jena University Hospital, Jena, Germany
3. Precision Neurology of Neuromuscular and Motor Neuron Diseases, Luebeck, Germany
4. Cluster for Precision Medicine in Inflammation, Universities of Kiel and Luebeck, Luebeck, Germany

P0025 User Expectations Of Eye-Control Glasses For Complex Power Wheelchairs In People With Amyotrophic Lateral Sclerosis: A Multicenter Observational Study

Ronja Schiemann (1), André Maier (2), Thorsten Grehl (3), Hanna Sophie Lapp (4), Patrick Weydt (5,6), Sarah Bernsen (5), Susanne Petri (7), Bogdan Bjelica (8), Rea Lumi (8), Ute Weyen (9), Annkathrin Rödiger (10,11), Uta Smesny (10), Robert Steinbach (10), Anne-Dorte Sperfeld (12), Dagmar Kettemann (2), Jenny Norden (2), Thomas Meyer (1,2), Susanne Spittel (1,2)

1. Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany
2. Charité – Universitätsmedizin Berlin, Center for ALS and other Motor Neuron Disorders, Berlin, Germany
3. Alfried Krupp Krankenhaus, Center for ALS and other Motor Neuron Disorders, Essen, Germany
4. Technische Universität Dresden, University Hospital Carl Gustav Carus, Dresden, Germany
5. Bonn University, Department for Neurodegenerative Disorders and Gerontopsychiatry, Bonn, Germany
6. DZNE, Deutsches Zentrum für Neurodegenerative Erkrankungen, Research Site Bonn, Bonn, Germany
7. Diakovere Henriettenstift, Ambulanz für ALS, Hannover, Germany
8. Hannover Medical School, Department of Neurology, Hannover, Germany
9. Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Center for ALS and other Motor Neuron Disorders, Bochum, Germany
10. Jena University Hospital, Department of Neurology, Jena, Germany
11. Jena University Hospital, ZSE, Zentrum für Seltene Erkrankungen, Jena, Germany
12. Sächsisches Krankenhaus für Psychiatrie und Neurologie Altscherbitz, Department of Neurology, Altscherbitz, Germany

P0026 Motor Performances Of Patients With Amyotrophic Lateral Sclerosis Using Different Riluzole Formulations: A “real-World” Longitudinal Analysis

Rosaria Notariale (1), Maria Agnese Pirozzi (1), Roberta Pepe (2), Minoo Sharbafshaaer (1), Carla Passaniti (1), Alessandro Tessitore (1,2), Francesca Trojsi (1,2)

1. Neurology Unit, First Division of Neurology and Neuro-physiopathology, AOU University of Campania “Luigi Vanvitelli”, Naples, Italy, Napoli, Italy

2. Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy, Napoli, Italy

PO027 Clinical Characteristics, Social Impact And Caregiving Burden In Locked-In And Complete Locked-In Syndrome ALS Patients

Rossella Spataro (1), Sofia Tomasello (1), Giorgio Mandalà (1), Dorothée Lulé (2), Vincenzo La Bella (3)

1. Neurorehabilitation Unit, Villa delle Ginestre Hospital, ASP Palermo, Palermo, Italy

2. Department of Neurology, Ulm University, Ulm, Germany

3. ALS Clinical Research Center, Department of Biomedicine, Neuroscience and Advanced Diagnostics, ALS Clinical Research Center, University of Palermo, Palermo, Italy

PO028 Italy's First International ALS Online Seminar Series: SLA In Chiaro By Associazione ConSLancio Onlus

Rossella Spataro (1,2), Tiziana Petrozziello (3), Lucilla Vestito (3), Michele Messmer Uccelli (3),

Roberta Schellino (3), Marina Boido (3), Silvia Pozzi (3), Marco Peviani (3), Daisy Sproviero (3),

Vittoria Lombardi (3), Monica Consonni (3), Jessica Mandrioli (3), Fabiola De Marchi (3),

Elena Grossini (3), Silverio F Conte (3), Nicoletta De Rossi (3), Andrea Zicchieri (3)

1. Neurorehabilitation Unit, Villa delle Ginestre Hospital, ASP Palermo, Palermo, Italy

2. Associazione conSLancio Onlus, Terracina (LT), Italy

3. Associazione conSLancio Onlus, Terracina (lt), Italy

PO029 Treatment Response To Tofersen In Respiratory Onset Amyotrophic Lateral Sclerosis And A Variant Of Unknown Significance In SOD1

Sean Willemse (1), Koen Demaegd (1), Wouter Koole (2), Ruben Van Eijk (1,3), Wouter Van Rheenen (1), Jan Veldink (1), Leonard Van Den Berg (1), Michael Van Es (1)

1. Department of Neurology, UMC Utrecht, Utrecht, The Netherlands

2. Department of Clinical Genetics, UMC Utrecht, Utrecht, The Netherlands

3. Biostatistics & Research Support, Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands

PO030 Longitudinal Real-World Evaluation Of Remote Digital ALSFRS-R Self-Assessment Using The ALS App

Senthil Subramanian (1), Christoph Münch (1,2), Torsten Grehl (3), Ute Weyen (4),

Dagmar Kettemann (2), Robert Steinbach (5,6), Annkathrin Rödiger (5,6), Julian Grosskreutz (7),

Susanne Spittel (1,2), Thomas Meyer (1,2)

1. APST Research, Berlin, Germany

2. Department of Neurology, Center for ALS and other Motor Neuron Disorders, Charité – Universitätsmedizin Berlin, Berlin, Germany

3. Department of Neurology, Essen, Germany

4. Department of Neurology, Center for ALS and other Motor Neuron Disorders, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Bochum, Germany

5. Department of Neurology, Jena University Hospital, Jena, Germany

6. ZSE, Zentrum für Seltene Erkrankungen, Jena University Hospital, Jena, Germany

7. Department of Neurology, Universitätsmedizin Schleswig-Holstein, Campus Lübeck, Lübeck, Germany

PO031 Functional Decline Vs. Perceived Burden: A Domain-Specific Analysis Of ALSFRS-R And ALSAQ-40

Yolanda Moran Benito (1), Javier Mascias Cadavid (2), Maria Hernandez Barral (2), Maria Varela Cerdeira (3), Teresa Salas Campos (4), Lara Martinez Gimeno (5), Gema Escobar Aguilar (5), Mar Zulueta Egea (5)

- 1. Case Manager Nurse. Multidisciplinary ALS Unit. Health Care Nurses Research Group. La Paz Institute for Health Research-IdiPAZ. La Paz University Hospital, Madrid, Spain*
- 2. Department of Neurology and Stroke Center. Multidisciplinary ALS Unit. Neurology and Cerebrovascular disease group. Neuroscience Area Hospital La Paz Institute for Health Research-IdiPAZ (La Paz University Hospital. Universidad Autónoma de Madrid), Madrid, Spain*
- 3. Palliative Care Department. Multidisciplinary ALS Unit. La Paz University Hospital, Madrid, Spain*
- 4. Neuropsychologist. Multidisciplinary ALS Unit. La Paz University Hospital, Madrid, Spain*
- 5. Universidad Pontificia de Comillas., Madrid, Spain*

PO032 Home-Based Non-Sedated Tracheostomy Tube Replacement In Patients With Amyotrophic Lateral Sclerosis: A Patient-Centered Multidisciplinary Care Model

Yolanda Moran Benito (1), M^a Antonia Gomez Mendieta (2), Ana Santiago Recuerda (2), Elena Corpa Rodriguez (3), Baltasar Liebert Alvarez (3), Iñigo Royo Crespo (3), Pilar Carbajo Gullon (4), Maria Varela Cerdeira (5), Javier Mascias Cadavid (6)

- 1. Case Manager Nurse. Multidisciplinary ALS Unit. Health Care Nurses Research Group. La Paz Institute for Health Research-IdiPAZ. La Paz University Hospital, Madrid, Spain*
- 2. Pneumology Department. Multidisciplinary ALS Unit. La Paz University Hospital, Madrid, Spain*
- 3. Thoracic Surgery Department. La Paz University Hospital, Madrid, Spain*
- 4. Case Manager Nurse. Multidisciplinary ALS Unit. La Paz University Hospital, Madrid, Spain*
- 5. Palliative Care Department. Multidisciplinary ALS Unit. La Paz University Hospital, Madrid, Spain*
- 6. Department of Neurology and Stroke Center. Multidisciplinary ALS Unit. Neurology and Cerebrovascular disease group. Neuroscience Area Hospital La Paz Institute for Health Research-IdiPAZ (La Paz University Hospital. Universidad Autónoma de Madrid), Madrid, Spain*

PO033 The Socioeconomic Resilience Phenomenon: How Income Modulates Functional Impact In ALS

Yolanda Moran Benito (1), Maria Hernandez Barral (2), Javier Mascias Cadavid (2), Francisco Javier Rodriguez De Rivera Garrido (2), Teresa Salas Campos (3), Saul Marin Esteban (3), Maria Varela Cerdeira (4), Mar Zulueta Egea (5), Gema Escobar Aguilar (5)

- 1. Case Manager Nurse. Multidisciplinary ALS Unit. Health Care Nurses Research Group. La Paz Institute for Health Research-IdiPAZ. La Paz University Hospital, Madrid, Spain*
- 2. Department of Neurology and Stroke Center. Multidisciplinary ALS Unit. Neurology and Cerebrovascular disease group. Neuroscience Area Hospital La Paz Institute for Health Research-IdiPAZ (La Paz University Hospital. Universidad Autónoma de Madrid), Madrid, Spain*
- 3. Neuropsychologist. Multidisciplinary ALS Unit. La Paz University Hospital, Madrid, Spain*
- 4. Palliative Care Department. Multidisciplinary ALS Unit. La Paz University Hospital, Madrid, Spain*
- 5. Universidad Pontificia de Comillas., Madrid, Spain*

PO034 Determinant Factors Of Quality Of Life In Amyotrophic Lateral Sclerosis Within The Context Of Humanized Care: From Evidence To Experience

Yolanda Moran Benito (1), Maria Hernandez Barral (2), Teresa Salas Campos (3), Saul Marin Esteban (3), Pilar Carbajo Gullon (4), Rafael Jenaro Martinez Marin (2), Javier Mascias Cadavid (2), Lara Martinez Gimeno (5)

1. Case Manager Nurse. Multidisciplinary ALS Unit. Health Care Nurses Research Group. La Paz Institute for Health Research-IdiPAZ. La Paz University Hospital., Madrid, Spain
2. Department of Neurology and Stroke Center. Multidisciplinary ALS Unit. Neurology and Cerebrovascular disease group. Neuroscience Area Hospital La Paz Institute for Health Research-IdiPAZ (La Paz University Hospital. Universidad Autónoma de Madrid), Madrid, Spain
3. Neuropsychologist. Multidisciplinary ALS Unit. La Paz University Hospital, Madrid, Spain
4. Case Manager Nurse. Multidisciplinary ALS Unit. La Paz University Hospital, Madrid, Spain
5. Universidad Pontificia de Comillas., Madrid, Spain

PO035 Flail Leg Syndrome: A Case Report

Zoran Vukojevic, Aleksandra Dominovic Kovacevic, Sanja Grgic, Srdjan Mavija
Clinic for Neurology, University Clinical Centre of Republic of Srpska, 78000 Banja Luka, Bosnia and Herzegovina

BIOMARKERS (included in the posters session II)

PO036 Protein-Based Patient Stratification In ALS Using Targeted Proteomics

Lina Al-Hanbali (1), Inci S Aksoylu (1), Louisa Azizi (2), Sofia Bergström (1), Linn Öijerstedt (2,3), Peter Nilsson (1), Fredrik Edfors (1), Caroline Ingre (2,3), Anna Månberg (1)

1. Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden
2. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
3. Department of Neurology, Karolinska University Hospital, Stockholm, Sweden

PO037 A MiRNA Signature In The Tear Fluid Of Patients With ALS

Antonia Franziska Demleitner (1), Akile Ebrar Mirat-çördük (1), Lea Helena Kunze (1), Lucas Caldi Gomes (1), Philipp Springer (1), Lara Wenz (1), Philipp Jie Müller (1), Paul Lingor (1,2,3)

1. TUM University Hospital, Munich, Germany
2. German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
3. Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

PO038 Tau Blood Biomarkers Capture Disease Burden But Not Progression Dynamics In Amyotrophic Lateral Sclerosis

Bernat Bertran Recasens (1,2), Paula Ortiz-Romero (3,4), Ferran Lugo Hernández (3), Sergio Vidal Notari (1,2), Marina De Diego-Osaba (3,4), Helena Blasco-Forniés (3,4), Esther Jiménez-Moyano (3,4), Mireia Llop Trujillano (1), Javier Torres-Torronteras (3,4), Marta Del Campo (3,4), Marc Suárez-Calvet (3,4,5), Miguel Ángel Rubio Pérez (1,2)

1. ALS/Motor Neuron Diseases Unit, Neurology Department, Hospital del Mar, Barcelona, Spain

2. *Systems Neurology and Neurotherapies Research Group, Neurosciences Program, Hospital del Mar Research Institute, Barcelona, Spain*
3. *BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain*
4. *Hospital del Mar Research Institute, Barcelona, Spain*
5. *Neurology Department, Barcelona, Spain*

PO039 Exploratory Endpoints From An Open-Label Phase 2a Study Of Fasudil In Amyotrophic Lateral Sclerosis

Claudia Pena (1), Casey Barker (1), Allison Grossberg (1), Ibrahim Mian (2), Sabrina Williams (2), Thomas Macallister (2), Daniel Linseman (1)

1. *University of Denver, Denver, United States*
2. *Woolsey Pharmaceuticals, New York, United States*

PO040 Biomarkers Of Inflammasome Activation And Pyroptosis In Amyotrophic Lateral Sclerosis

Denis Shevchuk (1), Inna Dolzhikova (2), Anna Kovyrshina (2), Maria Zakharova (1)

1. *Russian Center of Neurology and Neurosciences, Moscow, Russia*
2. *N. F. Gamaleya National Research Center, Moscow, Russia*

PO041 Characterising Neuro-Specific And Inflammatory Biomarkers To Define The Role Of The Immune System In ALS Progression

Elizabeth Lin (1), Renato Santos (2), Geena John (1), Ammar Al-Chalabi (2), Alfredo Iacoangeli (2,3), Andrea Malaspina (1,4,5)

1. *University College London, Institute of Neurology, London, United Kingdom*
2. *King's College London, London, United Kingdom*
3. *NIHR Maudsley Biomedical Research Centre (BRC), London, United Kingdom*
4. *UCL Queen Square Motor Neuron Disease Centre, London, United Kingdom*
5. *National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, United Kingdom*

PO042 Proteomic Profiling Of Tetraspanin-Captured Extracellular Vesicles Identifies Prognostic Biomarker Candidates In ALS

Elizabeth R Dellar (1), Iolanda Vendrell (2), Georgina Berridge (2), Roman Fischer (2), Kevin Talbot (1,3), Martin R Turner (1), Alexander G Thompson (1)

1. *Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom*
2. *Target Discovery Institute/Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom*
3. *Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, Oxford, United Kingdom*

P0043 Blood Monocyte Mitochondrial Morphology And Function In ALS: A Potential Biomarker For Clinical Stratification And Disease Monitoring?

Erik Winiarski (1,2), Laura Martínez-Palma (1,2), Valentina Colistro (3), Andreína Burgini (4), Natalia Trias (4), Daniela Lens (4), Federico Lecumberry (5), Adriana Cassina (6), Patricia Cassina (1)

1. Departamento de Histología y Embriología, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay

2. Centro de Esclerosis Lateral Amiotrófica del Uruguay, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay

3. Departamento de Métodos Cuantitativos, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay

4. Laboratorio de Citometría de Flujo, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay

5. Departamento de Procesamiento de Señales del Instituto de Ingeniería Eléctrica, Facultad de Ingeniería, Universidad de la República, Montevideo, Uruguay

6. Departamento de Bioquímica, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay

P0044 MicroRNA Biomarkers For ALS: From Systems Biology To Patient Derived Cells

Eva P. Cuevas (1,2), Enrique Madruga (1,2), Carmen Gil (1,2), Ana Martinez (1,2)

1. Centro de Investigaciones Biológicas "Margarita Salas"-CSIC, Madrid, Spain

2. Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain

P0045 Investigating Network-Based ALS Subtypes Using Motor And Cognitive Event-Related Potentials

Gabriel Rodrigues Palma (1), Eva Woods (1), Meher Sabharwal (1), Sanya Dalal (1),

Narin Suleyman (1,2), Serena Plaitano (3), Marjorie Metzger (3), Leah Nash (3), Eileen Giglia (3),

Niall Pender (3,4), Stefan Dukic (3,5), Orla Hardiman (3,2), Roisin Mcmackin (1,3)

1. Discipline of Physiology, School of Medicine, Trinity College, The University of Dublin, Ireland

2. Department of Neurology, Beaumont Hospital, Dublin, Ireland

3. Academic Unit of Neurology, School of Medicine, Trinity College, The University of, Dublin, Ireland

4. Department of Psychology, Beaumont Hospital, Dublin, Ireland

5. Department of Neurology, University Medical Centre Utrecht Brain Centre, Utrecht University, Utrecht, Netherlands Antilles

P0046 Plasma NfL, GFAP, And PTAU181 Capture Non-Overlapping Biological Processes In Amyotrophic Lateral Sclerosis

Gianmaria Senerchia, Valentina Virginia Iuzzolino, Myriam Spisto, Lucia Aruta, Fabiana Panico, Daniela Terracciano, Raffaele Dubbioso

Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples, Napoli, Italy

P0047 Non-Coding RNA Profiling In Serum, CSF, Olfactory Mucosa, Tears And Skin Identifies Novel Molecular Signatures In Amyotrophic Lateral Sclerosis And Frontotemporal Dementia

Giorgia Farinazzo (1,2), Carlotta Tiranzoni (1), Iliaria Linda Dellarole (3), Arianna Ciullini (3), Federico Cazzaniga (3), Linda Maldera (2,4), Giorgio Gelosa (5), Vittoria Aprea (5), Giacomina Rossi (5), Federico Verde (6), Andrea Giordano (7), Nilo Riva (7), Paola Caroppo (5), Maria Vizziello (7), Eleonora Dalla Bella (7), Fabio Moda (3,8), Erika Salvi (9,4), Stefania Marcuzzo (1,10)

1. Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

2. PhD Program in Bioengineering, Department of Electronics, Information and Bioengineering (DEIB), Politecnico di Milano, Milan, Italy

3. SSD Laboratory Medicine – Laboratory of Clinical Pathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

4. Computational multi-Omics of Neurological Disorders (MIND) Lab, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

5. Neurology 8 - Dementias and Degenerative Diseases of CNS Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

6. Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy

7. Neuroalgology and Motor Neuron Disease Centre, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

8. Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy

9. Data Science Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

10. Brain-Targeted Nanotechnologies (BrainS) Lab, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

P0048 Osteopontin As An Independent Prognostic Biomarker In Amyotrophic Lateral Sclerosis

Giulia Donelli (1), Elisabetta Zucchi (2), Iliaria Martinelli (2), Giulia Gianferrari (3,2), Andrea Ghezzi (3,2), Nicolò Mesini (1), Roberta Bedin (1), Jessica Mandrioli (1,2,4)

1. Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy

2. Department of Neurosciences, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy

3. Neuroscience PhD Program, University of Modena and Reggio Emilia, Modena, Italy

4. Centre for Neuroscience and Nanotechnology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy

P0049 A Comparison Of Speaking Rate Estimation Methods For ALS Speech

Vincent Aubanel (1,2), Thayabaran Kathiresan (1,2), Melanie Leitner (3), Gustavo Noffs (1,2), Adam P Vogel (1,2)

1. The University of Melbourne, Melbourne, Australia

2. Redenlab, Melbourne, Australia

3. Accelerating NeuroVentures, Boston, United States

P0050 Comprehensive Serum Proteomic Profiling Of MND Subtypes Interrogating Samples From The MND-SMART Platform Trial Using NUCleic Acid-Linked Immuno-Sandwich (NULISA) Technology

Hatice Bozkurt (1,2,3,4), Amy Stenson (1,2,3), Paolo Cucurachi (1,2,3), Judith Newton (1,2,3), Paul Baxter (1,2,3,4), Karen Burr (1,2,3,4), Amanda Heslegrave (5,6), Owen J Swann (5,6), Barbara Fernandes Gomes (5,6), Rachel Mulvaney (5,6), Henrik Zetterberg (5,6,7,8,9), David P. J. Hunt (1,2,3,4), Bhuvaneish T Selvaraj (1,2,3,4), Siddharthan Chandran (1,2,3,4,10), Suvankar Pal (1,2,3,4,10)

- 1. Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, United Kingdom*
- 2. Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, United Kingdom*
- 3. Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh, United Kingdom*
- 4. UK Dementia Research Institute, University of Edinburgh, Edinburgh, United Kingdom*
- 5. Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, United Kingdom*
- 6. UK Dementia Research Institute, University College London, London, United Kingdom*
- 7. Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China*
- 8. Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, United States*
- 9. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden*
- 10. MRC Centre of Research Excellence in Clinical Trial Innovation, London, United Kingdom*

P0051 Blood-Based Biomarkers Used As Outcome Measures In Interventional Clinical Trials For Motor Neuron Disease: A Systematic Literature Review Protocol And Preliminary Data

Hatice Bozkurt (1,2,3,4), Arushi Rastogi (5), Rebecca Tan (5), Vrishali Shetty (5), Joel Soul (5), Joshua Soul (5), Neeharika Dasari (5), Richa Kulkarni (5), Anish Subramaniam (5), Bhuvaneish T Selvaraj (1,2,3,4), David P. J. Hunt (1,2,3,4), Siddharthan Chandran (1,2,3,4), Suvankar Pal (1,2,3,4)

- 1. Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, United Kingdom*
- 2. Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, United Kingdom*
- 3. Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh, United Kingdom*
- 4. UK Dementia Research Institute, University of Edinburgh, Edinburgh, United Kingdom*
- 5. University of Edinburgh Medical School, Edinburgh, United Kingdom*

PO052 Anchoring ALS Prognosis: Neurofilament Light Chain Outperforms Inflammatory, Metabolic And CNS Barrier Biomarkers In The METABALS Cohort

Helene Blasco (1), Hugo Alarcán (1), Pierre-François Pradat (2), JULIEN Cassereau (3), Alain Destee (4), PHILIPPE Couratier (5), JEAN PHILIPPE Neau (6), MARIE CELINE Fleury (7), Philippe Corcia (1), Christian Andres (1)

1. *ibrain, Tours, France*
2. *APHP, Paris, France*
3. *chu angers, Angers, France*
4. *CHU LILLE, Lille, France*
5. *chu limoges, Limoges, France*
6. *CHU POITIERS, Poitiers, France*
7. *CHU STRASBOURG, Strasbourg, France*

PO053 Learning A Distance For The Clustering Of Patients With Amyotrophic Lateral Sclerosis

Guillaume Tejedor (1,2), Helene Blasco (3,4)

1. *ibrain, Tours, France*
2. *LIFAT, TOURS, France*
3. *Department of Biochemistry and Molecular Biology, Tours University Hospita, Tours, France*
4. *UMR U1253 iBrain, University of Tours, Inserm, Tours, France*

PO054 Cell Free MiRNAs Are Pharmacodynamic Biomarkers For Enhanced Dicer Activity By Enoxacin In Human Patients With Amyotrophic Lateral Sclerosis

Iddo Magen (1), Hannah Marlene Kaneb (2), Maria Masnata (2), Nisha Pulimood (2), Anna Emde (1), Angela Genge (2), Eran Hornstein (1)

1. *Weizmann Institute, Rehovot, Israel*
2. *Montreal Neurological Institute-Hospital, McGill University, Montreal, Canada*

PO055 Intrathecal Humoral Response And Blood-CSF Barrier Dysfunction In Amyotrophic Lateral Sclerosis

Ilaria Martinelli (1), Giorgia Maccione (2), Elisabetta Zucchi (1), Giulia Gianferrari (1,3), Andrea Ghezzi (1,3), Tommaso Fasano (4), Patrizia Natali (4), Federico Banchelli (1), Jessica Mandrioli (1,2)

1. *Department of Neurosciences, Azienda Ospedaliero Universitaria di Modena, Modena, Italy*
2. *Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy*
3. *Neuroscience PhD Program, University of Modena and Reggio Emilia, Modena, Italy*
4. *Department of Laboratory Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria and Azienda Unità Sanitaria Locale,, Modena, Italy*

PO056 Exploring Blood-Accessible CircRNAs As Minimally Invasive Biomarkers In ALS

Leticia Moreno-García (1,2), Christian Lunetta (3), Laura Expósito-Blázquez (4), Daniel Borrego-Hernández (4), Laura Moreno-Martínez (1,2), Paula Aparicio (1,2), Gabriel Rada (1,2), Elisa Gascón (1,2), Luis Folch-Cirujeda (1), Alberto García-Redondo (4), Rosario Osta (1,2), Ana Cristina Calvo (1,2), Janne Markus Toivonen (1,2)

1. LAGENBIO, University of Zaragoza, IIS Aragón & IA2 Aragón, Zaragoza, Spain

2. CIBERNED, Madrid, Spain

3. Maugeri Clinical Research Institutes IRCCS Milano, Milan, Italy

4. Genetic Diagnosis and Research Lab, Neurology Department, University Hospital 12 de Octubre, Instituto de Investigación Sanitaria H12O, Madrid, Spain

PO057 Evaluation Of Serum Cardiac Troponin T Levels As A Biomarker Of Phenotype Conversion In Presymptomatic ALS Gene Mutation Carriers

Johannes Dorst (1), Zeynep Elmas (1), Christine Herrmann (1), Maximilian Wiesenfarth (1), Jochen H Weishaupt (1), Patrick Weydt (2)

1. University of Ulm, Ulm, Germany

2. University of Bonn Medical Center, Bonn, Germany

PO058 Systematic Search And Meta-Analysis Of Proteomics Biomarker Discovery Targets In Blood Of Patients With Amyotrophic Lateral Sclerosis

Jurjen G A Van Meijeren, Nine J Lukassen, Ewout J N Groen, Leonard H Van Den Berg
University Medical Center Utrecht, Utrecht, The Netherlands

PO059 Secretome Biomarker Responses To Cellular Stress In iPSC-Derived Motor Neurons

Kathryn Knowles (1,2), Sandra Diaz Clavero (1,2), Jaqueline Casey (1,3), Charlotte Spicer (1), Aleksandra Mech (4,2), Jemeen Sreedharan (4,2), Giampietro Schiavo (1,3,2), Linda Greensmith (1,2), Andrea Malaspina (1,2,5)

1. UCL, London, United Kingdom

2. UKMNDRI, London, United Kingdom

3. UKDRI, London, United Kingdom

4. KCL, London, United Kingdom

5. UCL Queen Square MND Centre, London, United Kingdom

PO060 Intramuscular Myokine Profile And Muscle Vulnerability In End-Stage SOD1-G93A Mice Model

Laia Just-Borràs, Marina Díaz-Wallach, Antonio Pau-Butiñá, Meryem Jami-El Hirchi, Aleksandra Polishchuk, Carolina Silvera-Simón, Josep Tomàs, Erica Hurtado*, Maria Angel Lanuza**
Unitat d'Histologia i Neurobiologia - Universitat Rovira i Virgili, Reus, Spain

P0061 - Circular RNAs As Potential Diagnostic Biomarkers In The ALS-FTD Spectrum

Laura Expósito-Blázquez (1), Daniel Borrego-Hernández (1), Claudia Carrascal-Vento (1), Leticia Moreno-García (2), Ana Cristina Calvo-Royo (2), Janne Markus Toivonen (2), Pilar Cordero-Vázquez (3), Sara Llamas-Velasco (4), Marta González-Sánchez (4), Alberto Villarejo-Galende (4), Miguel Ángel Martín-Casanueva (5), Jesús Esteban-Pérez (3), Rosario Osta (2), Alberto García-Redondo (3)

1. Neurology department - ALS Unit. CIBERER U-723. Health research Institute, Hospital Universitario 12 de Octubre (imas12) - Avda. Córdoba s/n - 28041., Madrid, Spain

2. LAGENBIO-I3A, Aragonese Institute of Health Sciences (IACS), Faculty of Veterinary, University of Zaragoza - Miguel Servet, 177 - 50013, Zaragoza, Spain

3. Neurology department - ALS Unit. CIBERER U-723. Health research Institute, Hospital Universitario 12 de Octubre (imas12) - Avda. Córdoba s/n - 28041, Madrid, Spain

4. Neurology department - Dementia Unit. CIBERNED. Health research Institute, Hospital Universitario 12 de Octubre - Avda. Córdoba s/n - 28041, Madrid, Spain

5. Biochemistry department. CIBERER U-723. Health research Institute, Hospital 12 de Octubre - Avda. Córdoba s/n - 28041, Madrid, Spain

P0062 Identification Of Novel Neuronal Markers Associated With Extracellular Vesicles In Amyotrophic Lateral Sclerosis

Luisa Donini (1), Lorena Pisoni (1), Paola Gagni (2), Roberto Frigerio (3), Angelo Musicò (2), Davide Bressan (1), Fulvio Chiacchiera (1), Valentina Bonetto (4), Antonia Ratti (5,6), Federico Verde (5,7), Nicola Ticozzi (5,6), Jessica Mandrioli (8,9), Andrea Calvo (10,11,12), Riccardo Zuccarino (13), Raffaella Tanel (13), Paolo Arosio (3), Alessandro Gori (2), Manuela Basso (1)

1. Department of Cellular, Computational and Integrative Biology - CIBIO, University of Trento, Trento, Italy

2. National Research Council of Italy, Istituto di Scienze e Tecnologie Chimiche (SCITEC-CNR), Milano, Italy

3. Institute for Chemical and Bioengineering, ETH Zurich, Zurich, Switzerland

4. Research Center for ALS, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy

5. Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy

6. Department Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milano, Italy

7. Department of Pathophysiology and Transplantation (DEPT), Dino Ferrari Center, Università degli Studi di Milano, Milano, Italy

8. Department of Biomedical, Metabolic and Neuronal Sciences, University of Modena and Reggio Emilia, Modena, Italy

9. Department of Neurosciences, St. Agostino-Estense Hospital, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy

10. Dipartimento di Neuroscienze, Torino, Italy

11. AOU Città della Salute e della Scienza di Torino, Torino, Italy

12. Centro Regionale Esperto per la SLA, Torino, Italy

13. Centro Clinico Nemo, APSS Ospedale Riabilitativo Villa Rosa, Pergine Valsugana, Italy

P0063 Altered Salivary Cortisol As A Potential Biomarker Of HPA-Axis Dysregulation In Amyotrophic Lateral Sclerosis

Luisa T. Balz, Dorothee E. Lulé

University Hospital Ulm, Ulm, Germany

P0064 Clustering On CSF Biomarkers And Clinical Parameters Reveals A Signature Of Neuroinflammation

Luisa Donini (1), Sara Cabras (2), Enrico Matteoni (2), Lorena Pisoni (1), Giovanni De Marco (2), Laura Pasetto (3), Chiara Faccio (4), Francesco Rinaldi (4), Antonia Ratti (5,6), Valentina Bonetto (3), Antonio Canosa (2), Nicola Ticozzi (6,7), Raffaella Tanel (8), Nilo Riva (9), Jessica Mandrioli (10), Andrea Calvo (2), Manuela Basso (1)

1. Department of Cellular, Computational and Integrative Biology-CIBIO, University of Trento, Italy

2. Dipartimento di Neuroscienze "Rita Levi Montalcini", Università degli Studi di Torino and Centro Regionale Esperto per la SLA and AOU Città della Salute e della Scienza di Torino, Italy

3. Research Center for ALS, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy

4. Department of Mathematics, University of Padova, Padova, Italy, Padova, Italy

5. Department Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Italy

6. Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy

7. Department of Pathophysiology and Transplantation (DEPT), Dino Ferrari Center, Università degli Studi di Milano, Milano, Italy

8. Centro Clinico NeMO/U.O. Neurologia, APSS Ospedale Riabilitativo Villa Rosa, Trento, Italy

9. 3Rd Neurology Unit and Motor Neuron Disease Centre, Fondazione IRCCS, Milano, Italy

10. Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy

P0065 Serum MiRNA Profiling Identifies MiR-19b-3p As A Potential Biomarker For Primary Lateral Sclerosis

MARIA Vizziello (1), Giorgia Farinazzo (2,3), Elkadia Mehmeti (4), Marco Cattaneo (1,5),

Claudia Malacarne (2), Eleonora Giagnorio (2), Nilo Riva (1), Andrea Giordano (1,6),

Monica Consonni (1), Veronica Faltracco (1), Giuseppe Lauria Pinter (7,6), Erika Salvi (4,8),

Eleonora Dalla Bella (1), Stefania Marcuzzo (2,9)

1. Unit of Neurology 3 - Neuroalgology and Motor Neuron Disease Centre, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy

2. Unit of Neurology 4 - Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy

3. PhD Program in Bioengineering, Department of Electronics, Information and Bioengineering (DEIB), Politecnico di Milano, Milano, Italy

4. Data Science Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy

5. Department of Pharmacological and Biomolecular Sciences, University of Milan, Milano, Italy

6. Department of Medical Biotechnology and Translational Medicine, University of Milan, Italy

7. Scientific Directorate, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy

8. Computational multi-Omics of Neurological Disorders (MIND) Lab, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy

9. Brain-targeted Nanotechnologies (BrainS) Lab, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy

PO066 Exercise Intensity And Timing Influence Motor Function And Circulating Myokines In The SOD1-G93A Mouse Model Of Amyotrophic Lateral Sclerosis

Marina Díaz-Wallach, Antonio Pau-Butiñá, Meryem Jami-El Hirchi, Aleksandra Polishchuk, Carolina Silvera-Simón, Josep Tomàs, Maria Angel Lanuza, Laia Just-Borràs*, Erica Hurtado*
URV, Reus, Spain*

PO067 IGFBP7 As A Nexus Biomarker Identifying A Coordinated Treatment Response Phenotype In ALS: Post-Hoc Exploratory Analysis From Regimen C Of The HEALEY Platform Trial

Marjan Sepassi (1), Richard Bedlack (2), Jinsy Andrews (3), Robert Bowser (4), Bernard Caparrel (3), Austin Rynders (1), Jacob Evan (1), Jeremy Evan (1), Alan Hartford (1), Michael Hotchkin (1), Benjamin Greenberg (5)

- 1. Clene Nanomedicine, Salt Lake City, United States*
- 2. Duke, Durham, United States*
- 3. NYU Langone, New York City, United States*
- 4. Barrow Neurological Institute, Phoenix, United States*
- 5. UT Southwestern Medical Center, Dallas, United States*

PO068 Neurofilament Light Chain Trajectory Predicts Survival In ALS: Validation Across Independent Cohorts

Thomas Meyer (1,2), Robert Bowser (3), Jinsy Andrews (4), Caroline Ingre (5), Anne-Sophie Rolland (6), Benjamin Greenberg (7), Alan Hartford (8), Marjan Sepassi (8), Kyle McBride (9), Zachary Simmons (10), Michael Hotchkin (8), Julian Grosskreutz (11)

- 1. Center for ALS and other Motor Neuron Disorders, Charité - Universitätsmedizin Berlin, Germany*
- 2. APST Research, Berlin, Germany*
- 3. Barrow Neurological Institute, Phoenix, United States*
- 4. NYU Langone, New York City, United States*
- 5. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden*
- 6. CHU of Lille, Paris, France*
- 7. UT Southwestern Medical Center, Dallas, United States*
- 8. Clene Nanomedicine, Salt Lake City, United States*
- 9. Veristat, Southborough, United States*
- 10. Pennsylvania State, Hershey, United States*
- 11. University of Lubeck, Lubeck, Germany*

PO069 Nutritional Depletion And Iron Dysregulation As Independent Predictors Of ALS Progression Rate: Implications For Ferroptosis

*Matteo Farè, Andrea Lizio, Jessica Lops, Francesca Gerardi, Valeria Ada Sansone, Federica Cerri
Neuromuscular Omnicentre (NeMO), Fondazione Serena ETS, Milan, Italy*

PO070 Intrathecal Immunoglobulin Synthesis During Tofersen Treatment In SOD1-ALS: Evidence From Serial Kappa Free Light Chain Index Measurements In A Multicentre Italian Cohort

Matteo Giacchino (1), Giulia Gianferrari (2,3), Elisabetta Zucchi (2), Ilaria Martinelli (2), Andrea Ghezzi (2,3), Teresa Urbano (2), Francesca Cocconi (2), Roberta Bedin (1,2), Gianni Sorarù (4), Christian Lunetta (5), Francesca Trojsi (6,7), Jessica Mandrioli (1,2)

1. Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy

2. Department of Neurosciences, Azienda Ospedaliero Universitaria di Modena, Modena, Italy

3. Neuroscience PhD Program, University of Modena and Reggio Emilia, Modena, Italy

4. Department of Neurosciences, Neuromuscular Center, University of Padua, Padua, Italy

5. Neurorehabilitation Department, Istituti Clinici Scientifici Maugeri IRCCS, Milan, Italy

6. Department of Advanced Medical and Surgical Sciences, MRI Research Center, Luigi Vanvitelli Campania University, Naples, Italy

7. First Division of Neurology and Neurophysiopathology, University Hospital, Luigi Vanvitelli Campania University, Naples, Italy

PO071 Integrative Multi-Evidence Framework For Therapeutic Target Prioritization In Amyotrophic Lateral Sclerosis

Megha Gupta, Paras Verma, Monika Sharma

Plaksha University, Sas Nagar, Mohali, India

PO072 MiRNA And CircRNA Involvement In ALS

Metka Ravnik-Glavac (1), Blaž Koritnik (2,3), Damjan Glavac (4,5)

1. Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

2. Institute of Clinical Neurophysiology, Division of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia

3. Department of Neurology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

4. Department of Molecular Genetics, Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

5. Center for Human Genetics & Pharmacogenomics, Faculty of Medicine, University of Maribor, Maribor, Slovenia

PO073 Translational Validation Of A PBMC Gene-miRNA Signature With Specificity And Accuracy For Diagnosis Of ALS

Michela Congiu (1,2), Maria Francesca Manchinu (2), Matteo Massidda (2), Giuseppe Borghero (3,4), Jacopo Marongiu (1), Isabella Marzi (5), Andrea Maschio (2), Marcello Serra (1), Clara Porcedda (1), Maria Francesca Palmas (1), Andrea Angius (2), Valeria Sogos (4,1), Maria Ida Pateri (3), Anna Maristella Steri (2), Alfonso De Simone (6), Giovanni Cossu (7), Fabrizio Chiti (5), Anna Rosa Carta (1,2,4)

1. Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy

2. Institute for Genetic and Biomedical Research, The National Research Council (CNR), Monserrato, Italy

3. ALS Interdivisional Center, Cagliari, Italy; Neurology UOC, Azienda Ospedaliero-Universitaria di Cagliari, Cagliari, Italy
4. Interdepartmental Center for ALS and Motor neuron Diseases, University of Cagliari, Cagliari, Italy
5. Department of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Firenze, Italy
6. Department of Pharmacy, University of Naples Federico II, Napoli, Italy
7. Department of Neuroscience, Neurology and Stroke Unit, ARNAS Brotzu, Cagliari, Italy

PO074 Redox And Neurotrophic Biomarkers In Amyotrophic Lateral Sclerosis: Longitudinal Modulation Of Peripheral Nuclear Factor Erythroid 2-related Factor 2 (Nrf2)-Related Pathways Following Conjugated Linoleic Acid Supplementation

Minoo Sharbafshaaer (1), Paolo Bergamo (2), Roberta Pepe (3), Teresa Biscardi (2), Elvira Cortini (2), Diomira Luongo (4), Rosaria Notariale (1), Francesca Troisi (1,3)

1. Neurology Unit, First Division of Neurology and Neuro-physiopathology, AOU University of Campania "Luigi Vanvitelli", Naples, Italy, Naples, Italy
2. Institute of Biosciences and Bio-Resources, National Research Council (CNR-IBBR), 80100, Naples, Italy, Naples, Italy
3. Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy, Naples, Italy
4. Institute of Food Sciences, National Research Council (CNR-ISA), 83100, Avellino, Italy

PO075 Cerebrospinal Fluid TREM2 As A Candidate Neuroinflammatory Biomarker In Amyotrophic Lateral Sclerosis

Nicolò Mesini (1), Teresa Urbano (1), Iliaria Martinelli (2), Cecilia Simonini (1), Elisabetta Zucchi (2), Jessica Mandrioli (2,1)

1. University of Modena and Reggio Emilia, Modena, Italy
2. University Hospital of Modena, Modena, Italy

PO076 Longitudinal CSF And Serum Biomarker Dynamics In Tofersen Treated SOD1-ALS: A Real-World Multicentre Cohort Study

Andrea Giordano (1), Jessica Mandrioli (2,3), Federica Cerri (4), Christian Lunetta (5), Hamidreza Saebfar (1), Claudia Battipaglia (6), Francesca Troisi (7), Maria Vizziello (1), Gerardi Francesca (4), Rachele Piras (5), Aida Zulueta Morales (5), Giulia Gianferrari (2), Eleonora Dalla Bella (1), Raffaella Lombardi (1), Marcella Catania (6), Giuseppe Lauria (1), Nilo Riva (1)

1. Neurology 3 - Neuroalgology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
2. Department of Neurosciences, Ospedale Civile Baggiovara, Azienda Ospedaliero Universitaria di Modena, Modena, Italy
3. Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
4. NEuroMuscolar Omnicentre, Milan, Italy
5. Neurorehabilitation Department, Istituti Clinici Scientifici Maugeri IRCCS, Milan Institute, Milan,
6. Neurology 8 - Dementias and degenerative diseases of CNS Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
7. Dipartimento di Scienze Neurologiche, Seconda Università degli Studi di Napoli, Naples, Italy

PO077 Serum GFAP Captures Cognitive Vulnerability And Amyloid-Beta Co-Pathology Across The ALS-FTD Spectrum

Andrea Giordano (1,2), Hamidreza Saebfar (1), Veronica Faltracco (1), Marcella Catania (3), Laura Leone (1), Paola Caroppo (3), Maria Vizziello (1), Eleonora Dalla Bella (1), Raffaella Lombardi (1), Grazia Devigili (4), Dario Bonanomi (5), Anna Rosa Carta (6), Raffaele Dubbioso (7), Angelo Quattrini (5), Fiore Manganelli (7), Giuseppe Borghero (8), Monica Consonni (1), Nilo Riva (1)

*1. Neurology 3 - Neuroalgology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
2. Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Italy*

3. Neurology 8 - Dementias and degenerative diseases of CNS Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

4. Neurology 1 - Movement Disorders Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

5. Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy

6. Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy

7. Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Via Sergio Pansini, 5, 80131, Naples, Italy

8. Institute of Neurology, Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy

PO078 Establishing The Uses And Limitations Of Cryptic HDGFL2 As A Molecular Biomarker For Amyotrophic Lateral Sclerosis

Nine J. Lukassen (1), Katherine E. Irwin (2), Madhurima Chatterjee (3), Lisa A. Van Den Berg (1), Rob Haselberg (3), Philip C. Wong (2), Leonard H. Van Den Berg (1), Ewout J. N. Groen (1)

1. University Medical Center Utrecht, Utrecht, The Netherlands

2. Johns Hopkins Medicine, Baltimore, United States

3. VectorY Therapeutics B.V., Amsterdam, The Netherlands

PO079 Implementation Of Serum Biomarkers NfL And GFAP Using The Lumipulse Platform To Reduce Diagnostic Delay And Improve Prognostic Prediction In ALS

Laura Vilella Grau, Alena Arbós Aguilar, Cristina González Mingot, Cristina Nieva Sánchez, Laura Pérez Girona, Jhonatan Andrés Rojas Cristancho, Ignacio Saldaña Inda, Aureli Esquerda Serrano, Pascual Torres Cabestany

Hospital Universitari Arnau de Vilanova, Lleida, Spain

PO080 Tofersen In SOD1-ALS: Clinical Outcomes And Neurofilament Light-Chain Response In A Multicenter Observational Study Over 45 Months

Peggy Schumann (1,2), Patrick Weydt (3,4), Susanne Petri (5,6), Ute Weyen (7), Bettina M. Göricke (8), Matthias Boentert (9), Julian Conrad (10), Hanna-Sophie Lapp (11), André Maier (1), Yasemin Ruhan Koc (1), Felix Kozarek (2), Sarah Bernsen (1,3), Ivan Valkadinov (10), Maximilian Vidovic (11), Susanne Spittel (1,2), Christoph Münch (1,2), Péter Körtvélyessy (1), Thomas Meyer (1,2)

1. Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Neurology, Center for ALS and other Motor Neuron Disorders, Berlin, Germany

2. Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany

3. Bonn University, Department for Neurodegenerative Disorders, Bonn, Germany

4. DZNE, Deutsches Zentrum für Neurodegenerative Erkrankungen, Research Site Bonn, Germany

5. Hannover Medical School, Department of Neurology, Hannover, Germany

6. Department of Neurology, Diakovere Henriettenstift and Friederikenstift, Hannover, Germany

7. Ruhr-University Bochum, BG-Kliniken Bergmannsheil, Department of Neurology, Bochum, Germany

8. Universitätsmedizin Göttingen, Department of Neurology, Göttingen, Germany

9. Neuromedizinisches Zentrum, Klinikum Osnabrück, Osnabrück, Germany

10. University Medicine Mannheim, Heidelberg University, Mannheim Center for Translational Medicine, Neurology Department, Division for Neurodegenerative Diseases, Mannheim, Germany

11. Technische Universität Dresden, University Hospital Carl Gustav Carus, Department of Neurology, Dresden, Germany

PO081 Intraindividual Fluctuations Of Neurofilament Light Chain In Amyotrophic Lateral Sclerosis: Implications For Repeat Measurements

Philipp Schmitt (1), Peggy Schumann (1), Torsten Grehl (2), Ute Weyen (3), Annekathrin Rödiger (4), Robert Steinbach (4), Patrick Weydt (5), Sarah Bernsen (1), Rachel Fabian (6), Bettina Göricke (7), Susanne Petri (8), Rea Lumi (8), Bogdan Bjelica (8), Julian Großkreutz (9), Péter Körtvélyessy (1), Thomas Meyer (1)

1. Department of Neurology, Center for ALS and other Motor Neuron Disorders, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

2. Department of Neurology, Center for ALS and other Motor Neuron Disorders, Alfried Krupp Krankenhaus, Essen, Germany

3. Department of Neurology, Center for ALS and other Motor Neuron Disorders, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Bochum, Germany

4. Department of Neurology, Jena University Hospital, Jena, Germany

5. Department for Neuromuscular Disorders, Bonn University, Bonn, Germany

6. Department for Neuromuscular Disorders, Bonn University, Bonn, Germany

7. Department of Neurology, Universitätsmedizin Göttingen, Göttingen, Germany

8. Department of Neurology, Hannover Medical School, Hannover, Germany

9. Department of Neurology, Universitätsmedizin Schleswig-Holstein, Campus Lübeck, Germany

PO082 - Characterising The Metagenomic Landscape Of Amyotrophic Lateral Sclerosis From Unmapped Whole Genome Sequencing Data

Renato Santos (1), Elizabeth Lin (2), Andrea Malaspina (2,3), Ammar Al-Chalabi (1), Alfredo Iacoangeli (1,4,5)

1. King's College London, London, United Kingdom

2. University College London, London, United Kingdom

3. Queen Mary University of London, London, United Kingdom

4. Perron Institute for Neurological and Translational Science, Perth, Australia

5. NIHR Maudsley Biomedical Research Centre (BRC), London, United Kingdom

PO083 Correlations Between Plasma Neurofilament Levels And ALSFRS-R Subscores Assessed During Supplementation With Conjugated Linoleic Acid In Amyotrophic Lateral Sclerosis

Roberta Pepe (1), Teresa Biscardi (2), Elena Cortini (2), Daniela Luongo (3), Mino Sharbafshaaer (4), Rosaria Notariale (4), Nicolò Mesini (5), Jessica Mandrioli (5), Paolo Bergamo (2), Francesca Trojsi (1,4)

1. Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy, Napoli, Italy

2. Institute of Biosciences and Bio-Resources, National Research Council (CNR-IBBR), 80100, Naples, Italy

3. 2 Institute of Food Sciences, National Research Council (CNR-ISA), 83100, Avellino, Italy, Napoli

4. Neurology Unit, First Division of Neurology and Neuro-physiopathology,

AOU University of Campania "Luigi Vanvitelli", Naples, Italy

5. Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy

PO084 Longitudinal GFAP Levels In SOD1-Related ALS Patients Treated With Tofersen: Case Studies

Salvatore Tafaro (1), Giovanni De Marco (1), Sara Cabras (1,2), Claudia Paolantonio (1),

Umberto Manera (1,3), Rosario Vasta (1), Francesca Palumbo (1), Antonio Canosa (1,3),

Enrico Matteoni (1), Cristina Moglia (1,3), Andrea Calvo (1,3), Adriano Chio' (1,3)

1. ALS Center, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy

2. School of Advanced Studies, Center for Neuroscience, University of Camerino, Camerino, Italy

3. Neurology 1, AOU Città della Salute e della Scienza di Torino, Turin, Italy

PO085 Rationale For Digital Health Technology Assessments In FUNCTION ALS, A Phase 1/2 Trial Of TRCN-1023, An Antisense Oligonucleotide Restoring UNC13A, In Adult People Living With Amyotrophic Lateral Sclerosis

Sanjay Chandriani (1), Chao-Yin Chen (1), Anoopum Gupta (2), Fernando Vieira (3), Hardik Kothare (4), Michael Neumann (4), Vikram Ramanarayanan (4), Eric Green (1), Irina Antonijevic (1)

1. Trace Neuroscience, South San Francisco, United States

2. Harvard-MGH, Boston, United States

3. ALS Therapeutic Development Institute,, Watertown, United States

4. Modality.ai, San Francisco, United States

PO086 “Cruella” Deregulation Distinguishes Sporadic From SOD1-Linked ALS: A Differential Diagnose Biomarker For SALS And ALS-Mimic Disorders

Sergio Roca Pereira (1), Yaiza López Sampere (1), Pol Mengod Soler (1), Antonia Vinyals Rioseco (1), Marta Vela Martínez (1), Gisele Priscila Soares De Aguiar (2), Aina Huiyi Pros Marsal (1), Alejandro Caravaca Puchades (1), Raul Domínguez (3), Juan Francisco Vázquez Costa (4), Mónica Povedano Panadés (3), Pol Andrés Benito (5)

1. IDIBELL, Barcelona, Spain
2. School of Medicine University of Barcelona, Barcelona, Spain
3. Bellvitge University Hospital, Barcelona, Spain
4. Hospital Universitario y Politécnico La Fe and IIS La Fe, Valencia, Spain
5. Institute for Research in Biomedicine of Lleida (IRBLleida), Lleida, Spain

PO087 Cardiac Troponin T Tracks ALS Disease Dynamics: Towards Precision Biomarkers Using The D50 Framework

Sofia Waldorf (1), Julia Meyer (2), Janina Von Der Gablenz (2), Torsten Grehl (3), Huelya Nazlican (3), Thomas Meyer (4), Julian Grosskreutz (2), Patrick Weydt (1), Sarah Bernsen (1)

1. Center for Neurology, University Hospital Bonn, Bonn, Germany
2. Precision Neurology of Neuromuscular and Motor Neuron Disease, University Lübeck, Germany
3. Department of Neurology, Alfried Krupp Hospital, Essen, Germany
4. Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany

PO088 Integrated CSF–Blood Immune Profiling Reveals Immune Signatures Associated With Clinical Response To IL-2 Therapy In ALS

Timothy Tree (1), Yoana Arroyo Berdugo (1), Irma Pujol (1), Christine Payan (2), Phuong Pham (3), Janine Kirby (4), Pamela Shaw (5), Andrea Malaspina (6), Ammar Al-Chalabi (7), Nigel Leigh (8), Gilbert Bensimon (9)

1. King's College London, London, United Kingdom
2. King's College Hospital, Paris, France
3. Pitié-Salpêtrière Hospital, Saint-Malo, France
4. Centre of Neuroscience and Trauma, Sheffield, United Kingdom
5. Assistance Publique-Hôpitaux de Paris, Sheffield, United Kingdom
6. Department of Clinical Pharmacology, London, United Kingdom
7. Department of Neurology, London, United Kingdom
8. Blizzard Institute, Brighton, United Kingdom
9. Queen Mary University, Paris, France

PO089 Investigating The Role Of Cytokines As A Potential Biomarker In ALS

Triparna Roy (1), Debarghya Kumar Chakraborty (2), Mina Maaref Doost (1), Anna Carobin (1), James Bashford (1), Ahmad Al Khleifat (1)

1. King's College London, London, United Kingdom
2. King's College NHS Foundation Trust, London, United Kingdom

- PO090 Association Between HERV-K Expression And Neurofilament Light Chain Levels In Amyotrophic Lateral Sclerosis**
Triparna Roy, Mina Maaref Doost, Ammar Al-Chalabi
King's College London, London, United Kingdom
- PO091 The KCL MND Biobank: An Expanding Resource For Translational Motor Neuron Disease Research**
Triparna Roy, Mina Maaref Doost, Claire Troakes, Andrea Biondi, Amber Collingwood, Ammar Al-Chalabi
King's College London, London, United Kingdom
- PO092 Lighting Up Mislocalized TDP-43: Quantum Dot Probes For Multiplexed Cytoplasm-Selective Cell Profiling In ALS**
Valle Palomo (1), Paula Fernández-Gómez (1), Carlota Tosat-Bitrian (1), Tania Marugán (1), Laura Fernández-Hernández (2), Juan I Lopez-Carbonero (2), Jose A Martínez-Mulero (3), Jaime Pignatelli (3), Silvia Corrochano (2)
1. IMDEA Nanociencia, Madrid, Spain
2. Neurological Disorders Group, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain, Madrid, Spain
3. Instituto Cajal-Consejo Superior de Investigaciones Científicas (CSIC), Avenida Doctor Arce 37, 28002, Madrid, Spain., Madrid, Spain
- PO093 Prediction Of Inflammatory Subtypes Of Amyotrophic Lateral Sclerosis Using Machine Learning And Deep Learning On Histological Images**
Víctor Verdú-Samper (1,2), Shruti Sunil (1), Ana Manzollillo (1,2), Jemimah Kuruvilla (1), Vijaya Jagadeesan (1), Jenna Gregory (3), Kristine Roberts (3), Marta Vallejo (1)
1. Heriot-Watt University, Edinburgh, United Kingdom
2. Universidad Autónoma de Madrid, Madrid, Spain
3. University of Aberdeen, Aberdeen, United Kingdom
- PO094 Directional Sensorimotor Network Alterations In ALS Revealed By A Combined EEG-EMG Connectivity Framework**
Zahra Eshagh Nimvari (1), Saroj Bista (1), Amina Coffey (1), Serena Plaitano (1), Rosie giglia (1), Nina madeddu (1), Marjorie Metzger (1), Prabhav Mehra (1,2), Orla hardiman (1), Bahman Nasserolelami (1,2)
1. Trinity College of Dublin, Dublin, Ireland
2. FutureNeuro, Dublin, Ireland

CLINICAL TRIALS AND TRIAL DESIGN (included in the posters session I)

- PO095 Targeting Neuroinflammation With Enhanced Delivery Of Intravenous Immunoglobulin To The Motor Cortex Using Next-Generation Focused Ultrasound In ALS: A Phase I Trial**
Agessandro Abrahao (1,2), Pedro Saldanha-Castro (1), Ryan M. Jones (3), Dallan McMahon (3), Yuexi Huang (3), Denizart Santos-Neto (4), Jahan Mookshah (5), Caroline Giuricich (5), Liane Phung (5), Matheus Chupel (5), Isabelle Aubert (5), Maheleth Llinas (5), Kullervo Hynynen (5), Nir Lipsman (2,6), Lorne Zinman (5,7)
1. Division of Neurology, Department of Medicine, Sunnybrook Health Science Centre, University of Toronto, Canada
2. Harquail Centre for Neuromodulation, Sunnybrook Research Institute, University of Toronto, Canada
3. Physical science platform, Sunnybrook Research Institute, University of Toronto, Canada
4. Division of Neurology, Department of Medicine, Sunnybrook Health Science Centre, University of Toronto, Canada
5. Sunnybrook Research Institute, University of Toronto, Toronto, Canada
6. Division of Neurosurgery, Department of Surgery, Sunnybrook Health Science Centre, University of Toronto, Canada
7. Division of Neurology, Sunnybrook Health Science Centre, University of Toronto, Toronto, Canada
- PO096 Beyond The ALSFRS-R Slope: Multidimensional Structure Of Functional Decline In ALS**
Alejandro Caravaca Puchades (1,2,3), Ammar Al-Chalabi (4,5), Adriano Chiò (6), Philippe Corcia (7), Orla Hardiman (8), Caroline Ingre (9), Christopher Mcdermott (10), Philip Van Damme (11,12), Leonard Van Der Berg (13,14), Mònica Povedano Panadés (1)
1. Bellvitge University Hospital, L'Hospitalet De Llobregat, Barcelona, Spain
2. Biomedical Research Institute of Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
3. Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain
4. King's College London, London, United Kingdom
5. Maurice Wohl Clinical Neuroscience Institute, London, United Kingdom
6. University of Turin, Turin, Italy
7. Centre de Reference Maladies Rares SLA, Tours, France
8. Trinity Biomedical Sciences Institute, School of Medicine, Trinity College Dublin, Dublin, Ireland
9. Karolinska Institute, Stockholm, Sweden
10. Sheffield Institute for Translational Neuroscience, University of Sheffield, United Kingdom
11. University Hospitals Leuven, Leuven, Belgium
12. Leuven Brain Institute, University of Leuven, Leuven, Belgium
13. UMC Utrecht Brain Center, Utrecht, The Netherlands
14. University Medical Center Utrecht, Utrecht, The Netherlands
- PO097 Beyond The Hype: Real-World Evidence For Decentralized ALS/MND Research**
Alexander V. Sherman (1,2), Alex Korin (1), Chelsea Kosma (1), Igor Kuras (1), Derek T. D'Agostino (1), Ikjae Lee (3), Robert Bowser (4), James D. Berry (1,2)
1. Massachusetts General Hospital, Boston, United States
2. Harvard Medical School, Boston, United States
3. Columbia University, New York, United States
4. Barrow Neurological Institute, Phoenix, United States

P0098 Sex-Specific Effects In ALS Clinical Trials: Protocol For A Systematic Review And IPD Meta-Analysis

Ana Galhoz (1), Laura Tzeplaeff (2), Antonia F. Demleitner (2), Bernhard Haller (3), Michael P. Menden (1,4), Paul Lingor (2)

1. Helmholtz Munich, Munich, Germany

2. Rechts der Isar Hospital of the Technical University Munich, Munich, Germany

3. Institute for AI and Informatics in Medicine, TUM University Hospital, Munich, Germany

4. The University of Melbourne, Melbourne, Australia

P0099 Phase 2 Biomarker And Clinical Results Of AP-101, A Human Antibody Targeting Misfolded SOD1 In Amyotrophic Lateral Sclerosis

Angela Genge (1), Caroline Ingre (2), Seung Hyun Kim (3), Thomas Meyer (4), Patrick Weydt (5), Philip Van Damme (6), Wendy S. Johnston (7), Christen Shoesmith (8), Rami Massie (9), Lorne Zinman (10), John Ravits (11), Susanne Petri (12), Jochen H. Weishaupt (13), Karin M. E. Forsberg (14), Guy Rouleau (15), Merit E. Cudkowicz (16), Leonard H. Van Den Berg (17), Michael Salzman (1)

1. AL-S Pharma AG, Schlieren, Switzerland

2. Karolinska Institute, Stockholm, Sweden

3. Hanyang University Hospital, Seoul, South Korea

4. Charité – Universitätsmedizin Berlin, Berlin, Germany

5. University Of Bonn, Bonn, Germany

6. University Hospitals Leuven, Leuven, Germany

7. University of Alberta, Edmonton, Ab, Canada

8. London Health Sciences Centre, London, On, Canada

9. McGill University, Montreal, Qc, Canada, Canada

10. Sunnybrook Health Sciences Centre, Toronto, On, Canada

11. University Of California, San Diego, La Jolla, California, United States

12. Hannover Medical School, Hannover, Germany

13. Ulm University, Ulm, Germany

14. Umeå University, Umeå, Sweden

15. McGill University, Montreal, Qc, Canada

16. Massachusetts General Hospital, Harvard Medical School, Boston, Ma, United States

17. University Medical Center Utrecht, Utrecht, Netherlands Antilles

P0100 A Phase II Randomized Trial Of ILB® Versus Riluzole In Amyotrophic Lateral Sclerosis (IMPACT)

Angelina Maniaol

Department of Neurology, Oslo University Hospital, Oslo, Norway

P0101 NX210c, A Promising Drug Candidate For Neurodegenerative Diseases

Annette Janus (1), Emilien Bernard (2), Nicolas Rebergue (1), Juliette Le Douce (1), Sebastien Marie (1), Fianne Sips (3), Pauline Bambury (4), Daniel Röshammar (4)

1. Axoltis Pharma, Lyon, France
2. Hospices Civils de Lyon, H. Neurologique P. Wertheimer, Lyon, France
3. InSilicoTrials Technologies B.V., Amsterdam, The Netherlands
4. InSilicoTrials Technologies S.p.A., Trieste, Italy

P0102 Modulation Of Oxidative Stress, Lipid Metabolism And Hormonal Profiles After Treatment With Liposomal Resveratrol–Curcumin Plus Dutasteride In ALS Patients

Belén Proaño (1), María Benlloch (2), Sandra Sancho (2), José Luis Platero (2), Marta Garrido (2), Jose Enrique De La Rubia Ortí (2)

1. Escuela de doctorado, Universidad Católica de Valencia, Valencia, Spain
2. Universidad Católica de Valencia, Valencia, Spain

P0103 SEA-NOBI-ALS Expanded Access Program Of Ibudilast (MN-166)

Björn Oskarsson (1), Megan Donahue (1), Jess Rouborn (2), Shona Allen (2), Kazuko Matsuda (3), Stephen Johnson (4), Tania Gendron (1), Leonard Petrucelli (5), Michael Heckman (1), Marka Van Blitterswijk (1), SEANOBI Investigators (6)

1. Mayo Clinic, Jacksonville, United States
2. WideTrial, San Jose, United States
3. MediciNova, San Diego, United States
4. Mayo Clinic, Phoenix, United States
5. University of Miami, Miami, United States
6. Various, Various, United States

P0104 A Study To Evaluate The Efficacy And Safety Of VHB937 In People With ALS: Baseline Data From The ASTRALS Double-Blind, Randomized, Placebo-Controlled Study

Marie-Laure Rouzade-Dominguez (1), Ram Miller (2), Marie-Emmanuelle Riviere (1), Francesca Callegari (1), Lucie Bruijn (1), Chrystel Fernandes (1), Alit Bhatt (3), Vanessa Vallejo (1), Orla Hardiman (4), Leonard H. Van Den Berg (5), Richard Bedlack (6), Merit Cudkowicz (7), Christophe Lo Bianco (1)

1. Novartis Pharma AG, Basel, Switzerland
2. Novartis Pharmaceuticals Corporation, Cambridge, United States
3. Novartis Healthcare Pvt. Ltd., Hyderabad, India
4. Trinity Institute of Neurosciences, Trinity College Dublin, Dublin, Ireland
5. UMC Utrecht, Utrecht, The Netherlands
6. Dept. of Neurology, Duke University School of Medicine, Durham, United States
7. Massachusetts General Hospital, Harvard Medical School, Boston, United States

P0105 First Qualitative Study Exploring Unmet Post-Trial Support Needs In ALS Patients And Caregivers

Dalisha Dalisha

National Hospital of Neurology and Neurosurgery, London, United Kingdom

P0106 Reliability, Validity, And Usability Of Hand Grip Strength: Comparing Supervised And Unsupervised Performance Across Four Dynamometers

Doreen Lemmen, Adine van den Bosch, Stephan Goedee, Jaap Bakers, Leonard van den Berg, Ruben van Eijk

UMC Utrecht, Utrecht, The Netherlands

P0107 Optimizing Isometric Muscle Strength Assessments For Amyotrophic Lateral Sclerosis Clinical Trials: A Simulation-Based Approach

Doreen Lemmen, Jaap Bakers, Stephan Goedee, Leonard van den Berg, Ruben van Eijk

UMC Utrecht, Utrecht, The Netherlands

P0108 SEALS: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Evaluating Efficacy And Safety Of NX210c In Amyotrophic Lateral Sclerosis (ALS) Patients: Topline Results

Emilien Bernard (1), Gaëlle Bruneteau (2), Florence Esselin (3), Claire Boutoleau Bretonniere (4), Marie-Hélène Soriani (5), Julien Cassereau (6), Philippe Couratier (7), Gwendal Le Masson (8), Philippe Corcia (9), Véronique Danel Brumaud (10), Mathilde Lefilliatre (11), Raphaël Chouteau (12), Nathalie Guy (13), Steeve Genestet (14), Sophie Pittion-Vouyovitch (15), Shahram Attarian (16), Sébastien Marie (17), Annette Janus (17)

1. Hospices Civils de Lyon, H. Neurologique P. Wertheimer, Lyon, France

2. Groupe Hospitalier La Pitié Salpêtrière (AP-HP), Département de Neurologie, Paris, France

3. CHU Gui de Chauliac, Montpellier, France

4. Hôpital Laënnec, Département de Neurologie, Nante, France

5. Hôpital Pasteur 2, Pole Neurosciences - Rhumatologie, Nice, France

6. CHU d'Angers, Service de Neurologie, Angers, France

7. CHU de Limoges, Service neurologie, Limoges, France

8. Hôpital Pellegrin, Service Neurologie, pathologies neuromusculaires, Bordeaux, France

9. Hôpital Bretonneau, Service de Neurologie-Neurophysiologie Clinique, Tours, France

10. Hôpital Roger Salengro-CHU de Lille, Service Neurologie, Lille, France

11. CHU de Caen, Service de Neurologie, Caen, France

12. Hôpital Pontchaillou, Service d'Explorations Fonctionnelles Neurologiques, Rennes, France

13. Hôpital Gabriel Montpied, Service de Neurologie, Clermont-Ferrand, France

14. CHU de Brest - Hôpital de la Cavale Blanche, Service d'explorations fonctionnelles neurologiques, Brest, France

15. Hôpital Central, Service de Neurologie, Nancy, France

16. CHU Marseille - Hôpital de La Timone, Marseille, France

17. Axoltis Pharma, Lyon, France

P0109 Functionally-Adjusted Life Years

Eric A. Macklin (1,2)

1. Harvard Medical School, Boston, United States

2. Massachusetts General Hospital, Boston, United States

P0110 PRO-101, A Hybrid Phase 1 Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Prosetin In Participants With ALS

Erin Fleming (1), April Ruby (1), Kristiana Salmon (1), Hilde Williams (1), Leonard Van Den Berg (2), Angela Genge (3), Ingela Danielsson (1), Jinsy Andrews (4)

1. ProJenX, New York City, United States

2. University Medical Center Utrecht, Utrecht, The Netherlands

3. McGill University, Montréal, Canada

4. New York University, New York City, United States

P0111 Determinants Of Participation And Perceived Meaningful Benefit In ALS Clinical Trials: Toward A More Patient-Centric Study Design

Famke S. Cosijn, Daphne N. Weemering, Jordi W.j. Van Unnik, Leonard H. Van Den Berg

University Medical Center Utrecht, Utrecht, The Netherlands

P0112 Domain-Specific Response To Tofersen In SOD1-ALS: Real-World Evidence From A Tertiary Center

Daniel Bormann (1,2), Friedrich Haimberger (1,2), Omar Keritam (1,2), Hakan Cetin (1,2)

1. Department of Neurology, Medical University of Vienna, Vienna, Austria

2. Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria

P0113 Real-World In-Trial Performance Of A Modern Measurement Of Speech Intelligibility In ALS

Gustavo Noffs (1,2), Vincent Aubanel (1,2), Thayabaran Kathiresan (1,2), Adam Vogel (1,2)

1. University of Melbourne, Melbourne, Australia

2. Redenlab, Melbourne, Australia

P0114 Five Minutes Of Speech Screening Cuts Trial Costs In Half While Increasing Its Power

Gustavo Noffs (1,2), Vincent Aubanel (1,2), Thayabaran Kathiresan (1,2), Adam Vogel (1,2)

1. University of Melbourne, Melbourne, Australia

2. Redenlab, Melbourne, Australia

P0115 FUNCTION ALS: A Phase 1/2 Trial Evaluating The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Exploratory Efficacy Of TRCN-1023, An Antisense Oligonucleotide Restoring UNC13A, In Adult Persons With Amyotrophic Lateral Sclerosis

Irina Antonijevic, Chao-Yin Chen, Sanjay Chandriani, Jeffrey Davis

Trace Neuroscience, San Francisco, United States

P0116 Attitudes And Experiences Of Participants In The Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART)

Isaac Chau (1,2,3,4,5), Emily Beswick (6), Ethan Stoker (1,2,3), Tia Cainer (1,2,3), Judith Newton (1,2,3,4), Amy Stenson (1,2,3,4), Amarachi Ihenacho (1,2,3,4), Paolo Cucurachi (1,2,3,4), Bruce Virgo (8), Jacqui Casey (8), Steven Barrett (8), Richard Parker (9), Christopher Weir (9), Jeremy Chataway (1,10,11,12,13), James Carpenter (14,10,13), Mahesh Parmar (14,10,13), Siddharthan Chandran (1,2,3,4), Suvankar Pal (1,2,3,4,14)

1. MND-SMART Team, Edinburgh, United Kingdom
2. Euan MacDonald Centre for Motor Neuron Disease Research, Edinburgh, United Kingdom
3. Institute for Neurosciences and Cardiovascular Research, Edinburgh, United Kingdom
4. UK Dementia Research Institute, Edinburgh, United Kingdom
5. ACORD at MRC Clinical Trials Unit, University College London, United Kingdom
6. Academic Department of Neurology, Republic Of Ireland, Ireland
7. Institute of Clinical Trials and Methodology
8. MND SMART Patient and Public Involvement and Engagement Group, Edinburgh, United Kingdom
9. Edinburgh Clinical Trials Unit, Edinburgh, United Kingdom
10. MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, London, United Kingdom
11. Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, London, United Kingdom
12. National Institute for Health and Care Research, London, United Kingdom
13. MRC CoRE in Clinical Trial Innovation, London, United Kingdom
14. ACORD at MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, London, United Kingdom

P0117 Development And Validation Of A Stable And Clinically Applicable Classification Method With Personalized Prognostic Models For Amyotrophic Lateral Sclerosis

Jinghong Zhang, Shan Ye, Lu Chen, Xiaolu Liu, Dongsheng Fan
Peking University Third Hospital, Beijing, China

P0118 Three Randomized Controlled Trials In Amyotrophic Lateral Sclerosis: A Comparative Analysis

Joachim Schuster (1,2), Aya Dasan (2), Jens Dreyhaupt (3), Christine Herrmann (2), Kornelia Günther (2), Gneigh Sariffodeen (2), David Brenner (2,1), Johannes Dorst (2), Jochen Weishaupt (2)

1. German Center for Neurodegenerative Diseases (DZNE), Site Ulm, Ulm, Germany
2. Ulm University, Department of Neurology, Ulm, Germany
3. Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany

P0119 Advancing AMX0114 For ALS: Updates From The LUMINA Phase 1 Study

Sabrina Paganoni (1), Lauren Kett (2), Robert Bowser (3), Elaina Breznau (2), Lauren Kingston (2), John Pesko (2), Jamie Timmons (2), Angela Genge (4)

1. Spaulding Rehabilitation Hospital, Boston, United States
2. Amylyx Pharmaceuticals, Cambridge, United States
3. Barrow Neurological Institute, Phoenix, United States
4. Montreal Neurological Institute, Montreal, Canada

P0120 A Phase 2a Study To Assess The Safety, Tolerability, Efficacy, Pharmacokinetics, And Immunogenicity Of Adimanebart In Adults With Amyotrophic Lateral Sclerosis: Study Results From ReALiSe

Leonard H. Van Den Berg (1), Angela Genge (2), Boudewijn T. H. M. Sleutjes (1), Keith Mayl (3), Ann Swijsen (3), Thomas Christian Jürgens (4), Willem Talloen (3), Ruben P. A. Van Eijk (1)

1. University Medical Center Utrecht, Utrecht, The Netherlands

2. McGill University, Montreal, Canada

3. argenx, Ghent, Belgium

4. ThermoFisher/PPD, Waltham, United States

P0121 Interim Results From ANQUR: A Phase 1 MAD And Dose Range Finding Study To Assess Safety, Tolerability, Pharmacokinetics And Efficacy Of QRL-201, A STMN2 Targeting Splice Switching ASO For The Treatment Of Sporadic And C9orf72 ALS

Manoj Malhotra (1), Victoria Eon (1), Lisa Tatterson (1), Tracy Kemp (1), Taylor Gray (1), Keith Andrew Maccannell (2), Dave Donely (3), Thomas Bowman (1)

1. QurAlis, Cambridge, United States

2. ADME PKPD Consulting, Cambridge, United States

3. EMB Statistical Solutions, Cambridge, United States

P0122 Barriers To Participation In Phase 1 Clinical Trials In Amyotrophic Lateral Sclerosis
Marie-Lise Béland, Mohini Patel, Angela Genge

Centre for Innovative Medicine, McGill University Health Centre, Montreal, Canada

P0123 Composite Speech Biomarkers For ALS: Reliability, Measurement Error, And Generalization From Natural History To Clinical Trial

Michael Neumann (1), Hardik Kothare (1), David Suendermann-Oeft (1), Diego Cadavid (2), Robert H. Scannevin (2), Ines Hoffmann (2), Anil Tarachandani (2), Tara Haley (2), Shane Raines (3), Pentti Tienari (4), Eino Solje (5), Manu Jokela (6), Angela Genge (7), Colleen O'Connell (8), Ruben P.a. Van Eijk (9), Leonard H. Van Den Berg (9), Vikram Ramanarayanan (1), Philip Van Damme (10)

1. Modality.AI, San Francisco, United States

2. Verge Genomics, San Francisco, United States

3. 2b Analytics, Wallingford, United States

4. Helsinki University Hospital, Helsinki, Finland

5. University of Eastern Finland, Kuopio, Finland

6. Helsinki University Hospital, Turku, Finland

7. The Neuro - Montreal Neurological Institute Hospital, Montreal, Canada

8. Stan Cassidy Centre for Rehabilitation, Fredericton, Canada

9. Utrecht University Medical Center, Utrecht, The Netherlands

10. KU Leuven, Department of Neurology, Leuven, Belgium

PO124 PREVAiLS (Pridopidine Phase 3 Study To Evaluate Efficacy And Safety In ALS) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study In ALS

Leonard H. Van Den Berg (1), Angela Genge (2), Ruben Van Eijk (1), Bernd-Jan Sanson (3), Ryan Miller (3), Luvia Álvarez Ávila (4), Carla Varona (4), Wei Feng (3), Melanie Leitner (5), Noga Gershoni-Emek (3), Diderik Boot (3), Michael R. Hayden (3,6), Sabrina Paganoni (7,8)

1. Brain Center Utrecht, University Medical Center, Utrecht, The Netherlands

2. Department of Neurology, McGill University, Montreal, Canada

3. Prilenia Therapeutics, B.V., Naarden, The Netherlands

4. Grupo Ferrer Internacional, Barcelona, Spain

5. Accelerating Neuroventures, Boston, Ma, United States

6. CMMT, University of British Columbia, Vancouver, Canada

7. Healey Center for ALS at Massachusetts General Hospital, Boston, United States

8. Harvard Medical School, BC, United States

PO125 Results From QRL-101-04: Evidence Of Target Engagement With A Selective Kv7.2/7.3 Ion Channel Opener In ALS Patients

Samantha Rubino (1), Lisa Latterson (1), Nora Hagopian (1), Taylor Gray (1), Tracy Kemp (1), Thomas Bowman (1), Kieth Andrew Maccannell (2), Stephan Goedee (3), Boudewijn Sleutjes (3), Leonard Van Den Berg (3), Tommy Bunte (3), Manoj Malhotra (1)

1. QurAlis, Cambridge, United States

2. ADME PKPD Consulting, Cambridge, United States

3. University Medical Center Utrecht (UMCU), Utrecht, Denmark

PO126 Long-Term (5 Years) Evaluation Of Tofersen In SOD1-ALS: Final Results From The Integrated Analysis Of Study 101 Parts A/B, A Phase 1/2 Ascending Dose Trial, And The Open-Label Extension

Timothy M Miller (1), Robert C Bucelli (2), Merit E Cudkowicz (3), Pamela J Shaw (4,5), Manjit Mcneill (6), Steve Garafalo (8), Kaelin O'Connell (9), Jennifer Inra (10), Stephanie Fradette (11)

1. Department of Neurology, St Louis, United States

2. Neuromuscular Medicine, St Louis, United States

3. Washington University School of Medicine in St Louis, Boston, United States

4. Department of Neurology, Sheffield, United Kingdom

5. National Institute for Health and Care Research (NIHR) Sheffield Biomedical Research Centre and NIHR Clinical Research Facility, Sheffield, United Kingdom

6. Neuromuscular Medicine, Cambridge, United States

7. University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust

8. Washington University School of Medicine in St Louis, Cambridge, United States

9. Department of Neurology, Cambridge, United States

10. Massachusetts General Hospital, Cambridge, United States

11. Harvard Medical School, Cambridge, United States

P0127 Augmented Placebo Control Using Synthetic Patient Profiles In ALS Clinical Trials: A Methodological Framework

Sofia Azevedo (1), Niccolò Totis (2), Simona Catozzi (1), Maud Beneton (1), Mario Torchia (1), Juliette Le Douce (3), Sébastien Marie (3), Annette Janus (3), Yann Godfrin (3), Daniel Roeshammar (1), Pauline Bambury (1), Paolo Messina (1)

1. InSilicoTrials Technologies, Trieste, Italy
2. InSilicoTrials Technologies B.V., Amsterdam, The Netherlands
3. Axoltis Pharma, Lyon, France

P0128 Compassionate Use Of C9ORF72 Targeted ASOs In ALS – Experience From Eight Patients At Three German Centers

Patrick Weydt (1,2), Sarah Bernsen (1,3), Zeynep Elmas (4), Peter Körtvelyessy (5), Katherine Meijboom (6), Ullrich Wüllner (1), Yosef Caraco (7), Marc Gotkine (7), Thomas Meyer (3), Robert H. Brown (8), Jochen Weishaupt (9)

1. University Hospital Bonn, Bonn, Germany
2. German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
3. Charité, Berlin, Germany
4. University Hospital Ulm, Bonn, Germany
5. Charié, Berlin, Germany
6. University of Massachusetts, Worcester, United States
7. Hadassah University, Jerusalem, Israel
8. University of Massachusetts, Worcester, United States
9. University Hospital Ulm, Ulm, Germany

P0129 Understanding The Impact Of Modeling Choices In The Analysis Of Longitudinal Data With Informative Missingness In Amyotrophic Lateral Sclerosis

Daphne N Weemering, Leonard H Van Den Berg, Ruben P A Van Eijk
UMC Utrecht, Utrecht, The Netherlands

P0130 Enhancing Enrollment In ALS Clinical Research: The Acceleration Centers Of Enrollment (ACE) Initiative

Senda Ajroud-Driss (1), Dario Gelevski (2), Michelle Redenz (2), Elisa Giacomelli (2), Zia Mars (2), Jennifer Scalia (2), Doreen Ho (2), Emma Schmidt (3), Amanda Rueter (4), David Walk (5), Sabrina Paganoni (6), Merit Cudkowicz (6)

1. Les Turner ALS center at Northwestern Medicine, Boston, United States
2. Sean M. Healey & AMG Center for ALS & the Neurological Clinical Research Institute, Boston, United States
3. Les Turner ALS center at Northwestern Medicine, Chicago, United States
4. Department of Neurology, Minneapolis, United States
5. Department of Neurology, University of Minnesota Medical School, Minneapolis, United States
6. Sean M. Healey & AMG Center for ALS & the Neurological Clinical Research Institute, Boston, United States

P0131 Translating Clinical And Biomarker Insights Into Phase 3 Development Of A Multi-Targeted Therapy For Amyotrophic Lateral Sclerosis: The PrimeC Program

Jinsy A Andrews (1), Vivian E Drory (2), Adriano Chio (3), Christian Lunetta (4), Christen Shoosmith (5), Ruben P.a Van Eijk (6), Shiran Zimri (7), Niva Russek-Blum (7), Yonit Rosen Krauss (7), Racheli Gueta (7), Guy Shapira (8), Noam Shomron (8), Ferenc Tracik (7), Jeffrey Rosenfeld (9), Merit E Cudkowicz (10), Jeremy Shefner (11)

1. NYU Grossman School of Medicine, New York, United States

2. Neuromuscular Diseases Unit, Department of Neurology, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel

3. University of Turin, Turin, Italy

4. Istituti Clinici Scientifici Maugeri IRCCS, Department of Neurorehabilitation, Institute of Milan, Milan, Italy

5. Department of Clinical Neurological Sciences, Division of Neurology, London Health Sciences Centre, London, On, Canada

6. Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands

7. NeuroSense Therapeutics, Ltd, Herzliya, Israel

8. Gray Faculty of Medical and Health Science, Tel Aviv University, Tel-Aviv, Israel

9. Department of Neurology, Loma Linda University School of Medicine, Loma Linda, United States

10. Mass General Brigham Neuroscience Institute, Healey & AMG Center for ALS, Department of Neurology, MGH, Harvard Medical School, Boston, Ma, United States

11. Barrow Neurological Institute, Phoenix, Az, United States

P0132 Biological Pathways In Disease-Modifying Clinical Trials For Amyotrophic Lateral Sclerosis: A Systematic Review

Sophie J Plasmans (1), Pavol Zelina (2), R Jeroen Pasterkamp (2), Vamshidhar R Vangoor (2), Georgios Seitidis (3), Afroditi Tsatsi (3), Fani Apostolidou-Kiouti (4), Dimitris Mavridis (5), Leonard H. Van Den Berg (1), Stavros Nikolakopoulos (3), Ruben P A Van Eijk (1)

1. Department of Neurology, University Medical Center Utrecht, Utrecht, The Netherlands

2. Department of Translational Neuroscience, University Medical Center Utrecht, The Netherlands

3. Department of Psychology, University of Ioannina, Ioannina, Greece

4. Department of Hygiene, Social-Preventive Medicine & Medical Statistics, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

5. Department of Primary Education, University of Ioannina, Ioannina, Greece

P0133 Design & Methodology of FUSION, a Study to Assess Efficacy and Safety of Antisense Oligonucleotide Ulefnersen in Amyotrophic Lateral Sclerosis with Fused in Sarcoma (FUS-ALS) Mutations

Neil A Shneider (1), Roger Lane (2), Qingqing Yang (2), Frank Bennett (2), Stephan Miller (2)

1. Department of Neurology, Columbia University Irving Medical Center, New York, United States

2. Ionis Pharmaceuticals, Carlsbad, United States

P0134 Robust Digital Bulbar Monitoring In ALS Using A Minimal, Interpretable Speech Feature Panel

Tabea Thies (1), Elisa Mallick (1), Johannes Tröger (1), Salvatore Giugliano (2), Giovanna Sannino (3), Myriam Spisto (4,5), Raffaele Dubbioso (4)

1. ki:elements GmbH, Saarbrücken, Germany

2. Institute for High Performance Computing and Networking (ICAR), National Research Council (CNR), Naples, Italy

3. Institute for High Performance Computing and Networking (ICAR), National Research Council (CNR), Naples, Italy

4. Department of Neuroscience, University of Naples "Federico II", Naples, Italy

5. Department of Psychology, University of Campania Luigi Vanvitelli, Naples, Italy

P0135 Results From QRL-101-05: Proof Of Kv7.2/7.3 Peripheral And Cortical Excitability Modulation After A Single Dose At Two At Two Dose Levels Of QRL-101 In A 3-Way Cross Over Design Ph1 Healthy Volunteer Study.

Taylor Gray (1), Marjet Claessens (2), Samantha Rubino (1), Tracy Kemp (1), Thomas Bowman (1), Keith Andrew Maccannell (3), Kaye De Cuba (2), Philip Kremer (2), Manoj Malhotra (1)

1. QurAlis, Cambridge, United States

2. Centre for Human Drug Research (CHDR), Leiden, Denmark

3. ADME PKPD Consulting, LLC, Cambridge, United States

P0136 ALSTARS: A Precision Immunomodulatory Phase 2 Trial Of Coya 302 Targeting Regulatory T Cells And Neuroinflammation In ALS

Tyrell J Simkins (1), Fred Grossman (1), Stanley Appel (2), Karen King (1), James D Berry (3)

1. Coya Therapeutics, Houston, United States

2. Houston Methodist Neurological Institute, Houston, United States

3. Harvard Medical School, Boston, United States

P0137 Clinical Development Of LTX-002, An ASO For The Treatment Of Sporadic And Familial Forms Of ALS

W Lawrence Severt, Laura D Heckman, Asa Abeliovich

Leal Therapeutics, Worcester, United States

P0138 Clinical Development Of LTX-001, A Small-Molecule GLS1 Inhibitor For The Treatment Of ALS

W Lawrence Severt, Laura D Heckman, Paul Yarabe

Leal Therapeutics, Worcester, United States

DISEASE MECHANISMS (included in the posters session II)

- PO139 Microsecond Molecular Dynamics Of SOD1 Variants Suggest A Structural Basis For Divergent ALS Clinical Outcomes**
Abed Mosa (1), Richard Dobson (1), Konstantin Roeder (1), Edoardo Milanetti (2), Alfredo Iacoangeli (1)
1. King's College London, London, United Kingdom
2. Sapienza IIT Rome, Rome, Italy
- PO140 Investigating The Roles Of SCFD1 And G2E3 In ALS**
Alessandro Abram, Izzet Mehmet Akcay, Alfredo Iacoangeli, Jemeen Sreedharan
King's College London, London, United Kingdom
- PO141 Gliotransmission Is Dysfunctional In Spinal Motor Networks Of Presymptomatic SOD1 Mice**
Alyssa Corbett, Neela Murti, Carlotta Löer, Molly Roberts, Matt Broadhead, Gareth Miles
University of St Andrews, St. Andrews, United Kingdom
- PO142 Identifying Modifiers Of DNA Damage In A Zebrafish Model Of ALS**
Lenja De Cock (1), Amber Landmeters (1), Joris Van Lindt (1), Elke Braems (1), Philip Van Damme (2), Ludo Van Den Bosch (1)
1. KU Leuven - VIB, Leuven, Belgium
2. KU Leuven - University Hospitals Leuven, Leuven, Belgium
- PO143 Investigating Mitochondrial Involvement In ALS Using Human Genomics And Transcriptomics Data**
Aminah Ali, Ammar Al-Chalabi, Alfredo Iacoangeli
King's College London, London, United Kingdom
- PO144 Characterising The Temporal Progression Of Synaptic Proteome Changes In A TDP-43-Driven ALS Model**
Anna Mcfarlane (1), Zsofia Laszlo (1), Dinja Van Der Hoorn (1), Rebecca San Gil (2), Adam Walker (3), Chris Henstridge (1)
1. University of Dundee, Dundee, United Kingdom
2. University of Sydney, Sydney, Australia
3. University of Queensland, Queensland, Australia
- PO145 Characterization Of The Molecular Mechanisms Leading To ELAVL4/HuD Altered Levels In Oxidative Stress Conditions With Possible Implications For Sporadic ALS**
Beatrice Borhy (1), Adriano Setti (1), Oscar Wilkins (2,3), Simone Barattucci (2), Max Z. Y. J. Chien (2,3), Angelo D'Angelo (1), Daniele Piccolo (1), Alessandra Grosso (1), Emanuele Eufemi (1), Beatrice Silvestri (4), Pietro Fratta (2,3), Alessandro Rosa (1)
1. Università degli Studi di Roma - La Sapienza, Roma, Italy
2. University College London, London, United Kingdom
3. The Francis Crick Institute, London, United Kingdom
4. Sanford Burnham Prebys Medical Discovery Institute, San Diego, United States

PO146 STMN2 Protein Depletion Via Translation Deficits And Stress Granules Independent Of TDP-43 Loss Of Function

Brittany Ellis, Anna Avila, Wan-Ping Huang, Sabin John, Sam Bonsall, Rachel Hodgson, Vedanth Kumar, Johnathan Cooper-Knock, Robin Highly, Tatyana Shelkownikova, SITraN, The University of Sheffield, Sheffield, United Kingdom

PO147 Motor Neuron-Intrinsic IFN-I Signalling Is Neuroprotective In The Early Phase Of ALS In Mice

Merle Bayer (1), Esra Tunaboynu (1), Jochen Weishaupt (1,2), Karin Danzer (1,2), David Brenner (1,2)
1. Department of Neurology, Ulm, Germany
2. German Center for Neurodegenerative Diseases (DZNE), Ulm site, Ulm, Germany

PO148 Decoding A Pivotal Role Of Activity-Dependent Neuroprotective Protein (ADNP) In Microglial Polarization And Metabolic Reprogramming: Implications For ALS

Lucía Silvera-Carrasco (1), Raquel García-García (1), Daniel Tejada-Moreno (1), Alejandro Martin-Montalvo (2), Raul V Duran (2), Haley Vecchiarely (3), Marie Eve Tremblay (3), Kristine Freude (4), Roman Gonzalez-Prieto (2), Jose Carlos Reyes (5), Cintia Roodveldt (6), David Pozo (1)
1. University of Seville-CABIMER (Center for Molecular Biology and Regenerative Medicine-CSIC), Seville, Spain
2. CABIMER (Center for Molecular Biology and Regenerative Medicine-CSIC), Seville, Spain
3. Division of Medical Sciences, University of Victoria, Victoria, British Columbia, Canada, Institute on Aging and Lifelong Health, University of Victoria, Victoria, Canada
4. University of Copenhagen Faculty of Health and Medical Sciences Department for Veterinary and Animal Science, Grønnegårdsvej, Denmark
5. CABIMER (Center for Molecular Biology and Regenerative Medicine-CSIC), Seville, Spain
6. University of Seville-CABIMER (Center for Molecular Biology and Regenerative Medicine-CSIC), Seville, Spain

PO149 Characterising Regional And Synaptic Proteome Changes In A TDP43-Q331K Mouse Model

Dinja Van Der Hoorn (1,2), Aleksandra Kaliszewska (3), Jemeen Sreedharan (3), Christopher M Henstridge (1,2)
1. University of Dundee, Dundee, United Kingdom
2. Euan MacDonald Centre, Edinburgh, United Kingdom
3. King's College London, London, United Kingdom

PO150 Characterising NMD Sensitivity Of TDP-43-Associated Cryptic Splicing In Human Motor Neurons Using Long-Read Sequencing

Eduard Jelinek, Tomas Solomon, Alexandros Frydas
King's College London, London, United Kingdom

- P0151 The N6-Methyladenosine Epitranscriptomic Landscape Of Skeletal Muscle In The SOD1G93A Mouse Model**
Elisa Gascón (1,2,3,4), Janne Markus Toivonen (1,2,3,4), Laura Moreno-Martinez (1,2,3,4), Paula Aparicio (1,2,3,4), Gabriel Rada (1,2,3,4), Luis Folch-Cirujeda (1), Leticia Moreno (1,2,3,4), Pilar Zaragoza (1,2,3,4), Alberto García-Redondo (5,6), Ana Cristina Calvo (1,2,3,4), Rosario Osta (1,2,3,4)
1. LAGENBIO, University of Zaragoza, Zaragoza, Spain
2. Network Centre for Biomedical Research on Neurodegenerative Diseases (CIBERNED), Madrid,
3. Institute of Health Research of Aragon (IIS), Zaragoza, Spain
4. Agroalimentary Institute of Aragon (IA2), Zaragoza, Spain
5. Genetic Diagnosis and Research Lab, Neurology Department, University Hospital 12 de Octubre, Madrid, Spain
6. Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain
- P0152 Investigating Lipid Dysregulation In ALS-FTD Derived Stem Cells**
Emily Anna Anuario, Agnes Nishumura
Queen Mary University of London, London, United Kingdom
- P0153 Structural And Biophysical Characterization Of The Interaction Between Chchd10 And The C-Terminal Region Of Tdp-43 In Amyotrophic Lateral Sclerosis**
Karen S Alarcon-Morales (1), Mauro Aguilera-Toste (2), Sara Pozo (2), Sara Martin-Ramos (1), Rodrigo Damian Garcia (2), Carolina Muguruza (2), Oscar Millet (1), Ganeko Bernardo-Seisdedos (2)
1. CIC bioGUNE, Derio, Spain
2. Universidad de Deusto, Bilbao, Spain
- P0154 How Toxic Metals Contribute To Immune Dysfunction In Amyotrophic Lateral Sclerosis**
Giulia Adriana Virgilio, Heela Sarlus, Robert A. Harris
Karolinska Institutet, Stockholm, Sweden
- P0155 ALS Linked SFPQ Loss Causes Neurodegeneration Via ADARB2 Depletion Independently Of RNA Editing**
Giulia Tyzack (1,2), Giulia Manferrari (1,2), Hyomin Seo (3), Jack Humphrey (3), Koustav Pal (4,1,2), Rickie Patani (4,1,2)
1. University College London, London, United Kingdom
2. The Francis Crick Institute, London, United Kingdom
3. Icahn School of Medicine at Mount Sinai, New York, United States
4. National University of Singapore, Singapore, Singapore
- P0156 Oligogenic Action Of Pleiotropic Neurodegenerative Repeat Expansions Via Cooperative RNA Phase Separation**
Guste Venslovaite (1), Bríd Kavanagh (1), Jennifer Hengeveld (1), Ross Patrick Byrne (1), Orla Hardiman (2), Russell Lewis Mclaughlin (1)
1. Smurfit Institute of Genetics, Trinity College Dublin, Dublin 2, Ireland
2. Academic Unit of Neurology, Trinity College Dublin, Trinity Biomedical Sciences Institute, Dublin 2, Ireland

P0157 C9orf72 Hexanucleotide Repeat Expansion Disrupts The Astrocytic Glycolytic-Glyoxalase Axis In ALS

Hannah O. Timmons (1), Billie D. Ward (1), Trong Khoa Pham (2), Heather Walker (2), Kari E. Wong (3), Alexandros Siskos (4), Barnaby Read (1), Madiha Hussain (1), Paraskevi Klotsas (1), Mark O. Collins (2), Hector C. Keun (4), Pamela J. Shaw (1), Richard J. Mead (1), Scott P. Allen (1)

1. Sheffield Institute for Translational Neuroscience, The University of Sheffield, United Kingdom

2. School of Biosciences, The University of Sheffield, Sheffield, United Kingdom

3. Metabolon Inc., Morrisville, North Carolina, United States

4. Department of Surgery and Cancer, Imperial College London, London, United Kingdom

P0158 Distinct Mitochondrial Responses To Immune Stimulation In FTD/MND Associated Human Microglia

Ilke Guntan, Uroosa Chughtai, Gaynor A Smith, Owen M Peters

Cardiff University/Dementia Research Institute, Cardiff, United Kingdom

P0159 DP-43 Dysfunction Disrupts Brain Cholesterol Homeostasis And Is Exacerbated By A High-Fat Diet

Irene García-Toledo (1), Juan M. Godoy-Corchuelo (1,2), Laura Fernández-Hernández (1),

Luis C. Fernández-Beltrán (1,3), Jesús Jiménez-Rodríguez (1), Karen Javaloyes-García (1),

Ángeles Ocaña-Cara (1), Anna Fernández-Bernal (4), Estela Area-Gómez (5), Pablo Bascuñana (6),

Silvia Corrochano (1)

1. Neurological disorders group, Hospital Clinico San Carlos, IdISSC, Madrid, Spain

2. Cajal Neuroscience Center, CSIC, Madrid, Spain

3. Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain

4. BDepartment of Experimental Medicine, University of Lleida-Lleida Biomedical Research Institute (UdL-IRBLleida), Lleida, Spain

5. Department of Biomedicine, Centro de Investigaciones Biológicas Margarita Salas, CSIC, Madrid, Spain

6. Brain Mapping Group, Hospital Clínico San Carlos, IdISSC, Madrid, Spain

P0160 Region-Specific Activation Of Microglial Pyroptosis In ALS: Insights From TDP-43A315T Mice And Human Spinal Cord

Isabel Lastres-Becker (1), Javier Suárez-Fonseca (1), Carmen Rodríguez-Cueto (2),

Javier Fernández-Ruiz (2), Eva De Lago (2)

1. Universidad Autónoma de Madrid, Madrid, Spain

2. Universidad Complutense de Madrid, Madrid, Spain

P0161 Serum Profiling Of TBK1-ALS Compared To Other Genetic Disease Forms Using Targeted Proteomics

Jasper Hesebeck-Brinckmann (1), Fabiola de Marchi (2), Hakan Cetin (3), Omar Keritam (3), Ivana Munitic (4), David Brenner (1)

1. University Ulm, Ulm, Germany

2. University of Piemonte Orientale, Piemonte, Italy

3. Medical university Vienna, Vienna, Austria

4. Faculty of Biotechnology and Drug Development, University of Rijeka, Rijeka, Croatia

P0162 Novel TDP-43 Amyloid Polymorphs Uncover Aggregation Mechanisms In ALS

Javier Oroz (1), María Gasset (1), Rubén Hervás (2), Nicolás Enrique Van Nuland (1), Mayur Mukhi (2), Eva Álvarez Merchán (1)

1. Blas Cabrera Institute for Physical Chemistry (CSIC), Madrid, Spain

2. School of Biomedical Sciences, Hong Kong University, Hong Kong, Hong Kong SAR

P0163 A Distinct SPP1? Microglial Subset Initiates CD44-astrocyte Crosstalk In ALS

Jianing Lin, Kuo Liao, Stefan Bencina, Robert Harris, Sebastian A. Lewandowski
Karolinska Institutet, Stockholm, Sweden

P0164 Exon Level Differential Expression Reveals Isoform Specific Dysregulation And Convergent Neuronal Pathways In Amyotrophic Lateral Sclerosis

John Khattar Jammal, Aminah Ali, Simon Topp, Claire Troakes, Ahmad Al Khleifat, Ammar Al-Chalabi, Alfredo Iacoangeli

King's College London, London, United Kingdom

P0165 C9orf72 Repeat Expansion Affects Immune Response In A Xenografted Microglia Mouse Model

Laura Fumagalli (1), Baukje Bijmens (1), Tim Meese (1), Maxim Van Hoek (1), Paula Polanco Miquel (1), Bob Asselbergh (1), Simona Manzella (1), Siddharthan Chandran (2), Leonard Petrucelli (3), Renzo Mancuso (1)

1. VIB, Center for Molecular Neurology, University of Antwerp, Antwerpen, Belgium

2. University of Edinburgh, Edinburgh, United Kingdom

3. Mayo Clinic, Jacksonville, United States

P0166 Functional Alterations At The Neuromuscular Junction Following TDP-43 Depletion

Lucas Taoro-González (1,2), Francisco José Urbano (3), Santiago Yanes (4),

Davinia Domínguez-González (2,5,6), Arianna Vastola-Mascolo (2,5,6), Marcial Camacho (4), Ángel Acebes (1,2), Abraham Acevedo-Arozena (2,5,6)

1. Physiology Area, Department of Basic Medical Sciences, Faculty of Medicine, University of La Laguna (ULL), San Cristóbal De La Laguna, Spain

2. Institute of Biomedical Technologies (ITB), University of La Laguna (ULL), San Cristóbal De La Laguna, Spain

3. Department of Physiology, Molecular and Cellular Biology, 'Prof. Dr. Héctor Maldonado', Institute of Physiology, Molecular Biology and Neurosciences (IFIBYNE-UBA-CONICET), Faculty of Exact Sciences, University of Buenos Aires, Buenos Aires, Argentina

4. Pharmacology Area, Department of Physical Medicine and Pharmacology, Faculty of Medicine, University of La Laguna (ULL), San Cristóbal De La Laguna, Spain

5. Canary Islands Health Research Institute (FIISC), San Cristóbal de La Laguna, Spain

6. Research Unit, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain

PO167 ALS Associated TDP-43Q331K Mutation Disrupts MAM Localization And Alters Lipid Metabolism And Mitochondrial Function

Marta Torres-Montiel (1), Anna Fernàndez-Bernal (1), Miriam Ceron-Codorniu (1), Natalia Mota-Martorell (1), Pascual Torres (1), Chiara Rossi (1), Estela Area-Gomez (2), Abraham Acevedo-Arozena (3)

1. Universitat de Lleida - IRBLleida, Lleida, Spain

2. Centro de Investigaciones Biológicas (CIB) Margarita Salas, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain

3. Hospital Universitario de Canarias, IISC, ITB-ULL, San Cristóbal De La Laguna, Spain

PO168 Can A Revolution In Sports Medicine, Optimising Lactate Metabolism, Be Applied To Amyotrophic Lateral Sclerosis?

Michael Spedding

Spedding Research Solutions SAS, Le Vesinet, France

PO169 Mitochondria-Associated Membranes As Central Hubs Of Cholesterol And Sphingolipid Dysregulation In ALS

Miriam Ceron-Codorniu (1), Anna Fernàndez-Bernal (1), Pascual Torres (1), Marta Torres-Montiel (1), Natalia Mota-Martorell (1), Estela Area-Gomez (2), Reinald Pamplona (1), Manuel Portero-Otín (1)

1. Universitat de Lleida-IRBLleida, Lleida, Spain

2. Centro de Investigaciones Biológicas (CIB) Margarita Salas - Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain

PO170 Uncovering RNA Dysregulation In The ALS Cerebellum Using Integrated Short- And Long-Read RNA-Seq

Natalie Grima (1), Andrew N Smith (1), Claire E Shepherd (2,3), Lyndal Henden (1), Dominic B Rowe (1), Matthew C Kiernan (2,4,5), Ian P Blair (1), Kelly L Williams (1)

1. Macquarie University Motor Neuron Disease Research Centre, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia

2. Neuroscience Research Australia, Randwick, Australia

3. School of Biomedical Science, Faculty of Medicine and Health, UNSW, Sydney, Australia

4. Brain and Mind Centre, The University of Sydney, Sydney, Australia

5. Department of Neurology, Royal Prince Alfred Hospital, Sydney, Australia

- P0171 Monoaminergic Modulation Mitigates TDP-43 Mislocalization In A Targeted Drug Screen For Amyotrophic Lateral Sclerosis**
NOOR UL AIN Akram, BRYAN Ng, SHI YAN Ng, CAROLINE Wee
*A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB), Singapore, Singapore*
- P0172 Effect Of Pharmacological Inhibition Of The ISR Kinase GCN2 In The ALS Transgenic Mouse Model SOD1G93A**
Nuria Peregrín Pastor (1), Sergio López De Davalillo (2), Iranzu González Cuñado (3), Tomás Aragón Amonarriz (2), Montse Arrasate Iragui (2)
1. CIMA, Pamplona, Spain
2. Biobizkaia Health Research Institute, Barakaldo, Spain
3. Universidad de Navarra, Pamplona, Spain
- P0173 Identifying Disease Mechanisms In C9ORF72 ALS/FTD And SALS Using Spatial Transcriptomics With Single Cell Resolution**
Olatz Arnold-Garcia, Stephen Moore*, Sonia Vazquez-Sanchez*, Michael Baughn, Carlos Chillón-Marinas, Katelyn Mcnair, John Ravits, Jone Lopez-Erauskin, Bogdan Bintu, Don Cleveland*
University of California at San Diego, San Diego, United States
- P0174 Identifying Disease Mechanisms In Degenerating Motor Axons Of Sporadic And C9ORF72 ALS Using Multimodal Spatial Omics**
Olatz Arnold-Garcia, Michael Baughn, Melissa Mcalonis, Anita Hermann, Bogdan Bintu, John Ravits, Don Cleveland, Jone Lopez-Erauskin**
University of California at San Diego, San Diego, United States
- P0175 ATG5 Links Autophagy To RAN Translation And RNA Toxicity In ALS/FTD Models**
Enrique Carretero-Morán (1,2), Andrés Jiménez-Zúñiga (3,4), Alberto Giménez-Bejarano (1,2,4), Livvy Houghton (5,6), Sofia Konstantinidou (5,6), Tania Matamoros (7), Héctor Foronda (4), Miguel Domínguez-Eugenio (1), Javier Ojalvo-Pacheco (1,2), Ana Baz-Matamoros (1), Carmen Paradas (8), Gorka Gereñu (3,4,9), Sarah Mizielińska (5,6), Patricia Gómez-Suaga (1,2,4,5)
1. Department of Biochemistry and Molecular Biology, School of Nursing and Occupational Therapy, Universidad de Extremadura, Cáceres, Spain
2. Instituto Universitario de Investigación Biosanitaria de Extremadura (INUBE), Cáceres, Spain
3. Department of Neuroscience, Biodonostia Health Research Institute (IIS Biodonostia), San Sebastián, Spain
4. Network Center for Biomedical Research in Neurodegenerative Diseases, Instituto de Salud Carlos III (CIBER-CIBERNED-ISCIII), Madrid, Spain
5. Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Maurice Wohl Clinical Neuroscience Institute, London, United Kingdom
6. UK Dementia Research Institute at King's College London, London, United Kingdom
7. Electron Microscopy Facility, Molecular Biology Center (CBMSO-CSIC), Campus Universidad Autónoma de Madrid, Madrid, Spain

8. Department of Neurology, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Sevilla, Spain

9. Department of Physiology, Faculty of Medicine and Nursing, University of Basque Country (UPV-EHU), Leioa, Spain

P0176 Understanding The Role Of TDP 43 N-Terminal Fragments In ALS: From Aggregates To Cellular Toxicity

Anna A Chami, Lea Bedja-Iacocca, Elodie Richard, Debora Lanznaster, Sylviane Marouillat, Charlotte Veyrat-Durebex, Christian R Andres, Philippe Corcia, H  l  ne Blasco, Patrick Vourc'H
University of Tours, Tours, France

P0177 Transcriptomic Analysis Identifies Region-Dependent Alterations In Primary And Secondary Regions Affected In The ALS-FTD Spectrum Involving Canonical Transcripts And Cryptic Exons

Pol Mengod-Soler (1,2), Julia Sala-Jarque (3,4), Antonia Vinyals (1,2), Sergio Roca-Pereira (1,2), Yaiza L  pez-Sampere (1,2), Marta Vela-Mart  nez (1,2), Leila Romero-Elkhayat (5,6), Maya Aryanfar (3,4), Farida Dakterzada (5,6), Gerard Pi  ol-Ripoll (5,6,7), Kenneth S. Kosik (3,4), M  nica Povedano (1,2,8), Pol Andr  s-Benito (2,5)

1. Group of Neurological and Neurogenetic Diseases - Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet De Llobregat, Barcelona, Spain

2. Network Centre of Biomedical Research of Neurodegenerative Diseases - CIBERNED, Institute of Health Carlos III, Hospitalet De Llobregat, Barcelona, Spain

3. Neuroscience Research Institute, University of California Santa Barbara, California, United States

4. Department of Molecular, Cellular and Developmental Biology, University of California Santa Barbara, Santa Barbara, California, United States

5. Department of Experimental Medicine, Faculty of Medicine, Universitat de Lleida (UdL), Lleida

6. Cognition and Behavior Study Group, Institute for Research in Biomedicine of Lleida (IRBLleida), Lleida, Spain

7. Unitat de Trastorns Cognitius, Hospital Universitari Santa Maria de Lleida, Universitat de Lleida, IRBLleida, Lleida, Spain

8. Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, Hospitalet De Llobregat, Barcelona, Spain

P0178 Neuroxome: Small Extracellular Vesicles As Intercellular Communication Between Motor Neurons And Skeletal Muscle

Valeria Monreal-Bibi  n (1), A  da Gir  n-Santiago (2), Raquel Manzano (3,4,5,6)

1. University of Zaragoza, Zaragoza, Spain

2. University Rovira i Virgili, Tarragona, Spain

3. Aragon Health Research Institute (IIS Aragon), Zaragoza, Spain

4. AgroFood Institute of Aragon (IA2), Zaragoza, Spain

5. LAGENBIO laboratory, Faculty of Veterinary, University of Zaragoza, Zaragoza, Spain

6. Centre for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain

- P0179 Sigma-1 Receptor Stimulation Rescues FTD/ALS Mutant TDP43-Induced Disruption Of The VAPB-PTPIP51 ER-Mitochondria Tethering Proteins Via Inhibition Of GSK3b**
Raquel Martinez-Serra (1), Philippe Gosset (1), Kerry Blair (1), Sandra Martin Guerrero (1), Chris Miller (1), Andrea Markovinovic (2)
1. King's College London, London, United Kingdom
2. University Rijeka, Rijeka, Croatia
- P0180 Long Interval Intracortical Inhibition Is Similar In People With And Without Amyotrophic Lateral Sclerosis**
Roisin Mc Mackin (1), Yasmine Tadjine (1), Narin Suleyman (1), Eva Woods (1), Serena Platiano (1), Antonio Fasano (1), Friedemann Awiszus (2), Orla Hardiman (1), Richard G. Carson (1)
1. Trinity College Dublin, Dublin, Ireland
2. Otto-von-Guericke-University, Magdeburg, Germany
- P0181 Simulating ALSFRS-R Item-Level Data Using Longitudinal IRT To Develop A Novel Win Ratio Endpoint For ALS Trials**
Rong Liu, Yihan Tang, Yanping Chen, Shunguang Wang
Regeneron, Tarrytown, United States
- P0182 TDP-43 Mislocalization In Neurodegeneration Initiated By Its Acetylation By CREBBP**
Sonia Vazquez-Sanchez, Sitao Zhang, Jaisen Lim, Don W. Cleveland
UCSD, San Diego, United States
- P0183 - Extracellular Vesicles From C9ORF72 ALS Patient iPSC-Derived Motor Neurons Induce Apoptosis In Healthy Neurons**
Suzy Varderidou-Minasian, Lars Gal, Gina Rondei, Michell Forgione, Natalia Van Dijk, Jeroen Pasterkamp
UMCU, Utrecht, The Netherlands
- P0184 Glial Dysfunction In ALS: TDP-43 Mislocalisation Impairs Oligodendrocyte Maturation And Disrupts Myelin Gene Expression**
Tania Atienzar (1), Jonathan Mill (2), Akshay Bhinge (1,2)
1. Living Systems Institute, University of Exeter, Exeter, United Kingdom
2. University of Exeter Medical School, Exeter, United Kingdom
- P0185 Protein Aggregation Patterns In The Medulla Across ALS Genotypes**
Tatiana Langerova, Fiona L Read, Jenna M Gregory
University of Aberdeen, Aberdeen, United Kingdom

- P018 A Multidimensional Deep Mutational Scanning Of The ALS Protein SOD1: Dissecting The Effect Of Mutations On Protein Abundance And Dimer Formation**
Tomás Quiroga (1), Laz Ashcroft (2), Lauren Rice (2), Mariano Martín (1), Bryony Thompson (3), Luke Mcalary (2), Benedetta Bolognesi (1)
1. Institute for Bioengineering of Catalonia (IBEC), Barcelona, Spain
2. University of Wollongong, Wollongong, Australia
3. Royal Melbourne Hospital, Melbourne, Australia
- P0187 Long-Read Sequencing To Investigate Aberrant Splicing Caused By TDP-43 Depletion In iPSC-Derived Cortical And Spinal Neurons**
Tomas Solomon, Alexandros Frydas, Eduard Jelinek, Sarah Julia Marzi
King's College London UKDRI, London, United Kingdom
- P0188 M6A-Dependent RNA Condensation Underlies FUS Autoregulation And Can Be Harnessed For ALS Therapy Development**
Wan-Ping Huang (1), Vedanth Kumar (2), Michaela Müller-Mcnicoll (3), Eugene Makeyev (4), Tatyana Shelkovernikova (1)
1. University of Sheffield, Sheffield, United Kingdom
2. Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, United Kingdom
3. Institute of Molecular Biosciences, Goethe University, Frankfurt, Germany
4. King's College London, London, United Kingdom
- P0189 Proteomic Analysis Shows FUS Over-Expression In Fibroblasts From ALS Patients With And Without FUS Variants**
Viviana Greco (1), Paolo Niccolò Doronzio (2), Giuseppe Marangi (2), Amelia Conte (3), Katia Patanella (3), Andrea Urbani (1), Mario Sabatelli (4)
1. Department Unity of Chemistry, Biochemistry and Clinical Molecular Biology, Department of Diagnostic and Laboratory Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
2. Department of Life Sciences and Public Health, Section of Genomic Medicine, Catholic University of the Sacred Heart, Rome, Italy
3. NeMO Clinical Center-Rome. Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
4. Institute of Neurology, Catholic University of the Sacred Heart, Rome, Italy
- P0190 Proteomic And Histological Profiling Of The ALS Visual Cortex Reveals Early Presynaptic Dysfunction And White Matter Atrophy**
Zsofia Laszlo (1), Anna Avila Sanchez (1,2), Anna Mcfarlane (1), Tom Gillingwater (3), Chris Henstridge (1)
1. University of Dundee, Dundee, United Kingdom
2. University of Sheffield, Sheffield, United Kingdom
3. University of Edinburgh, Edinburgh, United Kingdom

COGNITION (included in the posters session I)**P0191 Silent Echoes Of The Day: Dream Content Analysis In Amyotrophic Lateral Sclerosis**

Alessandro Bombaci (1,2), Alessandra Giordano (3), Ilaria Lavalle (3), Alice Magnino (3), Andrea Calvo (4), Adriano Chiò (4), Alessandro Cicolin (3)

1. Vita-Salute San Raffaele University, Milan, Italy

2. IRCSS Policlinico San Donato, San Donato Milanese, Italy

3. Sleep Medicine Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Torino, Torino, Italy

4. Turin ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Torino, Italy

P0192 Different Contribution Of Nucleus Accumbens And Amygdala Subnuclei To The Emergence Of Positive And Negative Behavioural Symptoms In Amyotrophic Lateral Sclerosis

Alessio Maranzano (1), Giulia Scacciatella (2), Alessandro Cocuzza (3), Massimiliano Passaretti (4), Silvia Torre (1), Edoardo Niccolo Aiello (1), Claudia Maria Cinnante (5), Joana Braga Pereira (4), Vincenzo Silani (6), Federico Verde (1), Barbara Poletti (1), Nicola Ticozzi (1)

1. Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy

2. Neurology Residency Program, Università degli Studi di Milano, Milan, Italy

3. IUSS Cognitive Neuroscience (ICoN) Center, Institute for Advanced Studies, Pavia, Italy

4. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

5. Department of Radiology and Diagnostic Imaging, IRCCS Istituto Auxologico Italiano, Milan, Italy

6. Department of Pathophysiology and Transplantation Dino Ferrari Center, Università degli Studi di Milano, Milan, Italy

P0193 Exploring The Role Of Cognitive Reserve In C9ORF72-Related Amyotrophic Lateral Sclerosis: A 2-[18F]FDG-PET Study

Antonio Canosa, Grazia Zocco, Stefano Callegaro, Umberto Manera, Rosario Vasta, Francesca Palumbo, Sara Cabras, Enrico Matteoni, Alessandra Maccabeo, Giorgio Pellegrino, Emilio Minerva, Anastasia Dei Giudici, Vita Passidomo, Barbara Iazzolino, Marco Pagani, Cristina Moglia, Andrea Calvo, Adriano Chiò

University of Turin, Turin, Italy

P0194 Integrating Mind And Care: Assessing The Role Of Cognitive And Psychological Factors In Shaping Advance Directives Among Patients With Amyotrophic Lateral Sclerosis

Debora Pain (1), Alice Radici (2), Rachele Piras (1), Irene Piazza (1), Carola Parisi (1), Beatrice Marangon (1), Chiara Cerami (2), Christian Lunetta (3)

1. ICS Maugeri, Milan, Italy

2. IUSS Cognitive Neuroscience Center, Pavia, Italy

3. ICS Maugeri, Milano, Italy

P0195 When Emotions Drive Moral Decisions: Characterizing The Socio-Affective Moral Profile In Amyotrophic Lateral Sclerosis

Andrea Panzavolta (1), Alice Radici (2), Claudia Meli (3), Giulia Funghi (3), Alessandra Dodich (3), Christian Lunetta (1), Chiara Cerami (1,2)

1. *Istituti Clinici Scientifici Maugeri IRCCS, Milan, Italy*
2. *Scuola Universitaria Superiore IUSS, Pavia, Italy*
3. *University of Trento, Rovereto, Italy*

P0196 Dual-Task Gait Impairment In ALS: Evidence Of Cognitive-Motor Interference

Edoardo Gioele Spinelli (1,2), Elisabetta Sarasso (1,2), Andrea Gardoni (1), Maria Odierno (2), Elisa Canu (1), Tommaso Russo (1), Paride Schito (1), Yuri Falzone (1), Massimo Filippi (1,2), Federica Agosta (1,2)

1. *IRCCS Ospedale San Raffaele, Milano, Italy*
2. *Vita-Salute San Raffaele University, Milano, Italy*

P0197 Motor Reserve Might Be Associated With Memory Status In ALS Patients

Monica Consonni (1), Barbara Poletti (2,3), Edoardo Nicolò Aiello (2), Veronica Faltracco (1), Silvia Torre (2), Alessandra Telesca (4,5), Federico Verde (2), Alessio Maranzano (2), Stefano Messina (2), Alberto Doretti (2), Claudia Morelli (2), Nilo Riva (1), Eleonora Dalla Bella (1), Vincenzo Silani (2,6), Giuseppe Lauria (1,7), Nicola Ticozzi (2,6)

1. *3rd Neurology Unit and Motor Neuron Disease Centre, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy*
2. *Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy*
3. *Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy*
4. *Neuroalgology Unit, Department of Clinical Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy*
5. *Neurointensive Care Unit, Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy*
6. *Department of Pathophysiology and Transplantation, Dino Ferrari Center, Università degli Studi di Milano, Milan, Italy*
7. *Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Italy*

P0198 Correcting For Practice Effects Reveals Potential Cognitive Decline In ALS: Longitudinal ECAS Findings

Fenna Hiemstra (1), Annebelle Michielsen (1), Laura J. Hagedorn (1), Leonard H. Van Den Berg (1), Martine J. E. Van Zandvoort (1,2), Henk-Jan Westeneng (1), Michael A. Van Es (1)

1. *University Medical Centre Utrecht, Utrecht, The Netherlands*
2. *Utrecht University, Utrecht, The Netherlands*

PO199 Theory Of Mind Impairment Related To C9orf72 Repeat Expansion In Amyotrophic Lateral Sclerosis: A Case-Control Study.

Francesca Palumbo, Barbara Iazzolino, Antonio Canosa, Umberto Manera, Rosario Vasta, Maurizio Grassano, Enrico Matteoni, Sara Cabras, Alessandra Maccabeo, Giorgio Pellegrino, Anastasia Dei Giudici, Stefano Callegaro, Luisa Balz, Cristina Moglia, Adriano Chiò, Andrea Calvo, Dorothee Lulé

University of Turin, Torino, Italy

PO200 Domain-Specific Cognitive Performance And Decision-Making In ALS: Associations With Life-Sustaining And End-Of-Life Choices

Greta García-Escobar (1,2), Maria Polo Otal (3), Bernat Bertran-Recasens (1,2), Sergi Vidal-Notari (1,2), Sandra Blavi-Pujol (4), Anna Guillen-sola (5,6), Juana Maria Martínez Llorens (7,8), Ana Balaña Corberó (7), Montserrat Villatoro Moreno (9), Miguel Ángel Rubio (1,2)

*1. ALS/Motor Neuron Diseases Unit, Neurology Department, Hospital Del Mar, Barcelona, Spain
. Neurological Systems and Neurotherapies Research Group, Neuroscience Program, Hospital del Mar Medical Research Institute, Barcelona, Spain*

3. Faculty of Medicine, Universitat Pompeu Fabra, Barcelona, Spain

4. ALS Catalan Foundation Miquel Valls. Programa d'Atenció integral a persones amb malalties avançades de l'Obra Social "La Caixa", Barcelona, Spain

5. ALS/Motor Neuron Diseases Unit, Physical Medicine and Rehabilitation Department, Hospital Del Mar, Barcelona, Spain

6. Rehabilitation Research Group, Hospital Del Mar Medical Research Institute, Barcelona, Spain

7. ALS/Motor Neuron Diseases Unit, Pneumology Department, Hospital Del Mar, Barcelona, Spain

8. Universitat Pompeu Fabra, Barcelona, Spain, Barcelona, Spain

9. ALS/Motor Neuron Diseases Unit, Dietetics and Nutrition Department, Hospital Del Mar, Barcelona, Spain

PO201 Patterns Of Cognitive Impairment In ALS: ECAS Findings From An Uruguayan Referral Centre

Eric Romero-Atencio (1,2), Ana García-Pérez (1,2,3), Viviana Bella-García (1,3), Jessica Bracco (1,2), Elisa Demicheli (1,4), Alicia Silveira (5), Laura Martínez-Palma (1,6)

1. Centro de Esclerosis Lateral Amiotrófica del Uruguay (CELAU) - Hospital de Clínicas - Facultad de Medicina - Universidad de la República, Montevideo, Uruguay

2. Unidad Académica de Psicología Médica - Hospital de Clínicas - Facultad de Medicina - Universidad de la República, Montevideo, Uruguay

3. Unidad de Cuidados Paliativos - Hospital de Clínicas - Facultad de Medicina - Universidad de la República, Montevideo, Uruguay

4. Unidad Académica de Neurología - Hospital de Clínicas - Facultad de Medicina - Universidad de la República, Montevideo, Uruguay

5. Unidad Académica de Neuropsicología - Hospital de Clínicas - Facultad de Medicina - Universidad de la República, Montevideo, Uruguay

6. Unidad Académica de Histología y Embriología - Facultad de Medicina - Universidad de la República, Montevideo, Uruguay

- PO202 Mild Behavioral Symptoms (MBI) Drive Caregiver Burden (CB) And Psychological Distress In Amyotrophic Lateral Sclerosis (ALS): A Longitudinal Network Analysis Approach**
Myriam Spisto (1), Lucia Aruta (2), Valentina Virginia Iuzzolino (2), Gianmaria Senerchia (2), Fabiana Panico (2), Valeria Scodes (2), Elena Salvatore (2), Pasquale Moretta (3), Luigi Trojano (1), Raffaele Dubbioso (2)
1. University of Campania Luigi Vanvitelli, Caserta, Italy
2. University of Naples Federico II, Naples, Italy
3. ICS Maugeri, Telese, Italy
- PO203 The Relationship Between Apathy Subtypes, Anhedonia And Negative Mood In Amyotrophic Lateral Sclerosis**
Ratko Radakovic (1,2,3,4), Saúl Marín Esteban (5), Francisco Rodríguez-Santos (5), Ariana Vargas Paredes (5), Sharon Abrahams (2,6), Teresa Salas Campos (5)
1. Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, United Kingdom
2. Euan MacDonald Centre for Motor Neuron Disease Research, Edinburgh, United Kingdom
3. Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, Edinburgh, United Kingdom
4. Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, United Kingdom
5. Hospital Universitario La Paz/Canto Blanco/Carlos III, Madrid, Spain
6. Human Cognitive Neuroscience, School of Philosophy, Psychology and Language Science, University of Edinburgh, Edinburgh, United Kingdom
- PO204 Digital Remote Validation And AI-Assisted ECAS Copilot: Toward Standardized Cognitive Monitoring In ALS**
Indu Navar Bingham (1), Anusha Rao (2), Natalia Luchkina (2), Silviya Bastola (2), Stephanie Henze (2), Eduardo Locatelli (3), Lauren Tabor Gray (3), Merit Cudkowicz (4), Sharon Abrahams (5), Ammar Al-Chalabi (1)
1. King's College London, London, United Kingdom
2. EverythingALS, Los Altos, United States
3. Nova Southeastern University, Davie, United States
4. Mass General Hospital, Boston, United States
5. University of Edinburgh, Edinburgh, United Kingdom
- PO205 The Effect Of Cognitive Support Strategies In Decision-Making To Consent To A Gastrostomy In Motor Neuron Disease**
Natalene Ashok Vaswani (1), Milena Contreras (1,2,3), Brogan Brown-Blair (1), Sharon Mulhern (2,4), Julyan Everett (4), Judy Newton (2), Suvankar Pal (2), Theresa Chiwera (3), Ammar Al-Chalabi (3), Sharon Abrahams (1,2)
1. Department of Psychology, School of Philosophy, Psychology and Language Sciences, University of Edinburgh, Edinburgh, United Kingdom
2. Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, United Kingdom
3. Kings College London, London, United Kingdom
4. University of Glasgow, Glasgow, United Kingdom

GENETICS AND GENOMICS (included in the posters session II)**PO206 Epigenetic Regulation In The ALS Brain: Identifying Novel Cell Type-Specific Targets**

Alexandros Frydas (1,2), Tomas Solomon (1,2), Claire Troakes (2), Sarah Marzi (1,2)

1. UK Dementia Research Institute at King's College London, London, United Kingdom

2. Department of Basic and Clinical Neuroscience, King's College London, London, United Kingdom

PO207 Somatic Nuclear Single Base Substitutions During Development In Amyotrophic Lateral Sclerosis

Alvar Paris (1,2), Yu Nie (1,3), Kornélia Szabéni (1), Serena Nik-Zainal (2), Patrick Chinnery (1,3), András Lakatos (1)

1. Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom

2. Department of Genomic Medicine, School of Clinical Medicine & Early Cancer Institute, University of Cambridge, United Kingdom

3. MRC Mitochondrial Biology Unit, School of Clinical Medicine, University of Cambridge, United Kingdom

PO208 Global Taskforce On Genetic Counselling And Testing In ALS/MND: Developing Consensus-Based Guidelines

Ammar Al-Chalabi (1,2), Kristiana Salmon (2,3), Martina De Majo (2), Cathy Cummings (2)

1. King's College London, London, United Kingdom

2. International Alliance of ALS/MND Associations, Northampton, United Kingdom

3. McGill University, Montreal, Canada

PO209 Prevalence Of ALS Gene Variants In Control Cohorts

Andrew G L Douglas (1,2), Alexander G Thompson (1), Martin R Turner (1), Kevin Talbot (1)

1. University of Oxford, Oxford, United Kingdom

2. Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

PO210 Targeted Long-Read Sequencing To Investigate Somatic Instability And Epigenetic Signatures Of The C9orf72 Hexanucleotide Repeat Expansion In Blood

Beatrix Cardus (1), Andrew G L Douglas (1,2), Martin R Turner (1), Kevin Talbot (1),

Jonathan D Rohrer (3), Arabella Bouzigues (3), Eva Cullen (3), Olaf Ansorge (1), Jakub Scaber (1), Alexander G Thompson (1)

1. Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom

2. Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

3. Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, United Kingdom

PO211 Genetic Architecture Of Familial ALS In The Netherlands

Bi-Nan Wang, Daphne Van Oosten, Paul Beele, Joke Van Vugt, Paul Hop, Maarten Kooyman, Wouter Koole, Project MinE ALS Sequencing Consortium, Leonard Van Den Berg, Wouter Van Rheenen, Jan Veldink

University Medical Center Utrecht, Utrecht, The Netherlands

P0212 Long-Term Survival In A Patient With SOD1 G41S ALS Treated With Tofersen: Comparison With Rapidly Progressive Familial Cases

Caterina Meoni (1,2), Francesca Bianchi (3), Cecilia Carlesi (3), Lucrezia Becattini (1,2), Francesco Ginanni (1,2), Francesco Nicoletti (1,2), Maria Adelaide Caligo (4), Antonella Fogli (4), Gabriele Siciliano (2), Michelangelo Mancuso (2)

1. Neurological Clinic, Pisa, Italy
2. University of Pisa, Pisa, Italy
3. Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
4. Molecular Genetics Unit, Pisa, Italy

P0213 Hidden In Noise: Cross-Study Analysis Of ALS SnRNA-Seq Reveals Study-Specific Inconsistencies But Robust Changes In TDP43-Affected Nuclei

Charlotte H Van Dijk (1), Jingtian Zhou (2), Sam Bonsall (2), Rodrigo K Siqueira De Souza (2), Johnathan Cooper-Knock (2), Kevin P Kenna (1)

1. University Medical Center Utrecht, Utrecht, The Netherlands
2. University of Sheffield, Sheffield, United Kingdom

P0214 Identity-By-Descent Analyses Reveals C9orf72 Discordance, Cryptic Relatedness, And Expanded ALS Pedigrees

Ciara O'Donoghue (1,2,3), Emrah Kacar (1), Tomas Gomes (1), Guste Venslovaite (1), Marie Ryan (2), Mark Heverin (2), Russell Mclaughlin (1), Orla Hardiman (2,3), Ross Patrick Byrne (1)

1. Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland
2. Academic Unit of Neurology, Trinity College Dublin, Dublin, Ireland
3. Beaumont Hospital, Dublin, Ireland

P0215 Co-Development Of A Genetic Care Pathway For ALS: Real-World Perspectives From The North Of England.

Clementine Wood (1), Georgia Brown (2), Kirsten Chalk (2), Samantha Holden-Smith (3), Hayley Williams (3), Greg Broadhurst (4), John Ealing (3), Catherine Breen (2), Rhona Macleod (2), Amina Chaouch (3,5)

1. Warrington and Halton Teaching Hospitals NHS Foundation Trust, Warrington, United Kingdom
2. Manchester Centre for Genomic Medicine, Manchester, United Kingdom
3. Manchester Centre for Clinical Neurosciences, Manchester, United Kingdom
4. Motor Neurone Disease Association, Northampton, United Kingdom
5. Faculty of Biology Medicine and Health, University of Manchester, Manchester, United Kingdom

P0216 SOD1 And C9orf72: Genes Over Family History In ALS

Daniel Borrego-Hernández, Laura Expósito-Blázquez, Claudia Carrascal-Vento, Sara Herranz-Sanz, Pilar Cordero-Vázquez, Jesús Esteban-Pérez, Alberto García-Redondo

Neurology department – ALS Unit. CIBERER U-723. Health research Institute, Hospital Universitario 12 de Octubre (imas12) – Avda. Córdoba s/n – 28041, Madrid, Spain

- PO217 Exploring The Impact Of Genetic Risk On Age At Onset Of Amyotrophic Lateral Sclerosis**
Dharti Vasant Kumar, Oliver Pain, Ahmad Al Khleifat, Ammar Al-Chalabi
King's College London, London, United Kingdom
- PO218 Machine Learning In ALS Genetics: A Narrative Review**
Dominic Ng (1), Valentina Escott-Price (2), Matt Bracher-Smith (2), Guillermo Cimadevila (2), Zain Hussein (3)
1. University of Edinburgh, Edinburgh, United Kingdom
2. University of Cardiff, Cardiff, United Kingdom
3. University of Glasgow, Glasgow, United Kingdom
- PO219 Disease-Specific Patterns Of OPTN Variants In ALS, FTD, And Glaucoma**
Ema Jalsic (1), Toni Franjkic (1), Ahmad Al-Kleifat (2), Lucia Corrado (3), Fabiola De Marchi (4), Ivana Munitic (1)
1. Faculty of Biotechnology and Drug Development, Rijeka, Croatia
2. King's College London, London, United Kingdom
3. University of Piemonte Orientale UPO, Novara, Italy
4. Azienda Ospedaliero Universitaria Maggiore della Carità## and University of Piemonte Orientale, Novara, Italy
- PO220 Integrative Cross-Trait Analysis Identifies Shared Genes Driving Cognitive Deficits In ALS-FTD Spectrum**
Emrah Kacar, Tomas Gomes, Ciara O'Donoghue, Guste Venslovaite, Russell Mclaughlin, Ross Byrne
Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland
- PO221 RNA-Sequencing Reveals Distinct Transcriptional States Across ALS Subtypes**
Paola Ruffo (1,2), Francesco Perrone (2,3), Jessica Rosati (4,5), Benedetta Perrone (2,3), Rossella Spataro (6), Francesca De Amicis (3), Francesca Luisa Conforti (2,3)
1. Neuromuscular Diseases Research Section, National Institute on Aging, Bethesda, United States
2. Laboratory of Medical Genetics, Department of Pharmacy and Health and Nutritional Sciences, University of Calabria, Rende, Italy
3. Health Center, Department of Pharmacy and Health and Nutritional Sciences, University of Calabria, Rende, Italy
4. Departmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health Sciences, Roma, Italy
5. Cell Reprogramming Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
6. Intensive Neurorehabilitation Unit, Villa delle Ginestre Hospital, ASP Palermo, Palermo, Italy

- PO222 A Novel Homozygous P.Val98Leu Variant In SOD1 Associated With Mild Spinal-Onset ALS**
Giulia Scacciatella (1), Alessandro Gans (1), Lorena Mosca (2), Francesca Gerardi (3), Matteo Farè (3), Valeria Sansone (3), Federica Cerri (3)
1. Neurology Residency Program, Università degli Studi di Milano, Milan, Italy
2. Medical Genetics Unit, Department of Laboratory Medicine, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
3. NeMo Clinical Center in Milan, Neurorehabilitation Unit, Milan, Italy
- PO223 TBK1-Associated ALS In A Norwegian Population-Based Cohort**
Helle Høyer (1,2), Morten Horn (3), Magnus Evjensvold (4), Elin Dahl (5), Natasha Demic (6), Marianne Lund (7), Vetle Nilsen Malmberg (5), Camilla Novy (1,2), Åse Hagen Morsund (8), Cathrine Goberg Olsen (1), Grethe Kleveland (9), Trygve Holmøy (10,2)
1. Department of Medical Genetics, Telemark Hospital, Skien, Norway
2. Institute of Clinical Medicine, University of Oslo, Oslo, Norway
3. Department of Neurology, Oslo University Hospital, Oslo, Norway
4. Department of Radiology, Oslo University Hospital, Oslo, Norway
5. Department of Neurology, Telemark Hospital, Skien, Norway
6. Department of Neurology, Vestfold Hospital, Tønsberg, Norway
7. Department of Neurology, St. Olavs University Hospital, Trondheim, Norway
8. Department of Neurology, Møre and Romsdal Hospital Trust, Molde, Norway
9. Department of Neurology, Innlandet Hospital, Lillehammer, Norway
10. Department of Neurology, Akershus University Hospital, Lørenskog, Norway
- PO224 To Describe A Case Of Amyotrophic Lateral Sclerosis (ALS) In A Patient With Down Syndrome And Discuss Its Relevance, Given The Exceptional Coexistence Of Both Conditions.**
Javier Mascias Cadavid (1), Francisco Javier Rodriguez De Rivera Garrido (1), Teresa Salas Campos (2), Rosario Urbez Mir (3), M^a Antonia Gomez Mendieta (4), Susana Chajma Izquierdo (3), Rafael Jenaro Martinez Marin (1), Yolanda Moran Benito (5)
1. Department of Neurology and Stroke Center. Multidisciplinary ALS Unit. Neurology and Cerebrovascular disease group. Neuroscience Area Hospital La Paz Institute for Health Research-IdiPAZ (La Paz University Hospital. Universidad Autónoma de Madrid), Madrid, Spain, Madrid, Spain
2. Neuropsychologist. Multidisciplinary ALS Unit. La Paz University Hospital, Madrid, Spain
3. Rehabilitation and Physical Therapy Department. Multidisciplinary ALS Unit. La Paz University Hospital, Madrid, Spain
4. Pneumology Department. Multidisciplinary ALS Unit. La Paz University Hospital, Madrid, Spain
5. Case Manager Nurse. Multidisciplinary ALS Unit. Health Care Nurses Research Group. La Paz Institute for Health Research-IdiPAZ. La Paz University Hospital, Madrid, Spain

PO225 Cell-Free DNA Methylation Profiling By Enzymatic Methyl Sequencing Reveals The Liquid Biopsy Episignature Of Amyotrophic Lateral Sclerosis

Johana Alvarez (1), Sara Razquin (1), Mónica Macías (1), Maria Luisa Mansego (2), Idoia Blanco (1), Miren Roldan (1), Lidia Gonzalez (1), Eneko Cabezón (1), Maria Elena Erro (3,4), Inma Pagola (1), Ivonne Jericó (4,3), Maite Mendioroz (1,3)

1. Navarrabiomed, Pamplona, Spain

2. NASERTIC, Pamplona, Spain

3. Hospital Universitario de Navarra, Pamplona, Spain

4. IdiSNA, Pamplona, Spain

PO226 The Project MinE Browser: Interactive Exploration Of Large-Scale ALS Exome Variant Associations

Kees De Jong, Paul Hop, Kevin Kenna, Jan Veldink, On Behalf Of The Project Mine Als Sequencing Consortium

University Medical Center Utrecht, Utrecht, The Netherlands

PO227 Genetic Variability In Polish Patients With Amyotrophic Lateral Sclerosis: Results From A Single-Center Cohort

Krzysztof Nieporecki, Magdalena Kuzma- Kozakiewicz

Department of Neurology, Medical University of Warsaw, Warsaw, Poland

PO228 Early Cellular And Spatial Alterations In The Presymptomatic Spinal Cord Of ALS Revealed By Single-Cell And Spatial Transcriptomics

Kuo Liao

Karolinska Institutet, Stockholm, Sweden

PO229 A Novel PFN1 C.91G A (P.Val31Ile) Variant In Sporadic ALS: A Case Report

LUCREZIA Becattini (1), Francesca Bianchi (2), Carlesi Cecilia (2), Caterina Meoni (1), Francesco Ginanni (1), Francesco Nicoletti (1), Maria Adelaide Caligo (3), Antonella Fogli (3), Annalisa Lo Gerfo (3), Gabriele Siciliano (1), Michelangelo Mancuso (1)

1. Neurological Unit, University of Pisa, Pisa, Italy, Pisa, Italy

2. Neurological Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, Pisa, Italy

3. Molecular Genetics Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, Pisa, Italy

PO230 Insights From A Six Year Audit Of Genetic Testing In The ALS Clinic

Lucy E Farrimond (1,2), Jasmine J Thomas (2), Andrew G L Douglas (3,1), Jakub Scaber (1), Kevin Talbot (1), Alexander G Thompson (1,2), Martin R Turner (1,2)

1. Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom

2. John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

3. Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

P0231 Expanding The Genetic Landscape Of ALS In Czechia Using Long-Read Sequencing: A Pilot Study

Magui Khazaal (1,2), Filip Pardy (3), Eva Vlckova (4), Adam Betik (4), Monika Cechova (5), Lenka Slachtova (6,2)

1. Institute of Experimental Medicine, Czech Academy of Sciences, Prague, Czech Republic
2. First Faculty of Medicine, Charles University, Prague, Czech Republic
3. CEITEC, Brno, Czech Republic
4. Department of Neurology, Masaryk University and University Hospital, Brno, Czech Republic
5. Faculty of Informatics, Brno, Czech Republic
6. Institute of Experimental Medicine, Czech Academy of Sciences, Prague, Czech Republic

P0232 Mapping Of Relatedness In Norwegian ALS Cohort

Maria Fahlström (1,2), Camilla Novy (1,2), Daphne Van Oosten (3), Ole-Bjørn Tysnes (4,5), Wouter Van Rheenen (3), Jan H Veldink (3), Peter Munch Andersen (6), Øystein Holla (1), Magnus D Vigeland (7), Trygve Holmøy (2,8), Helle Høyer (1,2)

1. Department of Medical Genetics, Telemark Hospital Trust, Skien, Norway
2. Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
3. Department of Neurology, UMC Utrecht Brain Center, Utrecht, The Netherlands
4. Department of Neurology, Haukeland University Hospital, Bergen, Norway
5. Clinical Department 1, University of Bergen, Bergen, Norway
6. Department of Clinical Sciences, Neurosciences, Umeå University, Umeå, Sweden
7. Department of Forensic Medicine, Oslo University Hospital, Oslo, Norway
8. Department of Neurology, Akershus University Hospital, Lørenskog, Norway

P0233 Evaluating HTT Repeat Length As A Potential Genetic Modifier Of Disease Susceptibility And Onset Timing In ALS Cases

*Narges Matinazad, Alfredo Iacoangel, Ammar Al-Chalabi, Ahmad Al Khleifat
King's College London, London, United Kingdom*

P0234 A Multiomics Approach To Characterizing The Molecular Phenotypes Of ALS In The Human Lumbar Spinal Cord And Motor Cortex

Natalie Barretto (1,2), Ben Fullerton (1,2), Chris Jackson (2), Aidan Daly (2), Obadele Casel (2), Joana Petrescu (1,2), Olena Kuksenko (1,2), Brhan Gebremedhin (2), Hemali Phatnani (1,2)

1. Columbia University Irving Medical Center, New York, United States
2. New York Genome Center, New York, United States

P0235 C9orf72 Hexanucleotide Repeat Alleles Of 18 Repeats Units Or More Are Unstable And Demonstrate A Paternal Expansion Bias

*Osma Rautila, Karri Kaivola, Lilja Jansson, Pentti Tienari
University of Helsinki, Helsinki, Finland*

PO236 Exploring The Power To Detect Pathogenic Mutations Through Haplotype Analyses In Distantly Related Patients With ALS

*Paul Beele, Daphne Van Oosten, Bi-Nan Wang, Jan H. Veldink, Wouter Van Rheenen
University Medical Center Utrecht, Utrecht, The Netherlands*

PO237 Large-Scale Exome Analyses Reveal Novel Rare Variant Contributions In Amyotrophic Lateral Sclerosis

*Paul J. Hop, Maarten Kooyman, Project MinE ALS Sequencing Consortium, Kevin P. Kenna,
Jan H. Veldink
UMC Utrecht, Utrecht, The Netherlands*

PO238 Increasing The CMT-ALS Spectrum: A Case Report And Narrative Review

*Rafael Jenaro Martínez Marín (1), Raúl García Yu (1), Francisco Javier Rodríguez De Rivera Garrido (1),
María Hernández Barral (1), Yolanda Morán Benito (2), Susana Chajma Izquierdo (3),
Daniela Alexandres Ríos De Los Ríos (3), Saul Marín Esteban (4), Javier Mascías Cadavid (5)*
1. Department of Neurology and Stroke Center. Neurology and Cerebrovascular disease group. Neuroscience Area Hospital La Paz Institute for Health Research-IdiPAZ (La Paz University Hospital). Universidad Autónoma de Madrid), Madrid, Spain
2. Nurse Case Manager, Multidisciplinary ALS Unit. Health Care Nurses Research Group. La Paz University Hospital Research Institute (IdiPAZ), Madrid, Spain
3. Servicio Rehabilitación. Hospital Universitario La Paz., Madrid, Spain
4. Department of Neurology and Stroke Center. Neurology and Cerebrovascular disease group. Neuroscience Area Hospital La Paz Institute for Health Research-IdiPAZ (La Paz University Hospital). Universidad Autónoma de Madrid), Madrid, Spain
5. Department of Neurology and Stroke Center. Neurology and Cerebrovascular disease group. Neuroscience Area Hospital La Paz Institute for Health Research-IdiPAZ (La Paz University Hospital). Universidad Autónoma de Madrid), Madrid, Spain

PO239 Profiling The Clinical Characteristics Of UNC13A Rs12608932 Carriers In Ireland

*Ross Patrick Byrne (1), Emrah Kacar (1), Ciara O'Donoghue (1), Tomas Gomes (1), Emmet Costello (1),
Niall Pender (1,2), Mark Heverin (1), Russell L Mclaughlin (1), Orla Hardiman (1,3)*
1. Trinity College Dublin, Dublin, Ireland
2. Royal College of Surgeons Ireland, Dublin, Ireland
3. Beaumont Hospital, Dublin, Ireland

PO240 Multimodal Structural Profiling Of Plasma CfDNA In ALS: Integrating Fragmentomics And Nucleosome Footprinting

Sara Razquin-Sola (1), Johana Álvarez-Jiménez (1), Mónica Macías (1), María Luisa Mansego (2), Idoia Blanco-luquin (1), Miren Roldan (1), Lidia González-Villena (1), Eneko Cabezon-Arteta (1), Inma Pagola (3,4), María Elena Erro (1,3), Ivonne Jericó (3,4), Maite Mendioroz (1,3)

1. Neuroepigenetics Unit, Navarrabiomed, Hospitalario Universitario de Navarra (HUN),

Universidad Pública de Navarra (UPNA), Navarra Institute for Health Research, (IdiSNA), Pamplona, Spain

2. Department of Personalized Medicine & Laboratories, NASERTIC, Government of Navarra, Pamplona, Spain

3. Neurology Department, Hospital Universitario de Navarra-IdiSNA, Pamplona, Spain

4. Neuromuscular and Neuron Motor Neuron Diseases Laboratory, IdiSNA, Pamplona, Spain

PO241 Contribution Of RNA-Binding Protein Binding Sites To ALS Heritability: A Genome-Wide Enrichment Analysis.

*Susanna Höppener, Paul Hop, Ramona Zwamborn, Paul Beele, Jan Veldink, Wouter Van Rheenen
University Medical Center Utrecht, Utrecht, The Netherlands*

PO242 Combined Transcriptomic And Genomic Latent Variable Correction Improves The Performance Of Differential Expression Analysis In ALS Datasets

*Yadusayan Appulingam, John Jammal, Aminah Ali, Oliver Pain, Alfredo Iacoangeli
King's College London, London, United Kingdom*

PO243 CYP2D6 Variants In Middle Eastern Amyotrophic Lateral Sclerosis: An Association Study Of Risk, Survival And Comparison With European Populations

Yousra Semlali, Ahmad Al Khleifat

King' College London, London, United Kingdom

EPIDEMIOLOGY (included in the posters session I)**PO244 Environmental Exposures And Clinical Heterogeneity In ALS: A Geospatial Analysis Of A Longitudinal Cohort**

Alejandro Caravaca Puchades (1,2,3), Pol Andrés Benito (4,5), Núria Botella (6,3), Sami Petricola (6), Sergi Sanz (6,3), Mònica Povedano Panadés (6)

1. Bellvitge University Hospital, L'Hospitalet De Llobregat, Spain

2. Biomedical Research Institute of Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain

3. Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain

*4. Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED),
Institute of Health Carlos III, L'Hospitalet De Llobregat, Barcelona, Spain*

*5. Cognition and Behavior Study Group, Institute for Research in Biomedicine of Lleida (IRBLleida),
Lleida, Spain*

6. ISGlobal, Barcelona, Spain

- PO245 Diagnostic Delay Is Associated With Slower Functional Progression In Amyotrophic Lateral Sclerosis: Insights From A Real-World Cohort In Chile**
Bastián Navarrete, María Jose Cuello
Hospital Carlos Van Buren, Valparaíso, Chile
- PO246 - Epidemiological Study Of Clinical Progression And Cognitive Function In Brazilian Patients With Amyotrophic Lateral Sclerosis (ALS)**
Bruna Victorasso Jardim-Perassi (1), Maria Eduarda Tortorella (1), Eduarda Massa Sartori (1), Gabriel Tambellini Santoro (1), Giulia Tambellini Santoro (1), Rute Priscila De Almeida Gonçalves (1), Camila Marques Nadim Amstalden (1), Silvana Gregório (1), Silvia Tortorella (1), Agnes Lumi Nishimura (1,2)
1. *Paulo Gontijo Insitute, Sao Paulo, Brazil*
2. *Queen Mary University of London, London, United Kingdom*
- PO247 The Effect Of Social Deprivation And Sex On ALS Survival In The Republic Of Ireland: A Time-To-Event Analysis.**
Éanna Mac Domhnaill (1,2), Mark Heverin (1), Orla Hardiman (1,3), Cathal Walsh (2)
1. *Academic Unit of Neurology, School of Medicine, Trinity College Dublin, the University of Dublin, Dublin, Ireland*
2. *Discipline of Public Health and Primary Care, School of Medicine, Trinity College Dublin, the University of Dublin, Dublin, Ireland*
3. *Department of Neurology, Beaumont Hospital, Dublin, Ireland*
- PO248 Environmental Pollutants And Amyotrophic Lateral Sclerosis In A Population-Based Registry: Investigating Disease Susceptibility, Progression And Survival**
Elisabetta Pupillo (1), Elisa Bianchi (1), Enrico Pisoni (2), Luca Diamanti (3), Roberto Bergamaschi (3), Maurizio Angelo Leone (1)
1. *Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy*
2. *European Commission, Ispra, Italy*
3. *IRCCS Mondino Foundation, Pavia, Italy*
- PO249 Quantifying Survival Differences Between ALS Clinical Trial Participants And Population Cohorts: Evidence Of Prognostic Enrichment In Trial Populations**
Emeka Uzochukwu, Francesca Maher, Ahmad Al Khleifat, Ben Carter, Alfredo Iacoangeli
King's College London, London, United Kingdom
- PO250 Gut Microbiome Composition And Function In Amyotrophic Lateral Sclerosis: A Cross-Sectional Comparison In Sweden**
Emily E Joyce (1), Fredrik Boulund (1), Caroline Ingre (1), Christina Seitz (1), Ulf Kläppe (1), Kristin Samuelsson (1), Rayomand Press (1), Rosa Luisa Potenza (2), Weimin Ye (1), Yudi Pawitan (1), Lars Engstrand (1), Ina Schuppe-Koistinen (1), Justine W Debelius (3), Fang Fang (1)
1. *Karolinska Institutet, Stockholm, Sweden*
2. *Istituto Superiore di Sanità, Rome, Italy*
3. *Johns Hopkins Bloomberg School of Public Health, Baltimore, United States*

P0251 Increasing Prevalence Of Amyotrophic Lateral Sclerosis In Austria Correlates With Reduced Mortality

Omar Keritam (1,2), Raphael Wurm (1,2), Daniel Bormann (1,2), Felix Gruber (3), Martin Krenn (1,2), Gudrun Zulehner (1,2), Jakob Rath (1,2), Fritz Zimprich (1,2), Hakan Cetin (1,2)

1. Department of Neurology, Medical University of Vienna, Vienna, Austria

2. Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria

3. Austrian Federation of Social Insurances, Vienna, Austria

P0252 Prevalence Of Amyotrophic Lateral Sclerosis In The Valencian Community, Spain: A Population-Based Cross-Sectional Study

Pablo Ros-Arlanzón (1), Juan Francisco Vázquez-Costa (2), Rosa María Vilar Ventura (3), Elena Ronda-Pérez (4), Carmen Díaz Marín (1,5)

1. Neurology Department Dr. Balmis General University Hospital - Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain

2. MND and Neuromuscular Research Unit Hospital Universitario y Politécnico La Fe and Instituto de Investigación Sanitaria la Fe (IIS La Fe), Valencia, Spain

3. Department of Neurology Castellon General University Hospital, Castellon, Spain

4. Public Health Research Group University of Alicante - CIBER of Epidemiology and Public Health, Alicante, Spain

5. Medicine Area University of Alicante, Alicante, Spain

P0253 Diagnostic Delay In Early-Onset Amyotrophic Lateral Sclerosis: A Prospective Analysis From The First National Registry In Kazakhstan

Ulbolsyn Bekbolat (1), Larissa Kuanova (2)

1. University Medical Center Corporate Fund, Astana, Kazakhstan

2. Nazarbayev University, Astana, Kazakhstan

P0254 Investigating The Effects Of Metformin On Survival In ALS Using Real-World Data

Julia Geller (1), Alex Berger (1), Willow Butler (1), Alexander V. Sherman (1,2), Marie-Abele Bind (2,3)

1. Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, United States

2. Harvard Medical School, Boston, United States

3. Department of Biostatistics, Massachusetts General Hospital, Boston, United States

IMAGIN AND ELECTROPHYSIOLOGY AS BIOMARKERS (included in the posters session II)**PO255 - Neurophysiological Evaluation Of Edaravone And Tofersen Treatment In ALS Using Axonal Excitability And MScanFit MUNE**

Abir Alaamel (1), Nur Basçi (2), Aysegül Gündüz (2), Hilmi Uysal (3)

- 1. Edirne Sultan 1. Murat State Hospital, Edirne, Turkey*
- 2. Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, Türkiye*
- 3. Akdeniz University Medical Faculty, Antalya, Turkey*

PO256 Aptamer-Based Detection Of TDP-43 And FUS Across Motor Control Networks Identifies Distinct Pathological Trajectories In ALS

Angus Shorthouse (1), Katie Hanna (1), Marta Vallejo (2), Fergal M. Waldron (1), Jenna M. Gregory (1,3)

- 1. Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom*
- 2. Heriot-Watt University, Edinburgh, United Kingdom*
- 3. Department of Pathology, NHS Grampian, Aberdeen, United Kingdom*

PO257 Quantifying Motor Unit Loss Prior To Functional Impairment In Muscles Affected By ALS

Boudewijn Sleutjes (1), Anna Bystrup Jacobsen (2), Hatice Tankisi (2), N. Gorkem Sirin (3), A. Emre Oge (3), Robert D. Henderson (4), Pieter A. Van Doorn (5), Leonard H. Van Den Berg (1), Ruben P.A. Van Eijk (1)

- 1. University Medical Center Utrecht, Utrecht, The Netherlands*
- 2. Aarhus University Hospital, Aarhus, Denmark*
- 3. Istanbul University, Istanbul, Turkey*
- 4. Royal Brisbane & Women's Hospital, Brisbane, Australia*
- 5. Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands*

PO258 In Vivo Evidence Of Subcortical MGlur5 Upregulation In Amyotrophic Lateral Sclerosis

Charlotte Vogt (1), Valerie Treyer (2), Oleksandra Hoptar (1), Zylfjje Dibrani (1), Christoph Neuwirth (1), Markus Weber (1), Nathalie Braun (1)

- 1. Neuromuscular Diseases Unit/ALS Clinic, Sankt Gallen, Switzerland*
- 2. Department of nuclear medicine, Zurich, Switzerland*

PO259 Clinical And Imaging Predictors Of Outcome In Amyotrophic Lateral Sclerosis: A Multimodal MRI And CT Study

Chiara Gemelli (1), Corrado Cabona (1), Mehrnaz Hamedani (2), Giulia Benvenuto (2), Michele Trigiantè (2), Carolina Barone (2), Michela Spagnuolo (3), Antonella Bodini (3), Marco Guerra (3), Simone Cammarasana (3), Silvia Biasotti (3), Giuseppe Patanè (3), Ludovica Badino (2), Anna Cristina Meschiari (1), Alice Cappello (1), Luca Roccatagliata (1,4), Federico Zaottini (1,4), Angelo Schenone (1,2)

- 1. IRCCS Azienda Ospedaliera Metropolitana, Genova, Italy*
- 2. Department of Neuroscience, Rehabilitation, Ophthalmology, Maternal and Child Health, University of Genova, Genova, Italy*
- 3. CNR-Institute for Applied Mathematics and Information Technologies, Genova, Italy*
- 4. Department of Health Sciences (DISSAL), University of Genova, Genova, Italy*

PO260 Dissociable Mismatch Negativity Signatures Of ALS And Neuropsychiatric Endophenotype

Ciara O'Donoghue (1,2), Narin Suleyman (1,2), Eva Woods (3), Gabriel Palma (3), Stefan Dukic (4), Aoife Troy (1), Leah Nash (1), Serena Plaitano (1), Marjorie Metzger (1), Michael Broderick (1), Eileen Rosie Giglia (1), Teresa Buxo (1), Mark Heverin (1), Bahman Nasseroleslami (1), Orla Hardiman (1,2), Roisin McMackin (1,3)

1. Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland
2. Beaumont Hospital, Dublin, Ireland
3. Discipline of Physiology, School of Medicine, Trinity College Dublin, Dublin, Ireland
4. Department of Neurology, University Medical Centre Utrecht Brain Centre, Utrecht University, Utrecht, The Netherlands

PO261 Investigating The Clinical And Neurophysiological Architecture Of Amyotrophic Lateral Sclerosis: Insights And Implications From Exploratory Correlational Patterns And Phenotypic Clustering

Corrado Cabona (1), Cristina Schenone (2), Nicola Bragazzi (3), Flavio Villani (1), Lucio Marinelli (2,1), Chiara Gemelli (3), Andrea Santamato (4), Stefania Spina (4), Paola Mandich (2,3), Laura Mori (2,3), Angelo Schenone (5,6), Carlo Trompetto (2,3)

1. Azienda Ospedaliera Metropolitana Regione Liguria (AOM) Plesso Ospedale Policlinico San Martino IRCCS, U.O. Neurofisiopatologia, Genova, Italy
2. Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Sciences (DINOEMI), University of Genova, Genova, Italy
3. Azienda Ospedaliera Metropolitana Regione Liguria (AOM) Plesso Ospedale Policlinico San Martino IRCCS, Genova, Italy
4. Department of Medical and Surgical Sciences, Spasticity and Movement Disorders, Foggia, Italy
5. Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Sciences (DINOEMI), University of Genoa, Genoa, Italy
6. Azienda Ospedaliera Metropolitana Regione Liguria (AOM), Policlinico San Martino Hospital IRCCS, Genoa, Italy

PO262 MRI And Transcranial Magnetic Stimulation Biomarkers Of Upper Motor Neuron Involvement In ALS: Age-Related Differences In Corticospinal Tract Dysfunction

Lidia Giramé-Rizzo (1,2,3), Daniel Sánchez-Tejerina (1,2,3), Beatriz Martínez (4), Cinta Soler (2), Viviana Jaumandreu (2), Arnau Llauredó (1,2,3), Juan Luis Restrepo (1,2,3), Jose Alemañ (5,2,3), Maria Salvadó (1,2,3), Elena Lainez (6), Jose Luis Seoane (6), Margarida Gratacòs-Viñola (6), Jose Manuel Vidal-Taboada (3), Cristina Auger (4), Núria Ragué (6), Raúl Juntas (1,2,3)

1. Neurology service, Vall d'Hebron University Hospital, Barcelona, Spain
2. Neuromuscular Unit, Neurology service, Vall d'Hebron University Hospital, Barcelona, Spain
3. Peripheral Nervous System Laboratory, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain
4. Neuroradiology Unit, Radiology service, Vall d'Hebron University Hospital, Barcelona, Spain
5. Neurology service, Hospital de Mollet, Barcelona, Spain
6. Neurophysiology service, Vall d'Hebron University Hospital, Barcelona, Spain

PO263 ALS Detection By Structural MRI: An Exploratory Pipeline

Danilo Tornabene (1,2), Giulia Guicciardi (3), Chiara Pullega (1), Chiara Bonizzoni (1), Luca Diamanti (1), Anna Pichiecchio (1,2)

1. IRCCS C. Mondino Foundation, Pavia, Italy
2. Department of Brain and Behavioral Sciences, Pavia University, Pavia, Italy
3. Department of Mathematics, Pavia University, Pavia, Italy

PO264 DTI ALPS Impairment In GRN-Mutated Frontotemporal Dementia: A Distinct Pathophysiological Signature

Edoardo Gioele Spinelli (1,2), Ilaria Bottale (1,2), Alma Ghirelli (1,2), Silvia Basaia (1), Teresa Battani (2), Veronica Castelnovo (1), Elisa Canu (1), Giordano Cecchetti (1), Francesca Caso (1), Giuseppe Magnani (1), Teuta Domi (1), Paola Caroppo (3), Marcella Catania (3), Federico Verde (4), Nicola Ticozzi (4), Vincenzo Silani (4), Massimo Filippi (1,2), Federica Agosta (1,2)

1. IRCCS Ospedale San Raffaele, Milano, Italy
2. Vita-Salute San Raffaele University, Milano, Italy
3. Fondazione IRCCS Istituto Neurologico Carlo Besta, Unit of Neurology 5-Neuropathology, Milano, Italy
4. Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy

PO265 To Go Or Not To Go: Reproducibility Of N2 Amplitude Alterations In Amyotrophic Lateral Sclerosis

Eva Woods (1), Gabriel Rodrigues Palma (1), Meher Sabharwal (1), Sanya Dalal (1), Narin Suleyman (2,3), Serena Plaitano (3), Marjorie Metzger (3), Leah Nash (3), Eileen Rose Giglia (3), Niall Pender (3,4), Stefan Dukic (5), Orla Hardiman (2,3), Roisin McMackin (1,3)

1. Discipline of Physiology, School of Medicine, Trinity College, The University of Dublin, Ireland
2. Department of Neurology, Beaumont Hospital, Dublin, Ireland
3. Academic Unit of Neurology, School of Medicine, Trinity College, The University of Dublin, Ireland
4. Department of Psychology, Beaumont Hospital, Dublin, Ireland
5. Department of Neurology, University Medical Centre Utrecht Brain Centre, Utrecht University, Utrecht, The Netherlands

PO266 Spinal Cord Atrophy Across Clinical Phenotypes And Stages In Amyotrophic Lateral Sclerosis: Results From A Large Multicenter Magnetic Resonance Imaging Cohort

Giorgia Querin (1,2), Muriel Lefort (2), Gaelle Bruneteau (1), François Salachas (1), Timothée Lenglet (1), Maria Del Mar Amador (1), Adèle Hesters (1), Véronique Marchand-Pauvert (3), Anne-Sophie Rolland (4), David Devos (4), Mohamed Mounir El Mendili (2), Pierre-François Pradat (2,1)

1. APHP, Pitié-Salpêtrière Hospital, Department of Neurology, ALS reference center, Paris, France
2. Laboratoire d'Imagerie Biomédicale, Sorbonne Université, Inserm, CNRS, Paris, France
3. Laboratoire d'Imagerie Biomédicale, Sorbonne Université, Inserm, CNRS, Paris, France
4. Department of Medical Pharmacology, Expert Center of Parkinson's Disease, ALS and Neurogenetic, University of Lille, LilNCog, Lille Neuroscience & Cognition, INSERM UMR-S1172, Lille University Hospital, LICEND COEN Center Lille NS-PARK Network, Lille, France

P0267 Functional Classification Of Thalamic Nuclei In ALS: Contribution Of Limbic And Associative Nuclei To Behavioural Symptoms And Disease Progression

Giulia Scacciatella (1), Alessio Maranzano (2), Alessandro Cocuzza (3), Valerio Patisso (2), Simone Pierro (2), Massimiliano Passaretti (4), Silvia Torre (2), Edoardo Aiello (2), Barbara Poletti (2), Alberto Doretto (2), Claudia Morelli (2), Joana Pereira (4), Vincenzo Silani (2), Federico Verde (2)

1. Neurology Residency Program, Università degli Studi di Milano, Milan, Italy

2. Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy

3. IUSS Cognitive Neuroscience (ICoN) Center, Institute for Advanced Studies, Pavia, Italy

4. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

P0268 Towards Comprehensive Biomarkers In ALS: A High-Density EEG Study With Simultaneous EMG Acquisition

Inês Alexandra Ribeiro Lopes Alves (1), Bruno Miranda (1), Bahman Nasserolelami (2), Mamede De Carvalho (1)

1. Institute of Physiology, MUHCRI and Centro de Estudos Egas Moniz. Faculty of Medicine, University of Lisbon, Lisbon, Portugal., Lisbon, Portugal

2. Academic Unit of Neurology, School of Medicine, Trinity College Dublin, University of Dublin, Ireland.

P0269 Quantifying Neural Excitation-Inhibition Balance In ALS Using Resting-State EEG

Iris A Bastmeijer, Robin Jansen, Henk-Jan Westeneng, Leonard H Van Den Berg, Stefan Dukic
Department of Neurology, University Medical Centre Utrecht Brain Centre, Utrecht University, Utrecht, The Netherlands

P0270 Qualification Program For Harmonised M-Scan Implementation: A Multi-Centre Clinical Trial Experience

Isabelle A.m. Busman, Veerle C.j. Van Harmelen, Diederik J.l. Stikvoort García, Merel J.w. Flinsenberg, H. Stephan Goedee, Jesper Raaijman, Leonard H. Van Den Berg, Boudewijn T.h.m. Sleutjes
UMC Utrecht, Utrecht, The Netherlands

P0271 Quantification Of Amyotrophic Lateral Sclerosis Disease Accumulation With T1-Weighted High-Resolution Magnetic Resonance Imaging: Validation In An Independent Cohort

Philip Gremmler (1), Janina Von Der Gablentz (2), Julia Meyer (2), Benjamin Ilse (1), Behnaz Farahi Ghasraboonsr (2), Sophie Dalbert (2), Isabelle Jana Buchholz (2), Julian Großkreutz (2), Robert Steinbach (1)

1. University Hospital Jena, Departement of Neurology, Jena, Germany

2. University of Luebeck, Precision Neurology of Neuromuscular and Motor Neuron Diseases, Luebeck, Germany

P0272 Quantitative Muscle Ultrasound In Amyotrophic Lateral Sclerosis: Echotexture Parameters As Clinical Correlates Of Disease Activity

Jacinto J. Martínez-Payá (1), Edgar Aljaro-Arevalo (2), María Elena Del-Baño-Aledo (1), José Ríos Díaz (3,4), Juan Francisco Vázquez-Costa (5,6,7), José Ignacio Tembl-Ferrairo (8), Pedro Chana-Valero (3,4)

1. Physical therapy department, Faculty of Medicine, University of Murcia,, Murcia, Spain

2. Physical Therapy Department, Health Sciences Faculty, CEU-Cardenal Herrera University, CEU Universities, Elche, Spain

3. Comillas Pontifical University, Health Sciences, Department. San Juan de Dios School of Nursing and Physical Therapy, Madrid, Spain

4. San Juan de Dios Foundation, Madrid, Spain

5. Neuromuscular Research Unit, Instituto de Investigación Sanitaria la Fe (IIS La Fe), Valencia, Spain

6. ALS Unit, Department of Neurology, Hospital Universitario y Politécnico La Fe, Valencia, Spain

7. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, Spain

8. Neurosonology Laboratory, Department of Neurology, Hospital Universitario y Politécnico La Fe, Valencia, Spain

P0273 Combined B-Mode And Strain Sonoelastography Of Cervical Nerve Roots And Brachial Plexus As Image Biomarkers In Amyotrophic Lateral Sclerosis

José Ríos-Díaz (1,2), Jacinto J Martínez-Payá (3), Eva María Fages-Caravaca (4), María Elena Del-Baño-Aledo (3), Pablo Fabregat Calixto (3), Carlos Domingo Bernal-Leal (3), Constantino Malagón-Luque (5,1)

1. Comillas Pontifical University, Health Sciences, Department. San Juan de Dios School of Nursing and Physical Therapy, Madrid, Spain, Madrid, Spain

2. San Juan de Dios Foundation, Madrid, Spain, Madrid, Spain

3. Physical therapy department, Faculty of Medicine, University of Murcia, Spain, Murcia, Spain

4. Hospital Universitario Santa Lucía. Unidad Multidisciplinar de diagnóstico y tratamiento de Esclerosis Lateral Amiotrófica y otras enfermedades de Motoneurona, Murcia, Spain

5. ICAI-Comillas, Comillas Pontifical University, Madrid, Spain, Madrid, Spain

P0274 Echovariation In Biceps Brachii Predicts Weight Loss Rate In ALS Independently Of Disease Duration

Juan Francisco Vázquez-Costa (1,2,3), Jacinto J. Martínez-Payá (4), María Elena Del-Baño-Aledo (4), José Ríos-Díaz (5,6), José Ignacio Tembl-Ferrairo (7), Joaquín Zambrano-Martín (5,6)

1. Neuromuscular Research Unit, Instituto de Investigación Sanitaria la Fe (IIS La Fe),, Valencia, Spain

2. ALS Unit, Department of Neurology, Hospital Universitario y Politécnico La Fe, Valencia, Spain

3. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, Spain

4. Physical therapy department, Faculty of Medicine, University of Murcia, Murcia, Spain

5. Comillas Pontifical University, Health Sciences, Department. San Juan de Dios School of Nursing and Physical Therapy, Madrid, Spain

6. San Juan de Dios Foundation, Madrid, Spain

7. Neurosonology Laboratory, Department of Neurology, Hospital Universitario y Politécnico La Fe, Valencia, Spain

PO275 The Effect Of An UNC13A Polymorphism On Neuroimaging In ALS

Justus D. A. M. Van Nispen Tot Sevenaer, Pauline B. Van Lieshout, Sidney Van Der Wel, Bi-Nan Wang, Boaz Kalkhoven, Wytse Van Hoek, Annebelle Michielsen, Tessa F. C. Vogelaar-Floris, Wouter Van Rheenen, Jan H. Veldink, Leonard H. Van Den Berg, Henk-Jan Westeneng
University Medical Centre Utrecht, Utrecht, The Netherlands

PO276 Cortical And Subcortical Regional Iron Accumulation In ALS

Konrad Geiger (1), Paula Barthel (1), Julian Pfeiffer (1), Jakob Riffel (1), Patrick Kinz (1), Lucas Negri (1), Jochen Weishaupt (1,2), Julian Conrad (1)
1. Universitätsklinikum Mannheim, Mannheim, Germany
2. Universitätsklinikum Ulm, Ulm, Germany

PO277 Replication Of Beta EEG Oscillations Related To The Sustained Attention To Response Task In Irish And Dutch Cohorts

Marit Boxum (1), Gabriel Rodrigues Palma (2), Robin Jansen (1), Iris A. Bastmeijer (1), Sanya Dalal (2), Eva Woods (2), Narin Suleyman (2,3), Eileen Rose Giglia (4), Aoife Troy (4), Abby Field (2), Serena Plaitano (4), Marjorie Metzger (4), Niall Pender (4,5), Orla Hardiman (3,4), Leonard H. Van Den Berg (1), Roisin Mcmackin (2,4), Stefan Dukic (1)
1. Department of Neurology, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands
2. Discipline of Physiology, School of Medicine, Trinity College Dublin, University of Dublin, Ireland
3. Department of Neurology, Beaumont Hospital, Dublin, Ireland
4. Academic Unit of Neurology, School of Medicine, Trinity College Dublin, University of Dublin, Ireland
5. Department of Psychology, Beaumont Hospital, Dublin, Ireland

PO278 Implementation Of Neurophysiological Techniques In ALS Clinical Trials: A Systematic Review And Practical Guideline For Future Clinical Trials.

Merel Flinsenbergh, Ruben Van Eijk, Stephan Goedee, Leonard Van Den Berg, Boudewijn Sleutjes
UMC Utrecht, Utrecht, The Netherlands

PO279 Retinal Imaging In ALS: A Prospective Optical Coherence Tomography Study

Miracle Ozzoude, Isaac Chau, Ethan Stoker, Charlene Hamid, Christine Weaver, Judith Newton, Baljean Dhillon, Suvankar Pal, Tom Macgillivray
University of Edinburgh, Edinburgh, United Kingdom

PO280 A Multi-Level Framework For Technical Drift Detection And Harmonization In A Single-Site ALS MRI Cohort

Muhammad Abeer Irfan, Robert Ross, Aidan Meade
Technological University Dublin, Dublin, Ireland

PO281 Volumetric Deep Learning Embeddings As Imaging Biomarkers For Functional Decline And Progression In ALS

Muhammad Abeer Irfan, Robert Ross, Aidan Meade
Technological University Dublin, Dublin, Ireland

PO282 Frontotemporal Alpha Power Is Reduced In People With ALS But Alpha Modulation Remains Intact

Narin Suleyman (1,2), Marjorie Metzger (1), Eileen Rose Giglia (1), Matthew Mitchell (1), Serena Plaitano (1), Stefan Dukic (3), Roisin Mcmackin (1), Prabhav Mehra (1), Saroj Bista (1), Orla Hardiman (1,2), Bahman Nasserroleslami (1)

1. Trinity College Dublin, Dublin, Ireland

2. Beaumont Hospital, Dublin, Ireland

3. Utrecht University, Utrecht, The Netherlands

PO283 A High-Affinity Fluorescent Peptide Nucleic Acid Aptamer Enables Robust Detection Of Pathological TDP-43 Across Cellular And Tissue Models

Orjona Stella Taso (1), Fergal M Waldron (2), Holly Spence (2), Doaa Taha (1), Giulia Tyzack (1), Hannah Franklin (1), Rebecca Gabrielle (1), Selina Wray (1), Rickie Patani (1), Elsa Zacco (3), Gian Gaetano Tartaglia (3), Christine Vande Velde (4), Alicia Dubinski (4), Sergio Dall'angelo (2), Matthew J Keuss (1), Jenna M. Gregory (2)

1. UCL, London, United Kingdom

2. University of Aberdeen, Aberdeen, United Kingdom

3. Italian Institute of Technology, Genoa, Italy

4. University of Montreal, Montreal, Canada

PO284 Associations Between CSF Markers Of Neuronal Injury And Neuroinflammation And Cerebral Glucose Metabolism In People With ALS.

Joke De Vocht (1,2), Donatienne Van Weehaeghe (1), Jonas Dubin (1), Frederik Hobin (1), Fouke Ombelet (1,2), Maxim De Schaepdryver (1), Benjamin Gille (1), Nikita Lamaire (1), Michel Koole (1), Koen Poesen (1,2), Koen Van Laere (1,2), Philip Van Damme (1,2)

1. KULeuven, Leuven, Belgium

2. University Hospitals Leuven, Leuven, Belgium

PO285 Longitudinal Trajectories Of EEG Motor Cortex Oscillations In ALS

Stefan Dukic, Robin M. Jansen, Iris A. Bastmeijer, Henk-Jan Westeneng, Leonard H. Van Den Berg
University Medical Centre Utrecht, Utrecht, The Netherlands

PO286 Brain Metabolic Connectivity Across King's Stages In Amyotrophic Lateral Sclerosis

Umberto Manera (1,2), Francesca Di Pede (1), Sara Cabras (1,3), Rosario Vasta (1), Emilio Minerva (1), Enrico Matteoni (1), Giorgio Pellegrino (1), Francesca Palumbo (1), Stefano Callegaro (1), Alessandra Maccabeo (1), Giulia Polverari (4), Alessio Martino (5), Alessandro Giuliani (6), Cristina Moglia (1,2), Andrea Calvo (1,2,7), Marco Pagani (8,9), Adriano Chiò (1,2,7,8), Antonio Canosa (1,2,7,8)

1. ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy

2. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy

3. School of Advanced Studies, Centre for Neuroscience, University of Camerino, Camerino, Italy

4. Positron Emission Tomography Centre AFFIDEA-IRMET S.p.A, Turin, Italy

5. Department of AI, Data and Decision Sciences, LUISS Guido Carli University, Rome, Italy

6. Environment and Health Department, Istituto Superiore di Sanità, Rome, Italy

7. Neuroscience Institute of Turin (NIT), Turin, Italy

8. Institute of Cognitive Sciences and Technologies, C.N.R., Rome, Italy

9. Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden

PO287 Transcranial Magnetic Stimulation Detects Subclinical Corticobulbar Degeneration And Predicts Bulbar Outcomes In Amyotrophic Lateral Sclerosis

Valentina Virginia Iuzzolino (1), Federico Ranieri (2), Raffaele Dubbioso (1),

Italian Neurological Society (3), Italian Society Of Clinical Neurophysiology (4)

1. Department of Neurosciences, Reproductive Sciences, and Odontostomatology, University of Naples Federico II, Naples, Italy

2. Neurology Unit, Department of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy

3. MND Study Group, Siena, Italy

4. Neurostimulation-Neuromodulation Study Group, Rome, Italy

PO288 Compound Muscle Action Potential Decrement Across Different Muscles In Patients With ALS - A Systematic Review And Meta-Analysis

Veerle Van Harmelen, Isabelle Busman, Stephan Goedee, Leonard Van Den Berg, Boudewijn Sleutjes
UMC Utrecht, Utrecht, The Netherlands

PO289 Brain Mobile Macromolecule Maps In ALS And Asymptomatic C9orf72 Mutation Carriers Assessed With MR Spectroscopy At 7T.

Wytse Van Hoek, Abram Nitert, Kevin Van Veenhuijzen, Harold Tan, Carrie Wismans, Dennis Klomp, Jannie Wijnen, Leonard Van Den Berg, Henk-Jan Westeneng
UMC Utrecht, utrecht, The Netherlands

IN VITRO EXPERIMENTAL MODELS / CELLULAR MODELS (included in the posters session I)**PO290 Early Vulnerability And Altered Network Responsiveness In C9orf72 ALS Spinal Cord Spheroids Generated From A High-Purity Motor Neuron Differentiation Strategy**

Alba Sansa, Monica Feole, Clive N Svendsen

Cedars Sinai Medical Center, Los Angeles, United States

PO291 Bioinformatic Quality Control Of CRISPR-Cas9 Modified iPSC Lines In The UK MND Research Institute

Aleksandra Mech (1), Sandra Diaz Clavero (2), Dulcie Keeley (1), Giampietro Schiavo (2), Jemeen Sreedharan (1)

1. KCL, London, United Kingdom

2. UCL, London, United Kingdom

PO292 Chemical Induction Of Aging In iPSC-Motor Nerve Organoids To Model Amyotrophic Lateral Sclerosis

Valeria Casiraghi (1), Veronica Casarotto (2), Serena santangelo (2), Alireza Bourjarian (1), Enrico Pellegrini (1), Sabrina Longobardi (2), Sabrina Invernizzi (1), Serena Leoni (2), Vincenzo Silani (2,3), Patrizia Bossolasco (2), Antonia Ratti (2,1)

1. Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milano, Italy

2. Department of Neuroscience - Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy

3. "Dino Ferrari" Center, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy

PO293 Effect Of Noopept On Mutant Superoxide Dismutase 1 Cellular Model Of Amyotrophic Lateral Sclerosis

BANDANA Kumari Sahu (1,2), Sagar Verma (1), Shiffali Khurana (1), Dr Vibha Taneja (1), Nirmal Kumar Ganguly (1)

1. Sir Ganga Ram Hospital, Delhi, India

2. Manipal Academy of Higher Education, Udupi, India

PO294 Patient-Derived Cortical Brain Organoids Model Key Pathological Features Of ALS

Ana Belén García-Delgado (1), María Herrera-Sánchez (1), Sara Bega (1), Rafael Campos-Cuerva (2), Silvia Hucha (3,4), Josefa Álvarez-Fuentes (1), Lucía Martín-Banderas (1), Carmen Paradas (3,4), Rosario Sánchez-Pernaute (5,6), Beatriz Fernández-Muñoz (1)

1. Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain

2. Red Andaluza de Diseño y Traslación de Terapias Avanzadas (RADYTTA), Sevilla, Spain

3. CSUR/ERN Neuromuscular Disorders, Department of Neurology, Hospital Universitario Virgen del Rocío/ Instituto de Biomedicina de Sevilla, Sevilla, Spain

4. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Sevilla, Spain

5. Ikerbasque, Basque Foundation for Science, Bilbao, Spain

6. Biobizkaia Health Research Institute, Barakaldo, Spain

- PO295 Axonal Transport Defects And Extracellular Vesicle Alterations In TARDBP A382T IPSC-Derived Motor Neurons**
Carmen Pérez De La Lastra (1,2), Sofia Soria Utrilla (2), Carolina Alquézar (2), Valle Palomo (1)
1. IMDEA Nanoscience, Madrid, Spain
2. Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain
- PO296 Investigating Disease Related Phenotypes Of Novel ALS-Associated Genetic Variants In IPSC-Derived Motor Neurons**
Carola Kußerow, Pavol Zelina, Serife A. Uysal, R. Jeroen Pasterkamp
UMC Utrecht, Utrecht, The Netherlands
- PO297 Oral Treatment With Fasudil Diminishes The Capacity Of ALS Patient-Derived Exosomes To Induce TDP-43 Neuropathology And ALS-Relevant Proteomics Changes In Vitro**
Kevin Reynolds-Caicedo (1), Casey Barker (1), Allison Grossberg (1), Claudia Pena (1), Sunil Kumar (1), Thomas Macallister (2), Daniel Linseman (1)
1. University of Denver, Denver, United States
2. Woolsey Pharmaceuticals, New York, United States
- PO298 Generation Of Human Cell Models Carrying TARDBP And SOD1 Mutations For Precision Gene Editing In ALS.**
Claudia Carrascal-Vento (1,2), Martin Trujillo-Perez (2), Laura Exposito-Blazquez (3), Daniel Borrego-Hernandez (3), Alberto Garcia-Redondo (1), Raul Perez-Jimenez (2)
1. Neurology department – ALS Unit. Health research Institute, Hospital Universitario 12 de Octubre (imas12), Madrid, Spain
2. Synthetic Biology Laboratory - CIC BioGUNE, Bilbao, Spain
3. Neurology department – ALS Unit. CIBERER. Health research Institute, Hospital Universitario 12 de Octubre (imas12), Madrid, Spain
- PO299 Neuroprotective Potential Of Adipose Mesenchymal Stem Cell-Derived Extracellular Vesicles On Damaged Motoneurons: Impact Of Cell Source Activation State**
Davide Sganzerla, Mauro Caprioli, Ilaria Scambi, Arianna D'Alberto, Sofia De Marchi, Elisa Pelullo, Ermanna Turano, Raffaella Mariotti
University of Verona, Verona, Italy
- PO300 Characterising A Novel Amyotrophic Lateral Sclerosis Proteinopathy**
Emma Bray, Rachel Hodgson, Ya-Hui Lin, David Burrows, J Robin Highley, Tatyana Shelkownikova, Guillaume M Hautbergue
Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, United Kingdom

- PO301 Characterization Of Induced Pluripotent Stem Cell (IPSC)-Derived Microglia From Different ALS Genetic Backgrounds**
Enrico Pellegrini (1), Chiara Lattuada (2), Sabrina Invernizzi (1), Veronica Casarotto (3), Serena Santangelo (3), Sabrina Longobardi (3), Serena Leoni (3), Vincenzo Silani (3), Antonia Ratti (1), Patrizia Bossolasco (3)
1. Università degli Studi di Milano, Milano, Italy
2. University of Luxembourg, Luxembourg, Luxembourg
3. IRCCS Istituto Auxologico Italiano, Milano, Italy
- PO302 Epigenetic Characterization Of DNA Methylation In 2D Cultures And Motor Neuron Organoids From Sporadic ALS IPSCs**
Eveljn Scarian (1), Matteo Bordoni (1), Camilla Viola (1,2), Arianna Franchino (2), Luca Diamanti (1), Orietta Pansarasa (1)
1. IRCCS Mondino Foundation, Pavia, Italy
2. University of Pavia, Pavia, Italy
- PO303 Skeletal Muscle Cells Expressing The HSOD1G93A Mutation Show Mitochondrial Alterations And Impaired Mitochondrial Quality Control**
Gabriel Rada (1), Fernando Bartolomé (2), Paula Aparicio (1), Leticia Moreno García (1), Elisa Gascón (1), Nora Molina (1), Luis Folch Cirujeda (1), Mario Díaz (2), Carolina Alquézar (2), Ana Cristina Calvo (1), Janne Markus Toivonen (1), Antonio Musarò (3), Laura Moreno Martínez (1), Rosario Osta (1)
1. Universidad de Zaragoza, Zaragoza, Spain
2. Hospital Universitario 12 de Octubre Research Institute (imas12), Madrid, Spain
3. Sapienza University of Rome, Rome, Italy
- PO304 Machine Learning-Based Morphometric Profiling Of Patient-Derived Motor Neurons As A Scalable Platform For Amyotrophic Lateral Sclerosis Drug Discovery**
Gaspard Oudinot, Elena Pasho, Mark Zaidi, Manon Marchais, Sorana Ciura, Edor Kabashi
Institut Imagine, Paris, France
- PO305 Modelling The Human Neuromuscular Junction In Vitro**
Irene Mei (1), Lara Leal Hernández (1), Silvia Gómez (1), Christoph Schweingruber (1), Alexandra Barte (1), Gill Pollmeier (2), Jik Nijssen (2), Eva Hedlund (1)
1. Stockholm University, Stockholm, Sweden
2. Karolinska Institutet, Stockholm, Sweden
- PO306 L-Type Calcium Channel-Dependent Signalling And Therapeutic Modulation In Induced Pluripotent Stem Cell-Derived Motor Neurons Modelling Amyotrophic Lateral Sclerosis/ Frontotemporal Dementia**
Iris Stefania Pasniceanu, Monica Fox, Kevin Talbot
Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom

P0307 ALS-Causative KIF5A Mutations Impair Translation And Disrupt Metabolic And Proteostatic Pathways In HiPSCs Derived Motor Neurons

Isabel Loss (1,2,3), Rüstem Yilmaz (2), Babak Loghmani (1,2), Francesca Tuorto (2), Tessa Fabian (2), Elena Cairo (2), Philipp Koch (3), Jochen Weishaupt (1,2), Rosanna Parlato (2)

1. Ulm University, Ulm, Germany

2. Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

3. Hector Institute of Translational Brain Research, Central Institute of Mental Health, Mannheim, Germany

P0308 Comparative Analysis Of Different TBK1-ALS Mutations In Patient-Derived Motor Neurons Reveals Alterations In Autophagy-Lysosome Pathways And Ciliogenesis

Jahnavi Srinidhi (1,2), Babak Loghmani (3), Isabel Loss (1,2), Rüstem Yilmaz (1), Philipp Koch (2), Julian Conrad (1), Rosanna Parlato (1), Jochen Weishaupt (1,3)

1. Division of Neurodegenerative Disorders, Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neurosciences, Heidelberg University, Mannheim, Germany

2. Hector Institute of Translational Brain Research, Central Institute of Mental Health, Mannheim, Germany

3. Department of Neurology, University of Ulm, Ulm, Germany

P0309 Human Myoblasts Immortalization For The Study Of ALS

Jesús Alejandro Bueso De Barrio (1,2), Alberto Damborenea (2), Lorea Blázquez (2), Valle Palomo (1), Sonia Alonso-Martín (2)

1. IMDEA Nanociencia, Madrid, Spain

2. IIS Biogipuzkoa, Donostia, Spain

P0310 Distinct Cellular Stressors Differentially Modulate TDP-43 Localization And Stress Granule Dynamics

José Miguel Miguel Brito Armas (1), Beatriz Rodríguez Villa (2), Davinia Domínguez González (2), Ramón Alejo Bustillo Alfaro (2), Lucas Taoro González (3), Alessandro Marrero Gagliardi (4), Arianna Vastola-Mascolo (2), Abraham Acevedo Arozena (5)

1. CIBERNED, San Cristóbal De La Laguna, Spain

2. Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), San Cristóbal De La Laguna, Spain

3. Universidad de la Laguna (ULL), San Cristóbal De La Laguna, Spain

4. UCL Queen Square Institute of Neurology, London, United Kingdom

5. Hospital Universitario de Canarias (HUC), San Cristóbal De La Laguna, Spain

P0311 Investigating The Compartment-Specific Expression And Function Of Small Non-Coding RNAs In FUS-ALS iPSC-Derived Motor Neurons

Laura Wieg, Vamshidhar R. Vangoor, R. Jeroen Pasterkamp

Department of Translational Neuroscience, University Medical Center Utrecht Brain Center, Utrecht, The Netherlands

- P0312 Pharmacological Impact Of Anti-Inflammatory Compounds On IPSC Derived Motor Neurons In The Context Of Amyotrophic Lateral Sclerosis (ALS)**
Lennard Bernd Köster (1,2), Jana Tauschke (3), Thomas Gschwendtberger (1), Peter Claus (4,2), Susanne Petri (1,2)
1. Department of Neurology, MHH, Hannover, Germany
2. Center for Systems Neuroscience Hannover (ZSN), Hannover, Germany
3. Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, MHH, Hannover, Germany
4. Molecular Neurosciences, Dept. of Psychiatry, Social Psychiatry and Psychotherapy, MHH, Hannover, Germany
- P0313 HnRNP Q/SYNCRIP Contributes To Amyotrophic Lateral Sclerosis By Regulating Expression Of FXR1 And FXR2**
Lorena Decker (1), Simone Feldengut (2), Sonja Menge (1), Antonia Mayer (1,3), Maike Haas (1), Karin M. Danzer (1,4), Johannes Dorst (1), Deniz Yilmazer-Hanke (2), Axel Freischmidt (1)
1. University of Ulm, Ulm, Germany
2. University Hospital Ulm, Ulm, Germany
3. German Center For Neurodegenerative Diseases (DZNE), Tübingen, Germany
4. German Center For Neurodegenerative Diseases (DZNE), Ulm, Germany
- P0314 Multi-Omics Characterization Of C9orf72-Associated ALS Pathology In Patient-Derived Spinal Cord Organoids Reveals Convergent Molecular Signatures And Therapeutic Targets**
Lorenzo Brambilla (1), Giorgia Galvani (1), Mafalda Rizzuti (1), Noemi Galli (1), Michela Ripolone (1), Laura Napoli (1), Valentina Melzi (1), Giulia Magni (1), Federica Rizzo (1), Jeroen Pasterkamp (2), Linda Ottoboni (3), Stefania Corti (3)
1. IRCCS Ca' Granda Foundation - Ospedale Maggiore Policlinico, Milano, Italy
2. Brain Center Rudolf Magnus, Utrecht, The Netherlands
3. University of Milan, Milano, Italy
- P0315 TDP-43 Proteinopathy Drives Reversible Sarcomeric Collapse In ALS Patient-Derived Myotubes**
Lucía Gallego Alonso (1,2)
1. Cajal Neuroscience Center (CNC) - CSIC, Madrid, Spain
2. PhD Program in Neuroscience, Autonoma de Madrid University-Cajal Institute, Madrid, Spain
- P0316 Migration Mechanisms Of Extracellular Vesicles Derived From Adipose Mesenchymal Stem Cells Through An In Vitro Epithelium And Their Neuroprotective Effect On Damaged Motoneurons**
Mauro Caprioli, Davide Sganzerla, Ilaria Scambi, Arianna D'Alberto, Sofia De Marchi, Elisa Pelullo, Ermanna Turano, Raffaella Mariotti
University of Verona, Verona, Italy

PO317 Development Of A Human Cell-Based Model From Olfactory Neuroepithelium To Study TDP-43 In Amyotrophic Lateral Sclerosis

Ermanna Turano, Matilde Bongiani, Francesco Silvestri, Erika Bronzato, Valerio Arietti, Luca Sacchetto, Gianluigi Zanusso, Raffaella Mariotti, Mauro Caprioli
University of Verona, Verona, Italy

PO318 Axonal Accumulation Of TDP-43 In iPSC-Derived Motor Neurons From Sporadic ALS Patients

Monica Feole (1), Alba Sansa (2), Deepti Lall (1), Richard A. Smith (3), Clive N. Svendsen (1)
1. Board of Governors Regenerative Medicine Institute, Los Angeles, United States
2. Cedars-Sinai Medical Center, Los Angeles, United States
3. Cedars-Sinai Medical Center, San Diego, United States

PO319 Spinal Cord Organoids From iPSC Lines Carrying C9ORF72 Repeat Expansions

Nadia Jamshaid (1,2), Alberto Meana (1), Ana Belen García Delgado (3), Beatriz Fernandez Muñoz (3), Tomas Aragon (4), Montserrat Arrasate (4,5), Rosario Sanchez Pernaute (4,5)
1. Biobizkala Health Research Institute, Barakaldo, Spain
2. University of the Basque Country EHU, Doctoral program in Neuroscience, Leioa, Spain
3. Universidad de Sevilla, Sevilla, Spain
4. Biobizkaia Health Research Institute, Barakaldo, Spain
5. Ikerbasque, Bilbao, Spain

PO320 Ciclopirox Olamine And The SMG Inhibitor 11j Drive TDP-43 Loss Of Function: A Drug-Inducible Cellular Model

Sammra Maqsood, Santi Rico Ríos, Pascual Torres Cabestany, Victoria Ayala Jove, Reinald Pamplona Gras, Manuel Portero Otin
Metabolic Pathophysiology Research Group, Dept of Experimental Medicine, University of Lleida-IRB
Lleida, Avda Rovira Roure, 80 E25196, Lleida, Spain

PO321 Generation Of A Universal Human Cellular Platform For Drug Testing In ALS

Sandra Díaz Clavero (1,2), Aleksandra Mech (3,2), Kathryn Knowles (1,2), Dulcie Keeley (3), Charlotte Jayne Spicer (1), Jemeen Sreedharan (3,2), Andrea Malaspina (1,2,4), Giampietro Schiavo (1,2,5), Linda Greensmith (1,2)
1. University College London, Institute of Neurology, London, United Kingdom
2. UK MND Research Institute, London, United Kingdom
3. King's College London, London, United Kingdom
4. UCL Queen Square MND Centre, London, United Kingdom
5. UK Dementia Research Institute at UCL, London, United Kingdom

PO322 Proteasomal-Dependent CHK1 Degradation Leads To DNA Damage Accumulation In ALS Cellular Model Systems

Sofia Francia, Stefania Modafferi
Institute of Molecular Genetics, Pavia, Italy

PO323 CRISPR Kinome Screens In Human Motor Neurons Reveal Druggable Modulators Of TDP-43 Pathology

Tania Atienzar (1), Jonathan Mill (2), Akshay Bhinge (1,2)

1. Living Systems Institute, University of Exeter, Exeter, United Kingdom

2. University of Exeter Medical School, Exeter, United Kingdom

PO324 Overexpression Of Macrophage Migration Inhibitory Factor (MIF) In Motor Neurons Differentiated From Mutant SOD1-ALS Patient-Derived iPSCs Increases Neuronal Activity

Thomas Gschwendtberger, Susanne Petri

Hannover Medical School, Hannover, Germany

PO325 Analysis Of Extracellular Vesicle Cargo Dynamics In ALS-Derived Motor Neurons During Neuronal Differentiation

Youjung Han, Sandra De La Fuente Ruiz, Marco Terenzio

Okinawa Institute of Science and Technology, Okinawa, Japan

NEW DRUGS DEVELOPMENT (included in the posters session II)

PO326 Five-Year Survival Of 42% In ALS Patients Treated With Masitinib: Long-Term Outcomes From AB10015 Trial

Albert C Ludolph (1,2), Alain Moussy (3), Olivier Hermine (4,3,5)

1. Department of Neurology, University of Ulm, Ulm, Germany

2. German Center for Neurodegenerative Diseases, Ulm, Germany

3. AB Science, Paris, France

4. Imagine Institute, INSERM UMR 1163, University of Paris, Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutic Implication, Hospital Necker, Paris, France

5. Department of Hematology, Necker Hospital, Assistance Publique Hôpitaux de Paris, Paris, France

PO327 Tau Tubulin Kinase 1 Inhibition Does Not Affect Ciliogenesis And Restores TDP-43 Homeostasis In ALS And FTD-TDP Models

Cecilia Sánchez-Santos (1,2), Vanesa Nozal (1), Francesc R. García-Gonzalo (3,4,5), Lucia Baselga (1,2), Loreto Martínez-González (1,2), Eva De Lago (2,6), Carmen Gil (1,2), Ana Martínez (1,2)

1. Centro de Investigaciones Biológicas-CSIC, Ramiro de Maeztu 9, Madrid, Spain

2. CIBER de Enfermedades Neurodegenerativas. Instituto de Salud Carlos III, Madrid, Spain

3. Instituto de Investigaciones Biomédicas Sols-Morreal (IIBM), UAM-CSIC, 28029, Madrid, Spain

4. CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain

5. Departamento de Bioquímica, Facultad de Medicina, UAM, Madrid, Spain

6. Instituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain

- PO328 Structure-Guided Dual-Action Hybrid Therapeutics Targeting SOD1 In ALS**
Ilkin Yapici (1), Belgin Sever (2), Halilibrahim Ciftci (3), Hasan Demirci (1,4), Ayse Nazli Basak (5)
1. Department of Molecular Biology and Genetics, Koc University, Istanbul, Türkiye
2. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskisehir, Türkiye
3. Department of Molecular Biology and Genetics, Burdur Mehmet Akif Ersoy University, Burdur, Türkiye
4. Stanford PULSE Institute, SLAC National Laboratory, Menlo Park, CA, United States
5. Suna and Inan Kiraç Foundation, Neurodegeneration Research Laboratory (KUTTAM-NDAL), School of Medicine, Koc University, Istanbul, Türkiye
- PO329 Higher-Dose Riluzole Extends Survival Without Increasing Adverse Events In Motor Neuron Disease**
Isadora Rawlinson (1), Francesca Maher (1), Ben Carter (1), Ton Fang (2), Nigel Leigh (3), Gilbert Bensimon (4), Ammar Al-Chalabi (1)
1. King's College London, London, United Kingdom
2. Icahn School of Medicine, Mount Sinai, New York, United States
3. Brighton and Sussex Medical School, Brighton, United Kingdom
4. Assistance Publique-Hôpitaux de Paris, Paris, France
- PO330 Quinolinones Are A Novel Class Of Protective Compounds In Cellular, Zebrafish And Mouse Models Of ALS**
Julie Atkin
Macquarie University, North Ryde, Australia
- PO331 The Combination Of RT1999 And RT1972 From Preclinical To Clinical Development**
Kim A. Staats
Raya Therapeutic, Inc., Montreal, Canada
- PO332 Development Of LTX-002, A Novel ASO, For The Treatment Of ALS**
Laura D Heckman, Giulio Tomassy, Herve Rhinn, Anumeha Shah, Asa Abeliovich
Leal Therapeutics, Worcester, United States
- PO333 Patient-Reported Preferences And Longitudinal Adherence To Different Riluzole Formulations In ALS: A Real-World Survey**
Lucia Aruta (1), Myriam Spisto (2), Valentina Virginia Iuzzolino (1), Gianmaria Senerchia (1), Fabiana Panico (1), Valeria Scodes (1), Rosanna Balzano (1), Raffaele Dubbioso (1)
1. University of Naples Federico II, Naples, Italy
2. University of Campania Luigi Vanvitelli, Naples, Italy
- PO334 A Novel Circular RNA-Based Platform For Dual Targeting C9orf72 Sense And Antisense Transcripts In ALS**
Mònica B Mendoza, Florencia E Alonso, Marta Casas-Vilaseca, Ivan Dotu, Marc Talló-Parra
NoctuRNA Therapeutics SL, Barcelona, Spain

PO335 An Update From GOALS, A Phase 1b/2 Trial Of ALN-SOD, An Intrathecally-Administered Small Interfering RNA Targeting SOD1, In Symptomatic SOD1-ALS

Philip Van Damme (1), Angela Genge (2), Lorne Zinman (3), Peter Dobrowolski (4), Yuishin Izumi (5), Seung Hyun Kim (6), Jung-Joon Sung (7), Agessandro Abrahao (3), Dominic Rowe (8), Yi-Chung Lee (9), Oren Levy (10), Jeffery J. Anderson (10), Yanping Chen (10), Poulabi Banerjee (10), Maria Rosario (10), Alexandre Sostelly (11), Gary Wilson (10), Olivier Harari (10)

1. University of Leuven, Leuven, Belgium

2. Montreal Neurological Institute (MNI), McGill University Health Centre, Montreal, Qc, Canada

3. Sunnybrook Health Sciences Centre, Toronto, On, Canada

4. University of Alberta, Edmonton, Ab, Canada

5. Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan

6. Hanyang University Medical Center, Seoul, South Korea

7. Seoul National University Hospital, Seoul, South Korea

8. Macquarie University Hospital, Sydney, Australia

9. Taipei Veterans General Hospital, Taipei, Taiwan

10. Regeneron Pharmaceuticals, Inc., Tarrytown, Ny, United States

11. Alnylam Pharmaceuticals, Cambridge, Ma, United States

PO336 Targeting The VAPB-PTPIP51 Endoplasmic Reticulum (ER)-Mitochondria Tethering Proteins As A Novel Therapy For Amyotrophic Lateral Sclerosis And Frontotemporal Dementia

Philippe Gosset, Chris Miller

King's College London, London, United Kingdom

PO337 ORY-4001, A Potent And Selective Inhibitor Of HDAC6, Improves ALS-Related Pathology In Different Models Of ALS.

Raquel Larramona Arcas, Sarai Pacheco, Jordi Senserrich Velasco, Cristina Mascaró, Jordi Xaus Oryzon Genomics, S.A., Cornellà De Llobregat, Spain

IN VIVO EXPERIMENTAL MODELS / ANIMAL MODELS (included in the posters session I)

PO338 Investigating Diet-microbiota Interactions In Humanized ALS Mice

Alessio Lauricella (1), Emily E Joyce (2), Maria Puopolo (1), Monica Armida (1), Silvia Bullitta (1), Alessia Butera (1), Paola Piscopo (1), Christina Seitz (2), Maria Elena Pisanu (1), Rosa Luisa Potenza (1), Fang Fang (2)

1. Istituto Superiore di Sanità, Rome, Italy

2. Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

PO339 Synergistic Interaction Between C9orf72 Haploinsufficiency And Dipeptide Repeat Proteins In A Zebrafish Model Of ALS

Ana Quelle Regaldie (1), Manon Boivin (2), Nicolas Charlet-Berguerand (2), Edor Kabashi (1)

1. Translational Research for Neurological Disorders. Institut Imagine, Paris, France

2. Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France

PO340 C-Terminal Tardbp Mutations Produce Distinct Phenotypic And Molecular Effects In Knock-In Mice

Beatriz Rodríguez-Villa (1), José Miguel Brito Armas (2), Alla Mikheenko (3), Matteo Zanovello (3), Ramón Alejo Muñoz De Bustillo Alfaro (1), Davinia Domínguez-González (1), Arianna Vastola-Mascolo (1), Lucas Taoro-González (1), Pietro Fratta (3), Abraham Acevedo-Arozena (4)

1. *Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), San Cristóbal De La Laguna, Spain*
2. *CIBERNED, San Cristóbal De La Laguna, Spain*
3. *University College London (UCL), London, United Kingdom*
4. *Unidad de Investigación, Hospital Universitario de Canarias (HUC), San Cristóbal De La Laguna, Spain*

PO341 A New Tunable And Conditional Mouse Model Of ALS

Chiara Marullo (1,2), Benedetta Mir (1,3), Laura Croci (1), Aurora Badaloni (1), Luca Nestola (1,3), Dario Bonanomi (1), Giacomo Consalez (1,3)

1. *IRCCS San Raffaele Scientific Institute, Milano, Italy*
2. *Università degli studi di Parma, Parma, Italy*
3. *Università vita-salute San Raffaele, Milano, Italy*

PO342 Sex-Specific Hypothalamic Axis Disruption In The RNLS8 Mouse Model Of Amyotrophic Lateral Sclerosis

Cristina Benito-Casado (1), Águeda Ferrer-Donato (1), Carmen M. Fernandez-Martos (1,2)

1. *Universidad CEU San Pablo, Madrid, Spain*
2. *Wicking Dementia Research and Education Centre, Hobart, Australia*

PO343 Uncovering the role of TDP-43 autoregulation in the pathogenesis of ALS using a novel conditional mouse model

Davinia Domínguez-González, Felipe Fumagallo Reading, Arianna Vastola-Mascolo, Ramón Alejo Muñoz De Bustillo-Alfaro, Beatriz Rodríguez-Villa, Lucas Taoro-González, Jose Miguel Brito, Abraham Acevedo-Arozena

Unidad de Investigación Hospital Universitario de Canarias (HUC), ITB-ULL, La Laguna, Santa Cruz De Tenerife, Spain

PO344 In Vivo Evaluation Of Intrathecal AAV-HSPA1A Gene Delivery In A TDP-43 ALS Mouse Model

Giorgos Solomonidis (1), Alexia Kagiava (2), Kleopas Kleopa (3), Jan Richter (1)

1. *Department of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus*
2. *Translational Neurotherapeutics Group, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus*
3. *Neuroscience Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus*

- PO345 Disruption Of The Motor Neuron Translatome Is Disease-Specific In ALS And SMA But Converges On MCM5**
Hannah L. Smith (1), Dinja Van Der Hoorn (2), Fabio Lauria (3), Helena Chaytow (1), Yu-Ting Huang (1), Kiterie M. E. Faller (1), Marta Machioretto (3), Rachel A. Kline (1), Bernát Nógrádi (4), Ewout J. N. Groen (5), Gabriella Viero (3), Thomas H. Gillingwater (1)
1. University of Edinburgh, Edinburgh, United Kingdom
2. University of Dundee, Dundee, United Kingdom
3. University of Trento, Trento, Italy
4. University of Szeged, Szeged, Hungary
5. University Medical Centre Utrecht, Utrecht, The Netherlands
- PO346 TDP-43 Preserves Satellite Cell Viability And Myogenic Potential In Skeletal Muscle**
Oihane Pikatza-Menoio, Haser Sutcu, Ainhoa Vidal-Gil, María Rodríguez-Hidalgo, Amaia Elicegui-Aguirre, Mariya Ievchuk, Ignacio Azcue-Juaristi, Sonia Alonso-Martín
Biogipuzkoa HRI, Donostia / San Sebastián, Spain
- PO347 Sex Differences In Blood Peripheral Immune Signatures In ALS**
Isabel Rea (1), Evandro Beraldi (1), Sukyoung Lee (1), Yulan Jiang (1), Esther Álvarez-Sánchez (2), Oriol Dols-Icardo (2), Jeff Biernaskie (1), Keith Sharkey (1), Minh Dang Nguyen (1)
1. University of Calgary, Calgary, Canada
2. Institut de Recerca Sant Pau - Centre CERCA, Barcelona, Spain
- PO348 Optineurin Insufficiency Ameliorates Cognitive Defects And Lipopolysaccharide-Mediated Mortality In The TDP-43G348C Mouse Model**
Josip Peradinovic, Ivona Cargonja, Andrea Markovinovic, Ivana Munitic
University of Rijeka, Rijeka, Croatia
- PO349 Early Retinal Involvement In Amyotrophic Lateral Sclerosis: Insights From SOD1G93A Mice**
Lorenza Di Marsico (1,2), Eleonora Daghini (2), Rosario Amato (2), Maurizio Cammalleri (2), Pete A Williams (3), Massimo Dal Monte (2), Sebastian A Lewandowski (1)
1. Department of Clinical Neuroscience, Karolinska Institutet, Centre for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden
2. Department of Biology, University of Pisa, Pisa, Italy
3. Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Hospital, Karolinska Institutet, Stockholm, Sweden
- PO350 In Vivo Muscle Electrophysiology As A Tool To Assess Pathology And Therapeutic Efficacy In ALS Mouse Models**
Mhoriam Ahmed, Linda Greensmith
UCL Queen Square Institute of Neurology, London, United Kingdom

- P0351 Impact Of Magnetic Field Stimulation On Disease Progression In The SOD1G93A Mouse Model Of Amyotrophic Lateral Sclerosis (ALS)**
Nadine Thau-Habermann (1), Thomas Gschwendtberger (1), Lennard Köster (1), Tina Grüning (2), Arun Pal (2,3), Richard H W Funk (3,4), Thomas Herrmannsdörfer (2), Susanne Petri (1)
1. Hannover Medical School, Hannover, Germany
2. Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
3. Dresden University of Technology, Dresden, Germany
4. Dresden International University, Dresden, Germany
- P0352 FUS Orchestrates Conserved Metabolic Rewiring Of The PPAR–carnitine Axis In ALS, Revealing Clinically Relevant Therapeutic Targets**
Xhuljana Mingaj (1), Nour Halabi (1), Manon Marchais (1), Elena Pasho (1), Anca Marian (1), Luc Dupuis (2), Sorana Ciura (1), Edor Kabashi (1)
1. Institut Imagine, Paris, France
2. Université de Strasbourg, Strasbourg Translational Neuroscience and Psychiatry, Centre de Recherches en Biomédecine, Strasbourg, France
- P0353 TDP43 Proteinopathy In Specific Spinal Neuron Subtypes To Elucidate ALS Pathophysiology Beyond Motor Neurons**
Nuno A. S. Oliveira (1,2), Leonor Lima (1), Brígida R. Pinho (1), José Bessa (3), Jorge M. A. Oliveira (1)
1. UCIBIO, i4HB, Mitochondria and Neurobiology Lab, Faculty of Pharmacy, University of Porto, Portugal
2. Doctoral Programme of the Lisbon Academic Medical Centre, University of Lisbon, Portugal
3. Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Portugal
- P0354 ALS-Associated SOD1G93A Mutations Models Mirror Aging-Related Transcriptional Changes Of Sarcopenia-Related Genes In Skeletal Muscle**
Paula Aparicio (1), Gabriella Dobrowolny (2), Martina Lupoli (2), Antonio Musarò (2), Laura Moreno-Martínez (1), Tresa López-Royo (1), Gabriel Rada (1), Ana Cristina Calvo (1), Luis Folch (1), Elisa Gascón (1), Leticia Moreno-García (1), Janne Markus Toivonen (1), Raquel Manzano (1), Rosario Osta (1)
1. Universidad de Zaragoza, Zaragoza, Spain
2. Sapienza University of Rome, Rome, Italy
- P0355 MyoRep: A Novel Reporter System To Detect Early Muscle Atrophy In Vitro And In Vivo**
Andrea David Re Cecconi (1), Nicoletta Rizzi (2), Mara Barone (1), Federica Palo (1), Martina Lunardi (1), Mara Forti (1), Adriana Maggi (2), Paolo Ciana (2), Giulia Terribile (1), Michela Chiappa (1), Lorena Zentilin (3), Rosanna Piccirillo (1)
1. Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy
2. University of Milan, Milan, Italy
3. International Centre for Genetic Engineering and Biotechnology, Trieste, Italy

- P0356 Novel Targets Of ALS Degeneration: Neuromuscular Junctions And Kranocytes**
Sandra Fuertes-Alvarez (1), Amaia Elicegui (1), Rosario Osta (2), Ander Izeta (1), Sonia Alonso-Martín (1)
1. *Biogipuzkoa HRI, San Sebastián, Spain*
2. *Aragon Institute for Health Research, Zaragoza, Spain*
- P0357 Neurofilament Light Chain And Troponin T In ALS Mouse Models: Clinically Relevant Biomarkers For Preclinical Drug Development**
Valentina Bonetto, Laura Pasetto, Laura Camporeale, Monica Favagrossa, Alessia Ghioni, Serena Scozzari, Massimo Tortarolo, Sara Ficara, Cassandra Margotta, Paola Fabbrizio, Giovanni Nardo
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy
- P0358 MIF As A Neuroprotective Modulator In Sporadic ALS: Insights From A CSF-Transmission Mouse Model**
Yuval Avni Mann, Joy Kahn, Adrian Israelson
Ben-Gurion University of the Negev, Beer Sheva, Israel
- TECHNOLOGY, INNOVATION AND BIOENGINEERING (included in the posters session II)**
- P0359 Treatment Continuity With Orodispersible Film Riluzole In Patients With Amyotrophic Lateral Sclerosis Undergoing PEG Placement: A Preliminary Clinical Experience**
Annamaria Terlizzi
SS. Annunziata hospital, Taranto, Italy
- P0360 An Explainable Knowledge Graph Framework For Drug Repurposing In Amyotrophic Lateral Sclerosis**
Anqi Jiang (1), Yusuf Abdulle (1), Oliver Pain (2), Alfredo Iacoangeli (1,2,3)
1. *Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom*
2. *Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom*
3. *National Institute for Health Research Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and King's College London, London, United Kingdom*
- P0361 Eye-Tracking In Motor Neuron Diseases: A Systematic Review Of Clinical Applications Across Adult And Pediatric Populations**
Christian Lunetta (1), Alice Radici (2), Andrea Panzavolta (1), Chiara Cerami (2,1)
1. *Istituti Clinici Scientifici Maugeri IRCCS, Brain e-Health Aging (BeA) Laboratory, Department of Neurorehabilitation, Milano, Italy*
2. *IUSS Cognitive Neuroscience (ICoN) Center, Scuola Universitaria Superiore IUSS, Pavia, Italy*

P0362 Impact Of Built-In Ventilator Software Monitoring On Survival In ALS Patients Receiving Home Mechanical Ventilation

Clara Seghers-Carrera (1), Javier Sayas-Catalan (1,2,3), Miguel Jimenez-Gomez (1), Marta Corral-Blanco (1), Carmen Lorenzo-Martinez (1), Pedro Manso-Tejerina (1), Beatriz Martin-Garcia (1), Clara Mendez-Ponce (1), Gema Carvajal-Cuesta (1,5), Pilar Cordero-Vazquez (1), Jesus Esteban-Perez (1), Ana Hernandez-Voth (1)

1. Hospital Universitario 12 de Octubre, Madrid, Spain
2. Facultad de Medicina, Madrid, Spain
3. Instituto de Investigación I+12, Madrid, Spain
4. Universidad Complutense de Madrid
5. Instituto de Investigación I+12, Madrid, Spain
6. Nippon Gases

P0363 Temporal Knowledge Graph Embedding For ALS Progression Prediction

Erfan A. Shams (1), Alberto Bernardi (2), Luca Costabello (2), John D. Kelleher (1)

1. Trinity College Dublin, Dublin, Ireland
2. Accenture Labs, Dublin, Ireland

P0364 CRISPR-Targeted Silencing Of Mutant SOD1 Allele As A Treatment For Amyotrophic Lateral Sclerosis

Federica Marelli (1), Elisabetta Visentin (1), Giulia Vittoria Ruta (1), Pau Marin-Escudero (1), Daniele Menghini (1), Matteo Ciciani (1), Matteo Bello (1), Oihana Murillo-Sauca (2), Gloria González-Aseguinolaza (2), Anna Cereseto (1)

1. University of Trento, Department CIBIO, Trento, Italy
2. University of Navarra, CIMA, Pamplona, Spain

P0365 Exoskeleton-Assisted Gait Training In Amyotrophic Lateral Sclerosis: Safety, Efficacy, And Patients' Lived Experience.

Ghida Trad (1,2), Timothée Lenglet (3,4), Isabelle Ledoux (2), Giorgia Querin (1,3), Sophie Blancho (5), Véronique Marchand-Pauvert (1), Jean-Yves Hogrel (2), Pierre-François Pradat (1,3)

1. Sorbonne Université, Inserm, CNRS, Laboratoire d'Imagerie Biomédicale, Paris, France
2. Neuromuscular Physiology and Evaluation Lab, Neuromuscular Investigation Center, Institute of Myology, Paris, France
3. APHP, Sorbonne Université, Département de Neurologie, Centre de Référence SLA Ile de France, Hôpital Pitié-Salpêtrière, Paris, France
4. APHP, Département de Neurophysiologie, Hôpital Pitié-Salpêtrière, Paris, France
5. Institut pour la Recherche sur la Moelle Épineuse et l'Encéphale, Paris, France

P0366 Consumer Smartwatch Step Counts Detect Disease Progression In ALS

Gordon Jewett (1,2,3), Reed Ferber (4,5), Colin B Josephson (2,3,6,7,8), Joon Lee (1,6,9,10), Lawrence Korngut (2,3)

1. Data Intelligence for Health Lab, Cumming School of Medicine, University of Calgary, Canada
2. Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Canada
3. Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada
4. Human Performance Laboratory, Faculty of Kinesiology, University of Calgary, Calgary, Canada
5. Running Injury Clinic, University of Calgary, Calgary, Canada
6. Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Canada
7. O'Brien Institute for Public Health, University of Calgary, Canada
8. Centre for Health Informatics, University of Calgary, Calgary, Canada
9. Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary, Canada
10. Libin Cardiovascular Institute, University of Calgary, Canada

P0367 A Single ALS Mutation Destabilizes The Metal And Catalytic Architecture Of SOD1

Hasan Demirci (1,2), Ilkin Yapici (1), Belgin Sever (3), Halilibrahim Ciftci (4), Ayse Nazli Basak (5)

1. Department of Molecular Biology and Genetics, Koc University, Istanbul, Türkiye
2. Stanford PULSE Institute, SLAC National Laboratory, Menlo Park, CA, United States
3. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskisehir, Türkiye
4. Department of Molecular Biology and Genetics, Burdur Mehmet Akif Ersoy University, Burdur, Türkiye
5. Suna and Inan Kiraç Foundation, Neurodegeneration Research Laboratory (KUTTAM-NDAL), School of Medicine, Koc University, Istanbul, Türkiye

**P0368 Raman Spectroscopy For ALS Diagnosis And Disease Monitoring:
A Systematic Review And Meta-Analysis**

Katie Hanna (1), Fergal Waldron (2), Karen Faulds (1)

1. University of Strathclyde, Glasgow, United Kingdom
2. University of Aberdeen, Aberdeen, United Kingdom

P0369 How Might Generative AI Help A Scientist Newly Diagnosed With ALS/MND?

M. C. Collet, Mandi Bailey, Jill Brattain, Caroline Tredway
Morris ALS Principles team, Indianapolis, United States

P0370 Placement Shapes Measurement: Characterising Wrist And Hip Actigraphy In ALS

Marc Theo Jeffrey Elliott (1,2), Deirdre Murray (3), Emily Beswick (1), Lesley Doyle (1), Etain O'Meara (1), Orla Hardiman (1), Dara Meldrum (1)

1. Trinity College Dublin, Dublin, Ireland
2. ADAPT SFI Research Centre, Dublin, Ireland
3. Dublin City University, Dublin, Ireland

P0371 Clinical Validation Of Wearable Sensor-Derived Digital Gait Metrics For Monitoring Disease Progression In Amyotrophic Lateral Sclerosis

Marcin Straczekiewicz (1), Katherine M. Burke (2,3), Narghes Calcagno (4), Sravan Mandepudi (2), Alan Premasiri (5), Kendall T. Carney (2), Fernando G. Vieira (5), James D. Berry (2)

1. Department of Measurement and Electronics, AGH University of Krakow, Krakow, Poland

2. Neurological Clinical Research Institute and Sean M. Healey & AMG Center for ALS, Boston, United States

3. School of Health and Rehabilitation Sciences, PhD in Rehabilitation Sciences Program, MGH Institute of Health Professions, Boston, United States

4. Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy

5. ALS Therapy Development Institute, Watertown, United States

P0372 Digital Measures Of Real-World Gait In ALS Using Wearable Sensors

Narghes Calcagno (1), Margaux Poleur (2), Charlotte Rasser (3), Camila Gonzalez Barral (2,3), Katherine M. Burke (4,5), Kendall Carney (4), Sydney Hall (4), Sravan Mandepudi (4), Timothy Royse (4), Oihana Piquet (3), Charlotte Hermanne (2), Laura Buscemi (2), Damien Eggensteiner (3), Stéphanie Delstanche (2), Laurent Servais (6,2), James D. Berry (4)

1. Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy

2. CRMN, University department of neurology, Citadelle Hospital of Liège, Liège, Belgium

3. Sysnav, Vernon, France

4. Sean M. Healey and AMG Center for ALS at Massachusetts General Hospital, Boston, United States

5. School of Health and Rehabilitation Sciences, PhD in Rehabilitation Sciences Program, MGH Institute of Health Professions, Boston, United States

6. MDUK Oxford Neuromuscular Centre, John Radcliffe Hospital, Oxford, United Kingdom

P0373 Transcranial Pulse Stimulation (TPS) In Amyotrophic Lateral Sclerosis: Preliminary Findings On Safety And Cortical Excitability

Sergio Vidal Notari, Alba Leon Jorba, Gonzalo Fernandez Rizzoli, Delia Ceballos Saenz, Lilia Correa Marquez, Bernat Bertran Recasens, Pablo Villoslada Diaz, Miguel Angel Rubio Perez Hospital del Mar, Barcelona, Spain

P0374 Identify Determinants Of TDP-43 Pathology Using Synthetic Promoter Screen

Tamar Aminov, Zevik Melamed, Lior Nissim Hebrew University of Jerusalem, Jerusalem, Israel

P0375 SYN-MND: Privacy-Preserving Synthetic Motor Neuron Disease Patient Data Generation Using Parameter-Efficient Language Models

Yusuf Abdulle (1), Taiyu Zhu (1), Mandy Miresmaeili (1), Emeka Uzochukwu (1), Francesca Maher (1), Andrea Biondi (1), Amber Collingwood (1), Modupe Aggreh (1), Ben Carter (1), Julia Ive (1), Ahmed Al-Khleifat (1), Christopher Tomlinson (1,2), Zhi Yao (2), Honghan Wu (3), Richard Dobson (1,4), Alfredo Iacoangeli (1,4), Ammar Al-Chalabi (1)

- 1. King's College London, London, United Kingdom*
- 2. LifeArc, Stevenage, United Kingdom*
- 3. University of Glasgow, Glasgow, United Kingdom*
- 4. Biomedical Research Centre, London, United Kingdom*

PHENOTYPING / DISEASE STRATIFICATION (included in the posters session I)**P0376 A Multi-Linear Model For Predicting ALSFRS-R Score Progression Using Heterogeneous Longitudinal Data From Clinical Studies**

Alex De Nardi (1,2), Alessio Paris (1), Mario Lauria (1,2), Ilaria Martinelli (3), Elisabetta Zucchi (3), Nicolò Mesini (4), Jessica Mandrioli (3,4), Luca Marchetti (1,5)

- 1. Fondazione The Microsoft Research - University of Trento Centre for Computational and Systems Biology (COSBI), Rovereto, Italy*
- 2. Department of Mathematics, University of Trento, Trento, Italy*
- 3. Department of Neurosciences, Azienda Ospedaliero Universitaria di Modena, Modena, Italy*
- 4. Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy*
- 5. Department of Cellular, Computational and Integrative Biology (CIBIO), Trento, Italy*

P0377 Divergence In FUS-ALS: Neurocognition, Glucose Metabolism And Mutation Variant Distinguish Severe Juvenile-Onset From Adult-Onset Cases

Alexandra Jürs (1), Annaliis Lehto (1,2), Marcel Naumann (1), Hanna Schön (3), Jens Kurth (4), Johannes Prudlo (5,2), Andreas Hermann (1,2,6), Elisabeth Kasper (5,2)

- 1. Translational Neurodegeneration Section „Albrecht Kossel“, Department of Neurology, University Medical Center Rostock, Rostock, Germany*
- 2. German Center for Neurodegenerative Diseases (DZNE) Rostock/Greifswald, Rostock, Germany*
- 3. Institute of Diagnostic and Interventional Radiology, Pediatric Radiology and Neuroradiology, University Medical Center Rostock, Rostock, Germany*
- 4. Department of Nuclear Medicine, Medical Center Rostock, Rostock, Germany*
- 5. Department of Neurology, University Medical Center Rostock, Rostock, Germany*
- 6. Center for Transdisciplinary Neuroscience Rostock (CTNR), University Medical Center Rostock, Rostock, Germany*

P0378 The ALS-OPM Classification Identifies Distinct Trajectories Of Proximal Amyotrophic Arm-Onset Phenotype

André Maier (1), Thoralf Riederer (1,2), Torsten Grehl (3), Dagmar Kettemann (1), Jenny Norden (1), Philipp Schmitt (1), Susanne Spittel (1,4), Christoph Münch (1,4), Peggy Schumann (1,4), Thomas Meyer (1,4)

1. Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

2. Practice for Neurology and Epileptology, Teltow, Germany

3. Department of Neurology, Center for ALS and other Motor Neuron Disorders, Alfried Krupp Hospital, Essen, Germany

4. Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany

P0379 Milestone-Based Disease Progression In Tofersen-Treated SOD1-ALS: A Longitudinal Single-Centre Study

Branimir Ivan šepec, Hrvoje Bilic, Barbara Sitaš, Mirea Hancevic, Andrea Zemba cilib, Marina Petrovic, Kristina Gotovac Jercic, Fran Borovecki, Ervina Bilic

UHC Zagreb, Croatia, Zagreb, Croatia

P0380 Performance Of The ENCALs Risk Algorithm In Spanish ALS Patients: High Specificity For Extreme Phenotypes But Limited Intermediate Discrimination

Daniel Sanchez-Tejerina (1,2), Silvia Sanchez-Martin (2), Maria Salvado-Figueras (1,2), Raul Juntas-Morales (1,2), Jose M Vidal-Taboada (2)

1. ALS unit at Neurology Service, Vall d'Hebron University Hospital, Barcelona, Spain

2. Peripheral Nervous System, Vall d'Hebron Research Institute, Barcelona, Spain

P0381 Higher Muscle Quality Is Associated With Slower Functional Deterioration In Amyotrophic Lateral Sclerosis

Domenico Azzolino (1), Aida Zulueta (2), Rachele Piras (2), Paola Mariani (2), Riccardo Sideri (2), Simone Perna (3), Tiziano Lucchi (4), Christian Lunetta (2)

1. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy

2. Istituti Clinici Scientifici Maugeri IRCCS, Milan, Italy

3. Università degli studi di Milano, Milan, Italy

4. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

P0382 Clinicopathological Correlation Of Motor Neuron Disease: A 10-Year Retrospective Case Series

Isaac Chau (1,2,3,4), Dominic Ng (1,2,3), Neil Watson (5), Tracey Millar (3), Jessica Gill (1,2,3),

Judith Newton (1,2,3,4), Siddharthan Chandran (1,2,3,4,5), Colin Smith (1,2,3,4), Suvankar Pal (1,2,3,4,5)

1. Anne Rowling Regenerative Neurology Clinic, Edinburgh, United Kingdom

2. Euan MacDonald Centre for Motor Neuron Disease Research, Edinburgh, United Kingdom

3. Institute for Neurosciences and Cardiovascular Research, Edinburgh, United Kingdom

4. UK Dementia Research Institute, Edinburgh, United Kingdom

5. NHS Lothian, Edinburgh, United Kingdom

P0383 Sexual Dimorphism In Amyotrophic Lateral Sclerosis Phenotypes From The Canadian Neuromuscular Disease Registry

Gerald Pfeffer (1), Maya Binet (1), Christopher Labos (2), Victoria Hodgkinson (1), Lawrence Korngut (1), Gordon Jewett (1), CNDR ALS Investigator Network (1)

1. University of Calgary, Calgary, Canada
2. McGill University, Montreal, Canada

P0384 Metabolic Signatures Of Ferritin And TDP-43 Co-Pathology Provide A Mechanistic Basis For Stratified Therapeutic Approaches In ALS

Holly Spence, Fiona L Read, Fergal M Waldron, Jenna M Gregory

Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom

P0385 Plasma Profiling For Protein-Based Patient Stratification In ALS

Inci S. Aksoylu (1), Louisa Azizi (2,3), Solmaz Yazdani (2,3), Maria Bueno Alvéz (1), Linn Öijerstedt (2,3), Sofia Bergström (1), Fredrik Edfors (1), Evelina Sjöstedt (1), Mathias Uhlén (1), Peter Nilsson (1), Caroline Ingre (2,3), Anna Månberg (1)

1. Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden
2. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
3. Department of Neurology, Karolinska University Hospital, Stockholm, Sweden

P0386 Deep Phenotyping And Machine Learning-Based Clustering Reveal Metatypes Impacting Progression And Clinical Severity Of Amyotrophic Lateral Sclerosis And Frontotemporal Dementia

Juan Ignacio López Carbonero (1), Angélica Larrad Sainz (1), María José Gil Moreno (1), Antonio Guerrero Sola (1), Jordi A. Matías-Guiu (1), Alejandro Horga Hernández (1), Lucía Galán (1), Javier Mascías Cadavid (2), Javier Olazarán (3), Francisco Javier Martín Sánchez (4), Óscar Fuentes Bona (4), Enrique Muñoz De Maya (4), María Del Carmen Marcos Sastre (4), Fernando García Gutiérrez (5), José Ayala (5), Silvia Corrochano (1)

1. Neurological Disorders Group, Hospital Clínico San Carlos, IdISSC, Madrid, Spain
2. ALS Unit. Hospital Universitario La Paz-Hospital Carlos III, Madrid, Spain
3. Department of Neurology. Hospital General Universitario Gregorio Marañón, Madrid, Spain
4. ALS Day Care Center (CEADELA). Hospital Enfermera Isabel Zendal, Madrid, Spain
5. Department of Architecture and Technology of Computing Systems, Computer Science Faculty, Universidad Complutense de Madrid, Madrid, Spain

P0387 ALSFRS-R Subscore Progression Is Phenotype Specific And Stable Through Disease Accumulation In ALS Patients

Behnaz Farahi Ghasraboonsr (1), Isabelle Jana Buchholz (2), Chelsea Walter (2), Hanna Stüber (2), Julia Meyer (2), Kristin Loyal (2), Mohammad Kalaf (2), Maj-Britt Bartels (2), Clemens Runge (2), Janina Von Der Gablentz (2), Robert Steinbach (3), Julian Großkreutz (1)

1. Precision Neurology of Neuromuscular and Motoneuron Diseases, University of Lübeck, Germany
2. Precision Neurology Of Neuromuscular And Motoneuron Diseases, University Of Lübeck, Germany
3. Department of Neurology, Jena University Hospital, Jena, Germany

P0388 Onset Site-Specific Patterns Of The ALSFRS-R Subscore Progression Across Disease Phases And Aggressiveness Types.

Isabelle Jana Buchholz (1), Behnaz Farahi Ghasraboona (1), Philip Gremmler (2), Julia Meyer (1), Sophie Dalbert (1), Lena Pantke (1), Janina Von Der Gablentz (1), Robert Steinbach (2), Julian Grosskreutz (1,3)

1. Precision Neurology of Neuromuscular and Motor Neuron Diseases, Luebeck, Germany

2. Department of Neurology, Jena University Hospital, Jena, Germany

3. Cluster for Precision Medicine in Inflammation, Universities of Kiel and Luebeck, Luebeck, Germany

P0389 Prognostic Phenotyping In ALS: Real-World Validation Of The Revised OPM Classification

Kacper Mazurkiewicz (1), Krzysztof Nieporecki (2), Magdalena Kuzma-Kozakiewicz (2)

1. Department of Neurology, University Clinical Centre Of Medical University Of Warsaw, Poland

2. Department of Neurology, Medical University of Warsaw, Warsaw, Poland

P0390 Clinical Applicability Of The OPM Classification In ALS: A Retrospective Cohort Study

Lara Wenz (1), Antonia Franziska Demleitner (1), Luisa Semmler (1), Anne Buchberger (1),

Ricarda Von Heynitz (1), Vincent Gmeiner (1), Anne Gründel (1), Benedikt Becker (1),

Maike Hagemeyer (1), Bernhard Hemmer (1), Marcus Deschauer (1), Thomas Meyer (2), Paul Lingor (1,3,4)

1. Department of Neurology, rechts der Isar Hospital of the Technical University of Munich, Germany

2. Department of Neurology, Center for ALS and other Motor Neuron Disorders, Charité – University Medicine Berlin, corporate member of Free University Berlin and Humboldt University, Germany

3. German Center for Neurodegenerative Diseases (DZNE), Site Munich, Munich, Germany

4. Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

P0391 Real-World Investigation Of The ALS-FTD Spectrum Using An Electronic Patient Record Pipeline

*Mandy Miresmaeili, Yusuf Abdulle, Richard Dobson, Ammar Al-Chalabi, Alfredo Iacoangeli
King's College London, London, United Kingdom*

P0392 Progression Rate As A Continuous Prognostic Determinant In ALS: Clinical Profile And Dose-Dependent Survival Gradient In A Real-World Cohort

*Matteo Farè, Andrea Lizio, Jessica Lops, Francesca Gerardi, Valeria Ada Sansone, Federica Cerri
Neuromuscular Omnicentre (NeMO), Fondazione Serena ETS, Milan, Italy*

P0393 - Clinical Course Of FUS-ALS: A Retrospective Analysis Of Clinical And Genetic Modifiers

*Matthew Harms (1), Chris Shaw (2), Adriano Chio (3), Philip Van Damme (4), Andreas Hermann (5),
Albert Ludolph (6), Jan Veldink (7), Seung Hyun Kim (8), Jessica Mandrioli (9), Sean Smith (10),
Orla Hardiman (11), Magdalena Kuzma-Kozakiewicz (12), Monica Povedano Panades (13),
Naoki Suzuki (14), Gillian Kelly (2), Frederik Hobin (4), Neil A Shneider (1), Paul Malik,
Haoyue Zeigler, Roger Lane, Stephan Miller (15)*

1. *Columbia University, New York, United States*
2. *King's College London, London, United Kingdom*
3. *University of Turin, Turin, Italy*
4. *University Hospitals Leuven, Leuven, Belgium*
5. *Translational Neurodegeneration Section Albrecht Kossel, University Medical Center Rostock, Germany*
6. *University Hospital of Ulm, Ulm, Germany*
7. *University Medical Center Utrecht, Utrecht, The Netherlands*
8. *Hanyang University Hospital, Seoul, South Korea*
9. *University of Modena and Reggio Emilia, Modena, Italy*
10. *Washington University, St. Louis, United States*
11. *Academic Unit of Neurology, Trinity College Dublin, Dublin, Ireland*
12. *Medical University of Warsaw, Warsaw, Poland*
13. *Bellvitge University Hospital, Barcelona, Spain*
14. *Tohoku University, Sendai, Japan*
15. *Ionis Pharmaceuticals, Carlsbad, United States*

P0394 Correlation Between Subjective Respiratory Symptoms And Objective Respiratory Parameters In Patients With Amyotrophic Lateral Sclerosis: Experience From A Chilean Center.

Nicholas Earle (1,2), César Maquilón (1), Eduardo Paredes (1)

1. *Clínica Dávila, Santiago, Chile*
2. *Corporación de Neurología de Santiago, Santiago, Chile*

P0395 APOEε4 Homozygosity Accelerates The Onset And Progression Of ALS Neurodegeneration

Sebastian A. Lewandowski (1), Aditya Singh (1), Yigit Koray Babal (1), Steffi Jonk (1), Melissa Romei (1), Ana Ujevic (2), Jianing Lin (1), Simge Sengul (3), Martyna Kacprzak (1), Peter Swoboda (1), Eleonora Aronica (4), Pete Williams (5), Jan Veldink (6)

1. *Karolinska Institutet, Stockholm, Sweden*
2. *Croatian Institute for Brain Research, Zagreb, Croatia*
3. *University of Helsinki, Helsinki, Finland*
4. *Amsterdam University Medical Centre, Amsterdam, The Netherlands*
5. *Karolinska Institute, Stockholm, Sweden*
6. *Utrecht University Medical Centre, Utrecht, The Netherlands*

PO396 ALS Phenotypes Of Onset, Propagation, And Motor Neuron Dysfunction – The ALS-OPM Classification Demonstrates Distinct Profiles Of Disease Progression And Neurofilament Light Chain Elevation

Thomas Meyer (1,2), Torsten Grehl (3), Peggy Schumann (4), Ute Weyen (5), Annekathrin Rödiger (6,7), Uta Smesny (6), Robert Steinbach (6), Patrick Weydt (8), Matthias Boentert (9), André Maier (10)

1. Center for ALS and other Motor Neuron Disorders, Charité - Universitätsmedizin Berlin, Germany

2. APST Research, Berlin, Germany

3. Department of Neurology, Center for ALS and other Motor Neuron Disorders, Alfried Krupp Krankenhaus, Essen, Germany

4. Center for ALS and other Motor Neuron Disorders, Charité – Universitätsmedizin Berlin, Germany

5. Department of Neurology, Center for ALS and other Motor Neuron Disorders, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Bochum, Germany

6. Department of Neurology, Jena University Hospital, Jena, Germany

7. ZSE, Zentrum für Seltene Erkrankungen, Jena University Hospital, Jena, Germany

8. Department for Neuromuscular Disorders, Bonn University, Bonn, Germany

9. Neuromedizinisches Zentrum, Klinikum Osnabrück, Osnabrück, Germany

0. Center for ALS and other Motor Neuron Disorders, Charité – Universitätsmedizin Berlin, Germany

PRE-CLINICAL THERAPEUTIC STRATEGIES (included in the posters session I)

PO397 Modulating Microglial Dynamics Through CSF1R Inhibition Impacts Cognitive Performance In A FTD- TDP43 Mouse Model

Alberto Jiménez Amor (1,2,3), Raquel Martín Baquero (1,2,3), Javier Fernández Ruiz (1,2,3), Carmen Rodríguez Cueto (1,2,3), Eva De Lago Femia (1,2,3)

1. Instituto Universitario de Investigación en Neuroquímica, Dpto. de Bioquímica y Biología Molecular, Facultad de Medicina, UCM, Madrid, Spain

2. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain

3. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain

PO398 The Myokine Musclin Exerts Beneficial Effects In A Mouse Model Of Amyotrophic Lateral Sclerosis

Andrea David Re Cecconi (1), Massimo Tortarolo (1), Mara Barone (1), Isabella Rubino (1), Paola Fabbrizio (1), Giovanni Nardo (1), Gianni Sorarù (2), Lorena Zentilin (3), Caterina Bendotti (1), Rosanna Piccirillo (1)

1. Center for ALS Research, Department of Neuroscience, Mario Negri Institute for Pharmacological research IRCCS, Milan, Italy

2. Neurology Unit, Department of Neurosciences Padova Hospital, University of Padova, Padova, Italy

3. Molecular Medicine Laboratory International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy

PO399 PIKfyve Inhibitors Regulate Lipid Metabolism And Mitochondrial Dysfunction In Lymphoblastoid Cellular Lines Of ALS, Preserving Spinal Cord Motorneurons In SOD1 Animal Model

Virginia Garcia-Calvo (1,2), Elena Caballero (1,2), Loreto Martinez-Gonzalez (1,2), Hector Foronda (2,3), Patricia Gomez-Suaga (2,3), Eva De Lago (2,4), Estela Area (1,5), Ana Martinez (1,2), Carmen Gil (1,2)

1. CIB-CSIC, Madrid, Spain

2. CIBERNED, Madrid, Spain

3. Universidad de Extremadura, Caceres, Spain

4. Facultad de Medicina, Madrid, Spain

5. Universidad Complutense, Madrid, Spain

PO400 Stress-Response Dysregulation Drives Bulbar-Specific Vulnerability In ALS Motor Neurons: Biological Rationale For A Precision Therapeutic Strategy

Eleonora Giagnorio (1), Samanta Mazzetti (2), Marco Cattaneo (3,4), Claudia Malacarne (1), Giorgia Farinazzo (1,5), Maria Vizziello (3), Daniele Cartelli (3,6), Nilo Riva (3), Eleonora Dalla Bella (3), Ludo Van Den Bosch (7,8), Emmanuelle Abgueguen (9), Pierre Miniou (9), Giuseppe Lauria Pinter (3,10), Stefania Marcuzzo (1,11)

1. Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

2. Parkinson and Movement Disorders Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

3. ALS Centre, 3rd Neurology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

4. PhD Program in Pharmacological Biomolecular Sciences, Experimental and Clinical, University of Milan, Italy

5. PhD Program in Bioengineering, Department of Electronics, Information and Bioengineering (DEIB), Politecnico of Milano, Milano, Italy

6. Vision@Besta Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

7. KU Leuven, University of Leuven, Department of Neurosciences, Experimental Neurology, Leuven, Belgium

8. Leuven Brain Institute (LBI) and VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium

9. InFlectis BioScience, Nantes, France

10. Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy

11. Brain-targeted Nanotechnologies (BrainS) Lab, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

PO401 Targeting MicroRNA-129 As A Therapeutic Strategy And Biomarker In Amyotrophic Lateral Sclerosis

Francesca Sironi (1), Alberto Romano (2), Ottoboni Linda (1), Mafalda Rizzuti (2), Valentina Melzi (2), Delia Gagliardi (2), Claudia Alberti (1,2), Giulia Scacciatella (1,2), Pierluigi Di Vinci (1), Federico Verde (3), Antonia Ratti (3,1), Nicola Ticozzi (3), Vincenzo Silani (3), Giacomo Comi (1,2), Stefania Corti (1,2)

1. University of Milan, Milan, Italy

2. Foundation IRCCS Ca` Granda Ospedale Maggiore Policlinico, Milan, Italy

3. IRCCS Istituto Auxologico Italiano, Milan, Italy

PO402 SRSF1 Gene Inhibition Therapy For The Treatment Of C9orf72-Linked ALS/FTD

Kamallia Mohd Imran (1), Chloé E Moutin (1), David Burrows (1), Sophie E Badger (1), Amy F Keerie (1), Ya-Hui Lin (1), Adrian Higginbottom (1), Aurore Besse (2), Jonathan Foley (2), Pamela J Shaw (1,2), Mimoun Azzouz (1,2), Guillaume M Hautbergue (1,2)

1. University of Sheffield, Sheffield, United Kingdom
2. Crucible Therapeutics, Sheffield, United Kingdom

PO403 Antisense Lncrnas At The Tbk1 Locus Regulate Tbk1 Expression In Als

Hannah Kinsella (1), Maria Demestre (1), Maria Lucana Meneses (1), Irene Suárez Rojas (1), Bernat Bertran-Recasens (1,2), Sergio Vidal Notari (1,2), Pablo Villoslada (1), Miguel Angel Rubio Pérez (1,2)

1. Unsyn Lab. Systems Neurology and Neurotherapies Research Group, Neurosciences Program, Hospital del Mar Research Institute, Barcelona, Spain
2. ALS/Motor Neuron Diseases Unit, Neurology Department, Hospital del Mar, Barcelona, Spain

PO404 The Repurposed Drug Bexarotene Rescues ALS-Relevant Phenotypes In The Severe Thy1-TDP43 Mouse Model

Helena Chaytow (1), Rachel A. Kline (1,2), Thomas M. Wishart (2,3), Thomas H. Gillingwater (1)

1. University of Edinburgh, Edinburgh, United Kingdom
2. Roslin Institute, Royal (Dick) School of Veterinary Studies, Edinburgh, United Kingdom
3. Centre for Systems Health and Integrated Metabolic Research, Nottingham, United Kingdom

PO405 Anti-TDP-43 ScFv Therapy Achieves CNS Target Engagement And Reshapes Inflammatory And Metabolic Signatures In ALS

Helene Blasco

ibrain, Tours, France

PO406 Impact Of Intrathecal Administration Of INS1202 AAV9-SOD1-ShRNA Gene Therapy On Hallmarks Of Neurodegeneration In A Murine Disease Model Of ALS And A Patient-Derived In Vitro Model

Laura Ferraiuolo (1), Gretchen Thomsen (1), Erin Hurley (1), Hana Julazadeh (1), Jannigje Kok (1), Cleide Dos Santos Souza (1), Ashley Fox (2), Ryan Weiss (1), Haydee Gutierrez (1), Melissa Mcalonis-Downes (3), Robert Cano (1), Binh Chu (1), Angélique Braen (4), Junguo Zhou (4), W. David Arnold (5), Stephen J. Kolb (2), Allan Kaspar (1), Brian Kaspar (1)

1. Insmad Gene Therapy LLC, San Diego, California, United States
2. Ohio State University Wexner Medical Center, Columbus, Ohio, United States
3. University of California, San Diego, California, United States
4. Insmad Incorporated, Bridgewater, New Jersey, United States
5. University of Missouri, Columbia, Missouri, United States

- PO407 Lipid-Conjugated SRSF1-Targeting siRNAs Provide Neuroprotection In Multiple Models Of C9orf72 And Sporadic ALS**
Guillaume Hautbergue (1,2), Ya-Hui Lin (2), David Burrows (2), Sophie Badger (2), Amy Keerie (2), Adrian Higginbottom (2), Aurore Besse (1), Mimoun Azzouz (2), Pamela Shaw (2), Jonathan Foley (1)
1. Crucible Therapeutics, Sheffield, United Kingdom
2. Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, United Kingdom
- PO408 RT1999 Is Neuroprotective Across Multiple Models Of ALS And Neurodegeneration**
Kim A. Staats
Raya Therapeutic, Inc., Montreal, Canada
- PO409 A Multisystem And Multitarget Therapeutic Approach To Hamper Amyotrophic Lateral Sclerosis (Multitreatals)**
Laura Pasetto, Alessia Ghioni, Sara Ficara, Cassandra Margotta, Paola Fabbrizio, Giovanni Nardo, Valentina Bonetto
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy
- PO410 CK-1 Dysregulation Promotes TDP-43 Pathology In SOD1-ALS Models: AP-2 As A Therapeutic Candidate**
Loreto Martinez-Gonzalez (1,2), Virginia García-Calvo (1,2), Eva P. Cuevas (1,2), Carmen Gil (1,2), Eva De Lago (3,2), Ana Martinez (1,2)
1. Centro de Investigaciones Biológicas-CSIC, Madrid, Spain
2. CIBER de Enfermedades Neurodegenerativas. Instituto de Salud Carlos III, Madrid, Spain
3. Instituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain
- PO411 Effect Of Recombinant Mouse Glutamic Oxaloacetic Transaminase 1 Treatment In The SOD1*G93A Mouse Model Of ALS**
Lucía Del Pozo-Filíu (1), Clara Correa-Paz (1,2), Noelia Otero-Rial (1), Nuria Palomar-Alonso (1), Esteban López-Arias (1), Antonio Dopico-López (1), Lara Pérez-Gayol (1), Laura Moreno-Martínez (3), Rosario Osta (3), María Pérez-Mato (1), Ana Bugallo-Casal (1), Tania García-Sobrino (4), Beatrice Canneti-Heredia (4), Julio Pardo-Fernández (4), Francisco Campos (1)
1. Translational Stroke Laboratory (TREAT), Health Research Institute of Santiago de Compostela (IDIS), Santiago De Compostela, Spain
2. Neuroscience and Cerebrovascular Research Laboratory, Neuroscience Area of IdiPAZ Health Research Institute (IdiPAZ), Madrid, Spain
3. Laboratory of Genetics and Biochemistry (LAGENBIO), Faculty of Veterinary-IIS Aragón, IA2-CITA, CIBERNED, University of Zaragoza, Zaragoza, Spain
4. Department of Neurology, Hospital Clínico Universitario de Santiago, Santiago De Compostela, Spain

PO412 From Mechanisms To Therapy: A Multi-Target Combination Strategy In C9orf72-ALS

Marco Cattaneo (1), Flaminia Fruzzetti (2), Eleonora Giagnorio (1), Giorgia Farinazzo (1), Claudia Malacarne (1), Silvia Bonanno (1), Eleonora Dalla Bella (1), Elia Di Schiavi (3), Nina Bono (2), Gabriele Candiani (2), Giuseppe Lauria Pinter (1), Stefania Marcuzzo (1)

1. Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
2. Politecnico di Milano, Milan, Italy
3. Institute of Biosciences and BioResources, Consiglio Nazionale delle Ricerche, Naples, Italy

PO413 Targeting Neuromuscular Junction Regeneration As A Therapeutic Strategy In ALS

Michela Rigoni (1), Samuele Negro (1), Chiara Baggio (1), Giorgia D'Este (2), Federico Fabris (1), Giulia Zanetti (1), Marika Tonellato (1), Maria Lina Massimino (3), Roberta Schellino (4), Valentina Bonetto (5), Manuela Basso (6), Cristiano Corona (7), Gianni Soraru (8), Ersilia Fornetti (9), Andrea Mattarei (10), Aram Megighian (1), Cesare Montecucco (1), Marco Pirazzini (1)

1. Department of Biomedical Sciences, University of Padua, Padua, Italy
2. Neurobiology Lab, IRCCS San Camillo Hospital, Venice, Italy
3. Neuroscience Institute, Section of Padua, National Research Council, Padua, Italy
4. Department of Neuroscience Rita Levi-Montalcini, University of Turin, Turin, Italy
5. Research Center for ALS, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
6. Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Italy
7. Istituto Zooprofilattico Sperimentale del Piemonte Liguria e Valle d'Aosta (IZSPLV), Turin, Italy
8. Department of Neurosciences, University of Padua, Padua, Italy
9. Center for Life Nano-& Neuroscience, Fondazione Istituto Italiano di Tecnologia, Rome, Italy
10. Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy

PO414 Therapeutic Potential Of The X Protein Of Orthobornavirus Bornaense Type 1 Expressed In Astrocytes Of A Transgenic Mice Models Of Amyotrophic Lateral Sclerosis

Nicolas Boissart (1), Stéphanie Astord (2), Piera Smeriglio (2), Gwendal Le Masson (1), Stéphanie Chevallier (1)

1. Université de Bordeaux, Neurocentre Magendie - INSERM U1215, Bordeaux, France
2. Université de la Sorbonne, Institut de Myologie, Paris, France

PO415 Del01-ATG4B Shows Broad Central Nervous System Distribution And Reduces ATG4B Cryptic Exon Inclusion In A Pilot Therapeutic Study

Pascual Torres (1), Pol Andrés-Benito (2,3), Santiago Rico-Ríos (1), Míriam Cerón-Codorniu (1), Marta Torres (1), Anna Fernández-Bernal (1), Sammra Maqsood (1), Victòria Ayala (1), Yahya Jad (4,5), Manuel Sánchez-Martín (6), Miguel Varela (4,5), Matthew J A Wood (4,5), Reinald Pamplona (1), Manuel Portero-Otín (1)

1. Metabolic physiopathology group, Department of Experimental Medicine, University of Lleida (UdL), Lleida Biomedical Research Institute (IRBLleida), 25198, Lleida, Spain
2. Cognition and Behavior Study Group, Institute for Research in Biomedicine of Lleida (IRBLleida), Lleida, Spain
3. Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain

4. Department of Paediatrics, Institute of Developmental and Regenerative Medicine (IDRM), University of Oxford, Oxford OX3 7FZ, UK, Oxford, United Kingdom

5. MDUK Oxford Neuromuscular Centre, Department of Paediatrics, Oxford OX3 9DU, UK, Oxford, United Kingdom

6. Transgenesis Facility and Nucleus Platform for Research Services, University of Salamanca, 37007, Salamanca, Spain

PO416 RXR-Driven Molecular Dysregulation Drives Amyotrophic Lateral Sclerosis And Is Rescued By Bexarotene

Rachel A Kline (1,2), Reiss Pal* (2,3), Helena Chaytow* (2,4), Bhuvaneish T Selvaraj (2,3), Thomas H Gillingwater\$ (2,4), Thomas M Wishart\$ (1,2,5)

1. Roslin Institute, Royal (Dick) School of Veterinary Studies, University of Edinburgh, United Kingdom

2. Euan MacDonald Centre for Motor Neuron Disease Research, Edinburgh, United Kingdom

3. Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom

4. Department of Anatomy, Edinburgh Medical School, University of Edinburgh, United Kingdom

5. Centre for Systems Health and Integrated Metabolic Research, Nottingham, United Kingdom

PO417 Systemic Administration Of A Cell-Internalizing CYTOPE® Targeting PTDP-43 Reduces CNS Intraneuronal Pathology In A Mouse Model Of TDP-43 Proteinopathy

Ian David Gallager, Lauri Wan Li, Kimberly Thomas, Heather Prill, Gang Zhang, Joshua Salmans, Erich Goldbach, Brian Michael Campbell, Robert Patrick Brendza, Philip James Dolan, Tarlochan Nijjar, Stephen Jed Tam

Prothema Biosciences, Brisbane, United States

PO418 CPT1 Inhibition Restores Metabolic Balance And Slows Disease Progression In ALS

Viktória Reháková (1,2), Yuanyuan Zeng (3), Amanda Krøger (3), Anne Skøttrup Mørkholt (1), Caroline C. Real (4), Carsten Scavenius (5), Claire F. Meehan (2), Anne Landau (4),

John D. Nieland (1,3), Steinunn S. Helgudóttir (1)

1. Neurometa Therapeutics, Aalborg, Denmark

2. Department of Neuroscience, University of Copenhagen, Copenhagen, Denmark

3. Department of Health Science and Technology, Aalborg University, Aalborg, Denmark

4. Department of Clinical Medicine – Translational Neuropsychiatry Unit, Aarhus University Hospital, Aarhus, Denmark

5. Department of Molecular Biology and Genetics – Protein Science, Aarhus University, Aarhus, Denmark

PRESYMPTOMATIC (included in the posters session I)**PO419 Metabolic Reprogramming Of Skeletal Muscle In Asymptomatic ALS Gene Mutation Carriers**

Celine Buon (1), Dimitrije Milunov (2), Delphine Sapaly (1), Timothee Lenglet (3), Maria Del Mar Amador (3), Elsie Piller (1), Flore Cheguillaume (1), Stéphanie Bauche (4), Isabelle Le Ber (5), Francois Salachas (3), Foudil Lamari (6), Anthony Behin (6), Teresinha Evangelista (7), François-Jerome Authier (8), Soham Saha (2), Frederic Charbonnier (1), Laure Weill (1), Gaelle Bruneteau (1,9)

1. Paris Cité University, Paris, France
2. Medinsight, Paris, France
3. Paris ALS centre, APHP, Paris, France
4. Sorbonne University, Paris, France
5. Paris Brain Institute, Paris, France
6. Pitié-Salpêtrière, APHP, Paris, France
7. Myology Institute, Paris, France
8. Henri Mondor Hospital, APHP, Paris, France
9. Paris ALS center, APHP, Paris, France

PO420 Spatiotemporal Transcriptomics Reveals Early Immune-Stromal Dysregulation In Pre-Symptomatic ALS Skin

Kristine Roberts (1,2), Angus Macleod (3), Katie Hanna (1), Jayne Innes (2), Joan Wilson (2), Mattia Piana (2), Holly Spence (1), Jenna Gregory (1)

1. Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom
2. NHS Grampian Biorepository, Aberdeen, United Kingdom
3. Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom

PO421 Raman Spectroscopic Mapping Reveals Biochemical Alterations In Presymptomatic ALS Skin

Katie Hanna (1), Kristine Roberts (2), Joan Wilson (3), Jayne Innes (3), Fiona Read (2), Angus Macleod (2), Fergal Waldron (2), Karen Faulds (1), Jenna Gregory (2)

1. University of Strathclyde, Glasgow, United Kingdom
2. University of Aberdeen, Aberdeen, United Kingdom
3. Aberdeen Royal Infirmary, Aberdeen, United Kingdom

PO422 Longitudinal Changes In Urinary P75ECD Levels In Presymptomatic And Early ALS – A PremodiALS Study

Laura Tzeplaeff (1), Ana Galhoz (2), Danielle Renfrey (3), Philippe Corcia (4), Markus Weber (5), Monika Turcanova Koprusakova (6), Hilmi Uysal (7), Michael P Menden (8), Mary-Louise Rogers (3), Paul Lingor (1)

1. Rechts der Isar Hospital of the Technical University Munich, Munich, Germany
2. Helmholtz Munich, Munich, Germany
3. College of Medicine and Public Health of the Flinders University, Adelaide, Australia
4. CHRU Bretonneau, Tours, France

5. ALS Clinic of the Kantonsspital St. Gallen, St. Gallen, Switzerland

6. Jessenius Medical Faculty Comenius University, Martin, Slovakia

7. Akdeniz University Hospital, Antalya, Turkey

8. University of Melbourne, Melbourne, Australia

PO423 Molecular Insights Into Gastrointestinal Protein Aggregation And Neurodegenerative Disease Risk

Tatiana Langerova (1), Emma Macvicar (2), Kristine Roberts (1), Ewan Campbell (1), Fergal M Waldron (1), Rollo Press (2), George Ramsay (2), Jenna M Gregory (1)

1. University of Aberdeen, Aberdeen, United Kingdom

2. NHS Grampian, Aberdeen, United Kingdom

PO424 Structural Brain Alterations In Amyotrophic Lateral Sclerosis Pre-Diagnosis: A UK Biobank Study

Yezhou Li, Alicia Northall, Jiali Gao, Cory Holdom, Christos Chalitsios, Elizabeth Dellar, Kevin Talbot, Alexander Thompson, Martin Turner

Oxford University, Oxford, United Kingdom

TRANSLATIONAL RESEARCH, NETWORKS AND PLATFORMS (included in the posters session I)

PO425 Building A Scalable Global Framework For ALS/MND Natural History Research

Alexander V. Sherman (1,2), Senda Ajroud-Driss (3), Tawfiq Al-Lahham (4), Ximena Arcila Londono (5), Federica Cerri (6), Vivian Drory (7), Marc Gotkine (8), Mehdi Ghasemi (9), Kelly Gwathmey (10), Ghazala Hayat (11), Terry Heiman-Patterson (12), Christian Lunetta (13), Nicholas Olney (14), Jeffrey Rosenfeld (15), Melanie G. Taylor (16), David Walk (17), Abel Wu (18), James Wymer (19)

1. Massachusetts General Hospital, Boston, United States

2. Harvard Medical School, Boston, United States

3. Les Turner ALS Center at Northwestern Medicine, Chicago, United States

4. University of Pittsburgh, Pittsburgh, United States

5. Henry Ford Health Systems, Detroit, United States

6. Neuromuscular Omnicenter (NEMO), Milan, Italy

7. Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

8. Hadassah Medical Center, Jerusalem, Israel

9. Lahey Hospital & Medical Center, Burlington, United States

10. Virginia Commonwealth University Health, Richmond, United States

11. Saint Louis University School of Medicine, Saint Louis, United States

12. MDA/ALS Center of Hope, Temple University, Philadelphia, United States

13. ICS Maugeri, Milan, Italy

14. Providence ALS Center, Providence, United States

15. Loma Linda University, Loma Linda, United States

16. Trinity Health Grand Rapids, Grand Rapids, United States

17. University of Minnesota, Minneapolis, United States

18. Kaiser Permanente, Pasadena, United States

19. University of Florida, Gainesville, United States

P0426 Neuromine: An Open-Access Platform For Harmonized Clinical And Multi-Omics Data Across ALS Cohorts

Brandon Jernigan, Terri Thompson

Neuromine, San Diego, United States

P0427 SEED-ALS Project: Synergizing Efforts To Develop And Accelerate Breakthroughs In ALS Research

Carmen Paradas (1,2,3), Estela Area-Gómez (4,3), JUAN FRANCISCO Vazquez (5,6), Raúl Juntas (7), Ricard Rojas-García (8,3), Alberto Garcia-Redondo (9,10), Ana Martínez (11,3), Aurora Pujol (12,6), Manel Esteller (13,14,15,16), Anna Esteve (17), Davide Cirillo (20), Rosario Carmona (22,10), Oriol Dols (23,24), Fernando Martín (25,26,27), Pol Andrés (28,3), Monica Povedano (29,30), Adolfo López De Munain (31,3), SEED-ALS Consortia (30,3)

1. Neuromuscular Disorders Unit, Sevilla, Spain

2. Instituto de Biomedicina de Sevilla (IBiS), Sevilla, Spain

3. Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain

4. Department of Biomedicine, Centro de Investigaciones Biológicas Margarita Salas, CSIC, Madrid, Spain

5. Department of Neurology, Hospital Universitari i Politècnic la Fe, Valencia, Spain

6. Centro Investigación Biomédica en Red Enfermedades Raras (CIBERER), Madrid, Spain

7. Department of Biomedicine, Barcelona, Spain

8. Centro de Investigaciones Biológicas Margarita Salas, Barcelona, Spain

9. Neuromuscular Unit and ERN-NMD Group, Madrid, Spain

10. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain

11. Centro de Investigaciones Biológicas, Madrid, Spain

12. Neurometabolic Diseases Laboratory, IDIBELL-Hospital Duran I Reynals; and Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain

13. Neurology Department, Barcelona, Spain

14. Center for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain

15. Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain

16. Centro de Investigación Biomédica en Red Cancer, Madrid, Spain

17. Vall d'Hebron University Hospital, Badalona, Spain

18. Instituto de Salud Carlos III

19. Cancer Epigenetics Group

20. Motor Neuron Disease Clinic, Barcelona, Spain

21. Sant Pau Research Institute (IRSantPau)

22. Neuromuscular Diseases Unit, Sevilla, Spain

23. Department of Neurology, Barcelona, Spain

24. Instituto de salud Carlos III, Madrid, Spain

25. Hospital de la Santa Creu i Sant Pau, Madrid, Spain

26. Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain

27. Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Madrid, Spain

28. Biomedical Research Institute Sant Pau, l'Hospitalet De Llobregat, Spain

29. Departamento de Neurología, Barcelona, Spain

30. Centre for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain

31. Neurosciences Area, Biogipuzkoa Health Research Institute, Donostia, Spain

PO428 CAPTURE ALS: Comprehensive Analysis Platform To Understand, Remedy, And Eliminate ALS

HyungMo Kang (1), Tanushka Anand (2), Harpreet Bhinder (2), Alice Cornet (3), Nicolas Dupré (4), Yvonne Frater (5), Angela Genge (1), Shelagh K. Genuis (2), Wendy S. Johnston (2), Westerly Luth (2), Geneviève Matte (3), Clémence Tremblay-Desbiens (4), Lorne Zinman (5), Sanjay Kalra (2)

1. McGill University, Montreal, Canada

2. University of Alberta, Edmonton, Canada

3. Centre Hospitalier de l'Université de Montréal, Montreal, Canada

4. CHU de Québec-Université Laval, Quebec, Canada

5. Sunnybrook Research Institute, Toronto, Canada

PO429 GoALS – A Research Program For A Breakthrough In The Cure Of ALS

*Leonard H. Van Den Berg, Jan H. Veldink, Jeroen Pasterkamp, Suzanne E. Koch
UMC Utrecht, Utrecht, The Netherlands*

PO430 Establishing A High-Throughput Phenotypic Screening Platform For C21ORF2-Associated ALS Using iPSC-Derived Motor Neurons

*Pavol Zelina, Evgenia Kokosali, Serife Uysal, Jeroen Pasterkamp
UMC Utrecht Brain Center, Utrecht, The Netherlands*

PO431 Unraveling TBK1- And KIF5A-Linked Mechanisms Of Oligodendrocyte Dysfunction In Amyotrophic Lateral Sclerosis By Integrative Transcriptomic Profiling

Seyed Babak Loghmani (1), Rosanna Parlato (2), Jochen Weishaupt (1)

1. University Hospital Ulm, Ulm, Germany

2. University Hospital Mannheim, Mannheim, Germany

PO432 LLM-Based Conversational Analytics For ALS Use Cases From The Precision-ALS Framework

Tamara Matthews, Robert Ross

Technological University Dublin, Dublin, Ireland

ENCALS

European Network to Cure ALS

SECOND SECTION



Industry Sponsored session

AL-S PHARMA

AL-S Pharma Symposium
Tuesday, June 23rd
14.00-16.30
Buenos Aires – Havana – Mexico Room



Ferrer-Prilenia Symposium
Wednesday, June 24th
11.45-13.00
Buenos Aires – Havana – Mexico Room



Italfarmaco Symposium
Wednesday, June 24th
11.30-13.00
Caracas - Bogotá Room

AL-S PHARMA'S ENCALs 2026 INDUSTRY SYMPOSIUM**AL-S PHARMA**

Tuesday, June 23th

14.00-16.30

Buenos Aires–Havana–Mexico Room

Format: Three 20-25-minute talks with 5-10-minute Q&A for each,
followed by panel discussion and Q&A (45 minutes)**BEYOND “SPORADIC” ALS: GENETICS, BIOMARKERS, AND THE MISFOLDED SOD1 PATHWAY****Symposium Description**

This symposium will bring together internationally recognized leaders in ALS research to examine how advances in disease biology are reshaping clinical investigation and therapeutic development. Designed for neurologists, physician-scientists, clinical trialists, and industry professionals in drug development, the session will connect emerging insights in genetic architecture, biomarker interpretation, and protein misfolding biology to the practical realities of ALS diagnosis, stratification, and trial design. The symposium will open with a contemporary reappraisal of so-called sporadic ALS, challenging the traditional familial/sporadic divide and highlighting a more nuanced view of genetic contribution and disease architecture; it will then turn to neurofilament biomarkers in ALS clinical trials, focusing on what these markers have taught us over time, where they are most useful today, and how they should be interpreted in the context of therapeutic studies; and it will conclude with a deep dive into the misfolded SOD1 pathway, addressing its biologic significance, mechanistic implications, and relevance for biomarkers and targeted therapies.

Featured Speakers and Talk Titles**1. Prof. Ammar Al-Chalabi, PhD, FRCP, FMedSci**

Beyond “Sporadic” ALS: Rethinking Genetic Architecture and Disease Classification

- Reassessing the limitations of the traditional familial/sporadic divide in ALS
- Exploring how rare variants, polygenic risk, penetrance, and gene–environment interplay may shape sporadic disease and future precision trial design

2. Prof. Dame Pamela Shaw, DBE, MBBS, MD, FRCP, FAAN, FANA, FAAAS

Neurofilament Biomarkers in ALS Clinical Trials: Then, Now, and How to Interpret Them

- Tracing the evolution of neurofilament biomarkers from research tools to established components of ALS clinical development
- Examining their current utility and the key challenges in interpretation across prognosis, stratification, pharmacodynamic assessment, and trial design

3. Prof. Philip Van Damme, MD, PhD

The Role of SOD1 in ALS

- Reviewing the lessons learned from SOD1-ALS
- Discussing how misfolded SOD1 could play a role in the absence of SOD1 mutations

Panel Discussion: Translating ALS Biology into Better Trials**Moderator:** Angela Genge, MD, FRCP(C), eMBA, chief medical officer, AL-S Pharma AG

Panelists: Prof. Leonard van den Berg, PhD, Prof. Andrea Malaspina, MD, PhD,
Prof. Julian Grosskreutz, MD

A moderated panel discussion will follow the presentations, bringing together the speakers and invited experts to discuss how emerging insights in ALS genetics, biomarker interpretation, and misfolded protein biology can be translated into better trial design, patient stratification, and therapeutic development.

**ADVANCING NEUROPROTECTIVE
CARE IN RARE DISEASES
Strength Through Partnership**

Wednesday, June 24th

11.30-13.00

Buenos Aires - Havana – Mexico Room



11:30 - 11:45 PREVAiLS Phase 3 update:

Biological rationale, study design and implications for patient-relevant outcomes in ALS

MAs part of TRICALS Satellite Meeting

11.45-13.00 From Disease Burden to Meaningful Benefit in ALS:

Aligning Symptom Relevance, Management, and Novel Trial Endpoints

Ferrer-Prilenia Satellite Meeting

**ALS MILESTONES AND TOMORROW MEDICINE:
A JOURNEY FROM 1990 TO THE FUTURE**

Wednesday, June 24th

11:30 - 13:00

Caracas-Bogota Room



Chairman:

The European ALS Community's Commitment: Learning from the Past to Shape the Future.

Pr. Philippe Corcia, Tours (France)

Speakers:

Milestones in ALS over the last 30 years

Pr. Julian Grosskreutz, Luebeck (Germany)

The future of ALS diagnosis

Pr. Mónica Povedano, Barcelona (Spain)

The future of ALS care

Pr. Nicola Ticozzi, Milano (Italy)

Advancing Neuroprotective Care in Rare Diseases

Strength Through Partnership

Ferrer and Prilenia, are committed to changing the lives of people with neurodegenerative diseases. United to accelerate innovative new therapies for patients, Ferrer brings expertise in rare neurological diseases, while Prilenia brings experience with pridopidine and neurodegenerative diseases. Ferrer is the highest-rated pharma B Corp, reinvesting ~50% of profits in social and environmental initiatives. Prilenia is driven by unwavering commitment to scientific excellence in developing transformative medicines for neurodegenerative diseases.

Join the Scientific Exchange

Satellite Meetings

Location: BUENOS AIRES - HAVANA – MEXICO Room

📅 Wednesday, June 24th

11:30 - 11:45

PREVAiLS Phase 3 update: Biological rationale, study design and implications for patient-relevant outcomes in ALS.

As part of TRICALS Satellite Meeting

11:45 - 13:00

From Disease Burden to Meaningful Benefit in ALS: Aligning Symptom Relevance, Management, and Novel Trial Endpoints.

Ferrer-Prilenia Satellite Meeting



Prof. Leonard van den Berg, MD, PhD

UMC Utrecht, The Netherlands



Valérie Berlaimont, PhD

ALS Patient, member of ALS Liga and EUpALS



Assoc. Prof. Andrea Calvo, MD, PhD

Università degli Studi di Torino, Italy




Assoc. Prof. Ruben van Eijk, MD, PhD

UMC Utrecht, The Netherlands



Prof. Caroline Ingre, MD, PhD

Karolinska Institutet and Karolinska University Hospital, Sweden



PREVAiLS (Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS)
a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in ALS

📄 **Poster #471**

➔ Exhibition area

📅 Wednesday, June 24th

🕒 17:20h - 19:00h

🍽️ **Session: ENCALS RESEARCH FORUM – POSTERS SESSION**



QurAlisTM

Neuro Pioneers on a Quest to Cure

QurAlis is a proud sponsor of

ENCALS 2026

At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases.



www.quralis.com



MAKING BREAKTHROUGHS HAPPEN

We are proud to sponsor
the 2026 ENCALS meeting



May 2026. Biogen-287051

AXONIA

ACCREDITED WEBINAR SERIES

Meet Axonia, a four-part expert-led webinar series on rare neurodegenerative diseases

New WEBINAR! HIDDEN SIGNS: ALS and the Motor Neuron Spectrum

- Available from May 6th – 18:00h (GMT+1)
- Live session + later on-demand access with short video capsules for flexible learning

Webinar 2

xpeer | AXONIA



ACCREDITED BY THE UEMS



Prof. Thomas Meyer

Neurologist specialized in ALS and neuromuscular disorders




Prof. Leonard van den Berg

Neurologist specialized in ALS and motor neuron diseases

Live on xpeer

DESIGNED FOR CLINICAL IMPACT:

- **Evidence-informed content** distilled into a clear, practical format
- **Accredited learning** for continuous professional development
- Flexible access: **live interaction + on-demand replay**
- Content relevant for **neurologists, GPs, and multidisciplinary teams involved in ALS care**
- **Real clinical cases**



APP ENCALS MEETING 2026

Everything you need
is right in your pocket.

Scan the QR code
to download the official app.

**DOWNLOAD NOW
AND DON'T MISS A BEAT!**

1. DOWNLOAD TORRES PARDO EVENTS



2. CLICK HERE



GOLD SPONSORS



SILVER SPONSORS



STANDARD SPONSORS



SYMPOSIA SPONSORS



ENCALS

European Network to Cure ALS

With the Support of



Certificates of attendance and CME credits

You must scan your badge when entering and leaving the venue.

All certificates will be sent by email when the congress finishes.